Processing 00000000.tx.1: Combination therapy with PPAR and PPAR agonists increases glucose-stimulated insulin secretion in db/db mice Ken Yajima1,4, Hiroshi Hirose1, Haruhisa Fujita2, Yoshiko Seto2, Hiroshi Fujita2, Kaname Ukeda2, Kiichi Miyashita2, Toshihide Kawai1, Yukihiro Yamamoto1, Takeo Ogawa1, Taketo Yamada3, and Takao Saruta1 1Department of Internal Medicine, 2Institute for Advanced Medical Research, and 3Department of Pathology, Keio University School of Medicine, Tokyo 160-8582; 

Phrase: "Combination therapy with PPAR"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C0009429:Combination Therapy [Therapeutic or Preventive Procedure]
   778   C0556895:Combination therapy [Therapeutic or Preventive Procedure]
   748   C0039798:therapy [Functional Concept]
   748   C0087111:Therapy [Therapeutic or Preventive Procedure]
   748   C1363945:Therapy [Finding]

Phrase: "and"

Phrase: "PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "glucose-stimulated insulin secretion in db/db mice Ken Yajima1,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C1256369:insulin secretion [Cell Function]
   757   C1719133:Glucose/Insulin [Quantitative Concept]
   739   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   739   C0036536:secretion [Biologic Function]
   739   C0036537:Secretion [Body Substance]
   739   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   739   C1579433:Insulin [Pharmacologic Substance]

Phrase: "4,"

Phrase: "Hiroshi Hirose1,"

Phrase: "Haruhisa Fujita2,"

Phrase: "Yoshiko Seto2,"

Phrase: "Hiroshi Fujita2,"

Phrase: "Kaname Ukeda2,"

Phrase: "Kiichi Miyashita2,"

Phrase: "Toshihide Kawai1,"

Phrase: "Yukihiro Yamamoto1,"

Phrase: "Takeo Ogawa1,"

Phrase: "Taketo Yamada3,"

Phrase: "and"

Phrase: "Takao Saruta1 1Department of Internal Medicine,"

Phrase: "2Institute for Advanced Medical Research,"

Phrase: "and"

Phrase: "3Department of Pathology,"

Phrase: "Keio University School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0036375:School [Manufactured Object,Organization]

Phrase: "Tokyo 160-8582"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0040371:Tokyo [Geographic Area]

Phrase: ";"
Processing 00000000.tx.2: and 4Department of Internal Medicine, Hamamatsu Red Cross Hospital, Hamamatsu 430-0907,Japan  ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Although peroxisome proliferator-activated receptor (PPAR) agonists ameliorate insulin resistance, they sometimes cause body weight gain, and the effect of PPAR agonists on insulin secretion is unclear. 

Phrase: "and"

Phrase: "4Department of Internal Medicine,"

Phrase: "Hamamatsu Red Cross Hospital,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   812   C1510665:Hospital [Qualitative Concept]
   729 E C1609061:Hospitals [Intellectual Product]

Phrase: "Hamamatsu 430-0907,"

Phrase: "Japan  ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C1514811:Reference [Idea or Concept]
   779   C1706462:Reference [Conceptual Entity]

Phrase: "Although"

Phrase: "peroxisome proliferator-activated receptor (PPAR) agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "ameliorate"

Phrase: "insulin resistance,"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "they sometimes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1998882:Sometimes [Temporal Concept]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "body weight gain,"
Meta Candidates (Total=23; Excluded=9; Pruned=0; Remaining=14)
  1000   C0043094:Body Weight Gain [Finding]
           Weight Gain
  1000   C2986889:Body Weight Gain [Idea or Concept]
   901   C0005910:Body Weight [Organism Attribute]
           weight
   901   C1305866:body weight [Diagnostic Procedure]
           weight
   901   C2911647:Weight gain [Finding]
   859 E C0231246:weight gaining [Sign or Symptom]
   827   C0043100:Weight [Quantitative Concept]
   827   C0242821:body [Human]
   827   C0460148:Body [Anatomical Structure]
   827   C1268086:Body [Anatomical Structure]
   827   C1517378:Gain [Quantitative Concept]
   827   C1705104:Weight [Idea or Concept]
   771 E C0205217:Increased [Quantitative Concept]
   771 E C0439661:Acquired [Temporal Concept]
   771 E C0442805:Increase [Functional Concept]
   771 E C0442808:Increasing [Functional Concept]
   771 E C1301820:Obtain [Functional Concept]
   771 E C1706701:Acquire [Activity]
   771 E C3245488:acquired [Intellectual Product]
   743 E C1995017:Bodies [Cell Component]

Phrase: "and"

Phrase: "the effect of PPAR agonists"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "on insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "unclear."
Processing 00000000.tx.3: We evaluated the effects of combination therapy with a PPAR agonist, pioglitazone, and a PPAR agonist, bezafibrate, and a dual agonist, KRP-297, for 4wk in male C57BL/6J mice and db/db mice, and we investigated glucose-stimulated insulin secretion (GSIS) by in situ pancreatic perfusion. 

Phrase: "We"

Phrase: "evaluated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluated [Functional Concept]

Phrase: "the effects of combination therapy"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   781   C1518681:Therapy Effect [Finding]
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "with a PPAR agonist,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C2987634:Agonist [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "pioglitazone,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "a PPAR agonist,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C2987634:Agonist [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "bezafibrate,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "a dual agonist,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2987634:Agonist [Pharmacologic Substance]

Phrase: "KRP-297,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0760735:KRP 297 [Organic Chemical]
   861   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1706585:KRP [Gene or Genome]
   861   C1833135:KRP [Gene or Genome]

Phrase: "for 4wk"

Phrase: "in male C57BL/6J mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   875   C0025921:Mice, C57BL [Mammal]
   812   C0025914:Mice [Mammal]
   812   C0025929:mice [Mammal]
   812   C0026809:Mice [Mammal]

Phrase: "and"

Phrase: "db/db mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "and"

Phrase: "we"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "glucose-stimulated insulin secretion (GSIS) by in situ pancreatic perfusion."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   764   C1256369:insulin secretion [Cell Function]
   762   C0030296:Pancreatic Secretion [Body Substance]
   762   C0232787:Pancreatic secretion [Organ or Tissue Function]
   762   C1719133:Glucose/Insulin [Quantitative Concept]
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0036536:secretion [Biologic Function]
   742   C0036537:Secretion [Body Substance]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.4: Body weight gain in db/db mice was less with KRP-297 treatment than with pioglitazone or pioglitazone+bezafibrate treatment. 

Phrase: "Body weight gain in db/db mice"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   814   C0043094:Body Weight Gain [Finding]
           Weight Gain
   814   C2986889:Body Weight Gain [Idea or Concept]
   778   C0005910:Body Weight [Organism Attribute]
           weight
   778   C1305866:body weight [Diagnostic Procedure]
           weight
   778   C2911647:Weight gain [Finding]
   748   C0043100:Weight [Quantitative Concept]
   748   C0242821:body [Human]
   748   C0460148:Body [Anatomical Structure]
   748   C1268086:Body [Anatomical Structure]
   748   C1517378:Gain [Quantitative Concept]
   748   C1705104:Weight [Idea or Concept]
   737 E C0231246:weight gaining [Sign or Symptom]

Phrase: "was"

Phrase: "less with KRP-297 treatment"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   806   C0760735:KRP 297 [Organic Chemical]
   760   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0439092:less [Intellectual Product]
   760   C0547044:Less [Qualitative Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C1706585:KRP [Gene or Genome]
   760   C1833135:KRP [Gene or Genome]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "than"

Phrase: "with pioglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "or"

Phrase: "pioglitazone+bezafibrate treatment."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0039798:treatment [Functional Concept]
   827   C0087111:Treatment [Therapeutic or Preventive Procedure]
   827   C1522326:Treatment [Functional Concept]
   827   C1533734:Treatment [Therapeutic or Preventive Procedure]
   827   C1705169:Treatment [Conceptual Entity]
   827   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.5: Plasma glucose, insulin, triglyceride, and nonesterified fatty acid levels were elevated in untreated db/db mice compared with untreated C57BL/6J mice, and these parameters were significantly ameliorated in the PPAR agonist-treated groups. 

Phrase: "Plasma glucose,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0202042:Plasma glucose [Laboratory Procedure]
  1000   C0455280:plasma glucose [Laboratory or Test Result]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   861   C0032105:Plasma [Body Substance]
   861   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "triglyceride,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041004:Triglyceride [Biologically Active Substance,Lipid]

Phrase: "and"

Phrase: "nonesterified fatty acid levels"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   923   C0015688:Non-esterified fatty acid [Lipid]
   890   C1281901:Fatty acid level [Laboratory Procedure]
   861   C0015684:Fatty acid [Lipid]
   812   C0001128:Acid [Chemical]
   812   C0202406:Acid [Laboratory Procedure]
   812   C0441889:Levels [Qualitative Concept]
   779 E C0456079:Level [Classification]
   779 E C1547707:Level [Geographic Area]
   779 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "elevated in untreated db/db mice"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0205250:Elevated [Qualitative Concept]
   753   C0332155:untreated [Finding]
   753   C3163633:Elevated [Qualitative Concept]

Phrase: "compared with untreated C57BL/6J mice,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   783   C0025921:Mice, C57BL [Mammal]
           C57BL
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0332155:untreated [Finding]
   753   C1707455:Compared [Activity]

Phrase: "and"

Phrase: "these parameters"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0449381:Parameters [Finding]
   966 E C0549193:Parameter [Spatial Concept]
   966 E C1704769:Parameter [Conceptual Entity]
   966 E C2350001:Parameter [Quantitative Concept]

Phrase: "were"

Phrase: "significantly"

Phrase: "ameliorated in the PPAR agonist-treated groups."
Meta Candidates (Total=19; Excluded=2; Pruned=0; Remaining=17)
   806   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   806   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   760   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   739   C0332293:treated [Therapeutic or Preventive Procedure]
   739   C0441833:Group [Idea or Concept]
   739   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   739   C0687744:group [Population Group]
   739   C0752063:Peroxysome [Cell Component]
   739   C1257890:Group [Population Group]
   739   C1522326:Treated [Functional Concept]
   739   C1552516:Group [Health Care Related Organization]
   739   C1552839:groups [Idea or Concept]
   739   C1705428:Group [Conceptual Entity]
   739   C1705429:Group [Population Group]
   739   C1879547:Activated [Activity]
   739   C2984308:Peroxisome [Functional Concept]
   739   C2987634:Agonist [Pharmacologic Substance]
   706 E C1292734:TREAT [Functional Concept]
   706 E C1515877:Activate [Functional Concept]
Processing 00000000.tx.6: Also, PPAR agonists ameliorated the diminished GSIS and insulin content, and they preserved insulin and GLUT2 staining in db/db mice. 

Phrase: "Also,"

Phrase: "PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "ameliorated"

Phrase: "the diminished GSIS"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   853   C1719133:Glucose/Insulin [Quantitative Concept]
   840   C1256369:insulin secretion [Cell Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036536:secretion [Biologic Function]
   804   C0036537:Secretion [Body Substance]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "insulin content,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0423896:Content [Mental Process]
   861   C0456205:Content [Conceptual Entity]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "they"

Phrase: "preserved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033085:Preserved [Laboratory Procedure]

Phrase: "insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "GLUT2 staining in db/db mice."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0487602:Staining [Laboratory Procedure]
   753   C1704680:Staining [Finding]
Processing 00000000.tx.7: GSIS was further increased by PPAR and - agonists. 

Phrase: "GSIS"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "increased by PPAR"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   882   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   882   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   790   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   753   C0205217:Increased [Quantitative Concept]
   753   C0442805:Increased [Functional Concept]
   753   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   753   C0752063:Peroxysome [Cell Component]
   753   C1879547:Activated [Activity]
   753   C2984308:Peroxisome [Functional Concept]
   719 E C1515877:Activate [Functional Concept]

Phrase: "and -"

Phrase: "agonists."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0243192:agonists [Pharmacologic Substance]
  1000   C2987634:agonists [Pharmacologic Substance]
Processing 00000000.tx.8: We conclude that combination therapy with PPAR and PPAR agonists may be more useful with respect to body weight and pancreatic GSIS in type 2diabetes with obesity. peroxisome proliferator-activated receptor; 

Phrase: "We"

Phrase: "conclude"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "that combination therapy with PPAR"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0009429:Combination Therapy [Therapeutic or Preventive Procedure]
   770   C0556895:Combination therapy [Therapeutic or Preventive Procedure]
   744   C0039798:therapy [Functional Concept]
   744   C0087111:Therapy [Therapeutic or Preventive Procedure]
   744   C1363945:Therapy [Finding]

Phrase: "and"

Phrase: "PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "may"

Phrase: "be"

Phrase: "more useful with respect to body weight"

Phrase: "and"

Phrase: "pancreatic GSIS in type 2diabetes"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   770   C1256369:insulin secretion [Cell Function]
   767   C0030296:Pancreatic Secretion [Body Substance]
   767   C0232787:Pancreatic secretion [Organ or Tissue Function]
   767   C0457592:Insulin type [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   767   C1719133:Glucose/Insulin [Quantitative Concept]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0036536:secretion [Biologic Function]
   744   C0036537:Secretion [Body Substance]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]

Phrase: "with obesity. peroxisome proliferator-activated receptor"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: ";"
Processing 00000000.tx.9: glucose-stimulated insulin secretion; 

Phrase: "glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.10: glucolipotoxicity; 

Phrase: "glucolipotoxicity"

Phrase: ";"
Processing 00000000.tx.11: insulin resistance; 

Phrase: "insulin resistance"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.12: type 2diabetes with obesity  INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) agonists have been used for the treatment of type 2diabetic patients, especially those with obesity, all over the world. 

Phrase: "type 2diabetes with obesity  INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS"

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "(PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: ")"

Phrase: "agonists"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0243192:agonists [Pharmacologic Substance]
  1000   C2987634:agonists [Pharmacologic Substance]

Phrase: "have"

Phrase: "been"

Phrase: "used for the treatment of type 2diabetic patients,"
Meta Candidates (Total=15; Excluded=3; Pruned=0; Remaining=12)
   750   C1524063:Use of [Functional Concept]
   750   C1550335:Patient type [Classification]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0039798:treatment [Functional Concept]
   744   C0087111:Treatment [Therapeutic or Preventive Procedure]
   744   C0332307:Type [Qualitative Concept]
   744   C1273517:used [Finding]
   744   C1522326:Treatment [Functional Concept]
   744   C1533734:Treatment [Therapeutic or Preventive Procedure]
   744   C1547052:*Type [Quantitative Concept]
   744   C1705169:Treatment [Conceptual Entity]
   744   C3538994:TREATMENT [Research Activity]
   711 E C0042153:use [Functional Concept]
   711 E C0457083:Use [Functional Concept]
   711 E C1947944:Use [Intellectual Product]

Phrase: "especially"

Phrase: "those with obesity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0028754:Obesity [Disease or Syndrome]
   790   C1963185:Obesity [Finding]

Phrase: "all over the world."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2700280:World [Population Group]
Processing 00000000.tx.13: They ameliorate insulin resistance of peripheral tissues, such as skeletal muscle, liver, and adipocytes, by various suggested mechanisms. 

Phrase: "They"

Phrase: "ameliorate"

Phrase: "insulin resistance of peripheral tissues,"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   806   C0021655:Insulin Resistance [Pathologic Function]
   806   C2700570:INSULIN RESISTANCE [Gene or Genome]
   797   C1258192:Peripheral Resistance [Physiologic Function]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0237834:Resistance [Mental Process]
   760   C1514892:Resistance [Physiologic Function]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "such as skeletal muscle,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0242692:Muscle, Skeletal [Tissue]
  1000   C1280260:Skeletal muscle [Body Part, Organ, or Organ Component]
   861   C0026845:Muscle [Tissue]
   861   C0037253:skeletal [Body System]
   861   C0521324:Skeletal [Spatial Concept]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "liver,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0023884:Liver [Body Part, Organ, or Organ Component]
  1000   C0736268:LIVER [Body Part, Organ, or Organ Component]
  1000   C1278929:Liver [Body Part, Organ, or Organ Component]
  1000   C2346688:LIVER [Food]
   944 E C0205054:Hepatic [Body Location or Region]

Phrase: "and"

Phrase: "adipocytes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0206131:Adipocytes [Cell]

Phrase: "by various suggested mechanisms."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0441712:Mechanisms [Functional Concept]
   793 E C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.14: Although some literature has suggested effects of PPAR agonists on the pancreas (13, 32), only a few studies have investigated this issue (23, 29, 30). 

Phrase: "Although"

Phrase: "some literature"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0023866:Literature [Intellectual Product]
  1000   C0034036:LITERATURE [Intellectual Product,Manufactured Object]

Phrase: "has"

Phrase: "suggested effects of PPAR agonists"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C1280500:effects [Qualitative Concept]
   711 E C2348382:Effect [Qualitative Concept]

Phrase: "on the pancreas"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0030274:Pancreas [Body Part, Organ, or Organ Component]
  1000   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "(13,"

Phrase: "32"

Phrase: ")"

Phrase: ","

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "a few studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "have"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "this issue"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0033213:Issue [Finding]
  1000   C1706387:Issue [Intellectual Product]

Phrase: "(23,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "29,"

Phrase: "30"

Phrase: ")."
Processing 00000000.tx.15: Because the expression of PPAR is confirmed not only in rodent (1) but also in human islets (5), an effect of PPAR agonists on the pancreas has been suggested. 

Phrase: "Because"

Phrase: "the expression of PPAR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   774   C0597360:receptor expression [Genetic Function]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "is"

Phrase: "confirmed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirmed [Qualitative Concept]
  1000   C0750484:Confirmed [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "not only in rodent"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0035804:Rodent [Mammal]
   770   C0205171:Only [Quantitative Concept]
   770   C1518422:Not [Functional Concept]
   770   C1720467:Only [Intellectual Product]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")"

Phrase: "but"

Phrase: "also in human islets"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0086418:Human [Human]

Phrase: "(5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "an effect of PPAR agonists"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "on the pancreas"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0030274:Pancreas [Body Part, Organ, or Organ Component]
  1000   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "has"

Phrase: "been"

Phrase: "suggested."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]
Processing 00000000.tx.16: On the other hand, fibrates are PPAR agonists and have been used for patients with dyslipidemia. 

Phrase: "On the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "fibrates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1449704:Fibrates [Organic Chemical,Pharmacologic Substance]

Phrase: "are"

Phrase: "PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "and"

Phrase: "have"

Phrase: "been"

Phrase: "used for patients"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1273517:used [Finding]
   756 E C0042153:use [Functional Concept]
   756 E C0457083:Use [Functional Concept]
   756 E C1947944:Use [Intellectual Product]

Phrase: "with dyslipidemia."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0242339:Dyslipidaemia [Disease or Syndrome]
Processing 00000000.tx.17: Some literature has reported that PPAR agonists also ameliorated insulin resistance (6, 7, 14, 19, 24, 28, 36), but the effect on insulin secretion is unclear. 

Phrase: "Some literature"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0023866:Literature [Intellectual Product]
  1000   C0034036:LITERATURE [Intellectual Product,Manufactured Object]

Phrase: "has"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that PPAR agonists also ameliorated insulin resistance"
Meta Candidates (Total=13; Excluded=5; Pruned=0; Remaining=8)
   842   C0034818:receptor insulin [Amino Acid, Peptide, or Protein,Enzyme,Receptor]
   807   C0021655:Insulin Resistance [Pathologic Function]
   807   C2700570:INSULIN RESISTANCE [Gene or Genome]
   791   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   791   C0237834:Resistance [Mental Process]
   791   C1514892:Resistance [Physiologic Function]
   791   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   791   C1579433:Insulin [Pharmacologic Substance]
   735 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   720 E C0332325:Resistant [Functional Concept]
   720 E C1550464:resistent [Idea or Concept]
   720 E C2827757:RESISTANT [Laboratory or Test Result]
   708 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(6,"

Phrase: "7,"

Phrase: "14,"

Phrase: "19,"

Phrase: "24,"

Phrase: "28,"

Phrase: "36"

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "the effect on insulin secretion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "is"

Phrase: "unclear."
Processing 00000000.tx.18: Dual agonists of PPAR and -, KRP-297 (12, 25, 26) and JTT-501 (34), have been developed, and their utility for diabetes and/or metabolic syndrome has been suggested. 

Phrase: "Dual agonists of PPAR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0243192:agonists [Pharmacologic Substance]
   748   C2987634:agonists [Pharmacologic Substance]

Phrase: "and -"

Phrase: ","

Phrase: "KRP-297"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0760735:KRP 297 [Organic Chemical]
   861   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1706585:KRP [Gene or Genome]
   861   C1833135:KRP [Gene or Genome]

Phrase: "(12,"

Phrase: "25,"

Phrase: "26"

Phrase: ")"

Phrase: "and"

Phrase: "JTT-501"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0675074:JTT 501 [Organic Chemical,Pharmacologic Substance]

Phrase: "(34"

Phrase: ")"

Phrase: ","

Phrase: "have"

Phrase: "been"

Phrase: "developed"

Phrase: ","

Phrase: "and"

Phrase: "their utility for diabetes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0582205:utility [Organization]

Phrase: "and/or"

Phrase: "metabolic syndrome"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0524620:Metabolic syndrome [Disease or Syndrome]
   861   C0039082:Syndrome [Disease or Syndrome]
   861   C0311400:Metabolic [Functional Concept]
   861   C1524026:Metabolic [Cell Function]
   861   C2707259:Metabolic [Clinical Attribute]

Phrase: "has"

Phrase: "been"

Phrase: "suggested."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]
Processing 00000000.tx.19: However, studies of combination therapy with a PPAR agonist and a PPAR agonist are rare (2, 21), and their effect on insulin secretion has not been reported. 

Phrase: "However,"

Phrase: "studies of combination therapy"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   833   C0009429:Combination Therapy [Therapeutic or Preventive Procedure]
   833   C0556895:Combination therapy [Therapeutic or Preventive Procedure]
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C0205195:Combination [Qualitative Concept]
   770   C0557651:Study [Manufactured Object]
   770   C0947630:studies [Laboratory Procedure]
   770   C1363945:Therapy [Finding]
   770   C1947911:Combination [Physical Object]
   770   C2603343:Study [Research Activity]

Phrase: "with a PPAR agonist"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C2987634:Agonist [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "and"

Phrase: "a PPAR agonist"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C2987634:Agonist [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "are"

Phrase: "rare"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521114:Rare [Temporal Concept]
  1000   C0522498:Rare [Qualitative Concept]
  1000   C1514917:RARE [Gene or Genome]

Phrase: "(2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "21"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "their effect on insulin secretion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "has"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "reported."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]
Processing 00000000.tx.20: We hypothesized that combination therapy with PPAR and - agonists would be useful for reducing lipotoxicity (10, 20, 37) in type 2diabetes with obesity by augmenting the lipid-lowering effects. 

Phrase: "We"

Phrase: "hypothesized"

Phrase: "that combination therapy with PPAR"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0009429:Combination Therapy [Therapeutic or Preventive Procedure]
   770   C0556895:Combination therapy [Therapeutic or Preventive Procedure]
   744   C0039798:therapy [Functional Concept]
   744   C0087111:Therapy [Therapeutic or Preventive Procedure]
   744   C1363945:Therapy [Finding]

Phrase: "and -"

Phrase: "agonists"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0243192:agonists [Pharmacologic Substance]
  1000   C2987634:agonists [Pharmacologic Substance]

Phrase: "would"

Phrase: "be"

Phrase: "useful for reducing lipotoxicity"

Phrase: "(10,"

Phrase: "20,"

Phrase: "37"

Phrase: ")"

Phrase: "in type 2diabetes"

Phrase: "with obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "by augmenting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0205217:augment [Quantitative Concept]

Phrase: "the lipid-lowering effects."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C1280500:effects [Qualitative Concept]
   793 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.21: We used the PPAR agonist pioglitazone (PIO), combination therapy with the PPAR agonist PIO and the PPAR agonist bezabibrate (P+B), and a dual agonist of PPAR and -, KRP-297, in male C57BL/6J mice and male db/db mice as a model of type 2diabetes with obesity. 

Phrase: "We"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the PPAR agonist pioglitazone (PIO),"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   799   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "combination therapy with the PPAR agonist PIO"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0009429:Combination Therapy [Therapeutic or Preventive Procedure]
   760   C0556895:Combination therapy [Therapeutic or Preventive Procedure]
   739   C0039798:therapy [Functional Concept]
   739   C0087111:Therapy [Therapeutic or Preventive Procedure]
   739   C1363945:Therapy [Finding]

Phrase: "and"

Phrase: "the PPAR agonist bezabibrate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   734   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "(P+B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "a dual agonist of PPAR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C2987634:Agonist [Pharmacologic Substance]

Phrase: "and -"

Phrase: ","

Phrase: "KRP-297,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0760735:KRP 297 [Organic Chemical]
   861   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1706585:KRP [Gene or Genome]
   861   C1833135:KRP [Gene or Genome]

Phrase: "in male C57BL/6J mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   875   C0025921:Mice, C57BL [Mammal]
   812   C0025914:Mice [Mammal]
   812   C0025929:mice [Mammal]
   812   C0026809:Mice [Mammal]

Phrase: "and"

Phrase: "male db/db mice as a model of type 2diabetes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   741   C2986594:Mouse Model [Experimental Model of Disease]
   739   C0025914:Mice [Mammal]
   739   C0025929:mice [Mammal]
   739   C0026809:Mice [Mammal]

Phrase: "with obesity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]
Processing 00000000.tx.22: We measured body weight, food and water intake, and metabolic parameters, and we investigated the effects on the pancreas by determining GSIS with in situ pancreatic perfusion and also by histopathological examination.  

Phrase: "We"

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "body weight,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0005910:Body Weight [Organism Attribute]
           weight
  1000   C1305866:body weight [Diagnostic Procedure]
           weight
   861   C0043100:Weight [Quantitative Concept]
   861   C0242821:body [Human]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1705104:Weight [Idea or Concept]
   777 E C1995017:Bodies [Cell Component]

Phrase: "food"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016452:Food [Food]

Phrase: "and"

Phrase: "water intake,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013123:Water Intake [Organism Function]
   861   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   861   C0599638:WATER [Substance]
   861   C1512806:Intake [Functional Concept]
   861   C1550678:Water [Inorganic Chemical]
   789 E C0443350:Watery [Qualitative Concept]

Phrase: "and"

Phrase: "metabolic parameters,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0449381:Parameters [Finding]
   827 E C0549193:Parameter [Spatial Concept]
   827 E C1704769:Parameter [Conceptual Entity]
   827 E C2350001:Parameter [Quantitative Concept]

Phrase: "and"

Phrase: "we"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "the effects on the pancreas"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "by determining GSIS"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   853   C1719133:Glucose/Insulin [Quantitative Concept]
   840   C1256369:insulin secretion [Cell Function]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0036536:secretion [Biologic Function]
   804   C0036537:Secretion [Body Substance]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "with in situ pancreatic perfusion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   923   C0031006:In situ perfusion [Therapeutic or Preventive Procedure]
   812   C0031001:Perfusion [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "also by histopathological examination."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   783   C0677043:Histopathologic Examination [Biomedical Occupation or Discipline]
Processing 00000000.tx.23: MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Materials. 

Phrase: "MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS TOP ABSTRACT INTRODUCTION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Materials."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520510:Materials [Substance]
Processing 00000000.tx.24: Pioglitazone, bezafibrate, and KRP-297 were donated by Takeda (Osaka, Japan), Kissei (Matsumoto, Japan), and Kyorin Pharmaceuticals (Tokyo, Japan), respectively. 

Phrase: "Pioglitazone,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "bezafibrate,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "KRP-297"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0760735:KRP 297 [Organic Chemical]
   861   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1706585:KRP [Gene or Genome]
   861   C1833135:KRP [Gene or Genome]

Phrase: "were"

Phrase: "donated by Takeda"

Phrase: "(Osaka,"

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")"

Phrase: ","

Phrase: "Kissei"

Phrase: "(Matsumoto,"

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "Kyorin Pharmaceuticals"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1135440:Pharmaceuticals [Therapeutic or Preventive Procedure]
   861   C1254351:Pharmaceuticals [Pharmacologic Substance]
   827 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]

Phrase: "(Tokyo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")"

Phrase: ","

Phrase: "respectively."
Processing 00000000.tx.25: Normal chow, CE-2, was purchased from Japan Clea (Tokyo, Japan). 

Phrase: "Normal chow,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0324335:chow [Mammal]

Phrase: "CE-2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1413348:CE-2 [Gene or Genome]
   861   C2827664:CE [Idea or Concept]

Phrase: "was"

Phrase: "purchased from Japan Clea"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0022341:Japan [Geographic Area]
   770   C0869011:purchased [Activity]

Phrase: "(Tokyo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")."
Processing 00000000.tx.26: Pioglitazone, P+B, and KRP-297 were each blended with CE-2 by use of 0.1% carboxymethylcellulose. 

Phrase: "Pioglitazone,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "P+B,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "KRP-297"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0760735:KRP 297 [Organic Chemical]
   861   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1706585:KRP [Gene or Genome]
   861   C1833135:KRP [Gene or Genome]

Phrase: "were"

Phrase: "each"

Phrase: "blended with CE-2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1413348:CE-2 [Gene or Genome]
   770   C0678946:blended [Human-caused Phenomenon or Process]
   770   C2827664:CE [Idea or Concept]

Phrase: "by use"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "of 0.1% carboxymethylcellulose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0007068:Carboxymethyl Cellulose [Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.27: Animals. 

Phrase: "Animals."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]
Processing 00000000.tx.28: Five-week-old male C57BL/6J mice and male db/db mice were purchased from Japan Clea. 

Phrase: "Five-week-old male C57BL/6J mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   829   C0025921:Mice, C57BL [Mammal]
   795   C0025914:Mice [Mammal]
   795   C0025929:mice [Mammal]
   795   C0026809:Mice [Mammal]

Phrase: "and"

Phrase: "male db/db mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0025914:Mice [Mammal]
   812   C0025929:mice [Mammal]
   812   C0026809:Mice [Mammal]

Phrase: "were"

Phrase: "purchased from Japan Clea."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0022341:Japan [Geographic Area]
   770   C0869011:purchased [Activity]
Processing 00000000.tx.29: Our institution's guidelines for the care and use of laboratory animals were followed. 

Phrase: "Our institution's guidelines for the care"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0162791:Guidelines [Intellectual Product]
   753   C0220845:guidelines [Intellectual Product]
   753   C0282423:guidelines [Intellectual Product]

Phrase: "and"

Phrase: "use of laboratory animals"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C1524063:Use of [Functional Concept]
   770   C0042153:use [Functional Concept]
   770   C0457083:Use [Functional Concept]
   770   C1947944:Use [Intellectual Product]

Phrase: "were"

Phrase: "followed."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0332283:followed [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]
Processing 00000000.tx.30: Both mouse strains were fed CE-2 control chow and water ad libitum for 1wk and each of the following drug-blended chow and water ad libitum for the following 4wk: PIO [C57BL/6J: 0.02% (wt/wt), 31.30.3mg kg1 day1; 

Phrase: "Both mouse strains"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C1513684:Mouse Strains [Mammal]
   861   C0080194:Strains [Injury or Poisoning]
   861   C0456178:strains [Intellectual Product]
   827 E C1518614:Strain [Organism]
   827 E C2987481:Strain [Mental Process]

Phrase: "were"

Phrase: "fed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0342895:FED [Disease or Syndrome]
   966 E C0204695:Feed [Health Care Activity]
   966 E C2987508:Feed [Activity]

Phrase: "CE-2 control chow"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0324335:chow [Mammal]

Phrase: "and"

Phrase: "water"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
  1000   C0599638:WATER [Substance]
  1000   C1550678:Water [Inorganic Chemical]
   928 E C0443350:Watery [Qualitative Concept]

Phrase: "ad libitum for 1wk"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C1879743:ad libitum [Qualitative Concept]

Phrase: "and"

Phrase: "each of the following drug-blended chow"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0013227:Drug [Pharmacologic Substance]
   748   C0324335:chow [Mammal]
   748   C0678946:blended [Human-caused Phenomenon or Process]
   748   C1254351:Drug [Pharmacologic Substance]
   748   C1457900:Each [Quantitative Concept]
   714   C0332283:follow [Temporal Concept]
   714   C1719822:Follow [Intellectual Product]

Phrase: "and"

Phrase: "water"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
  1000   C0599638:WATER [Substance]
  1000   C1550678:Water [Inorganic Chemical]
   928 E C0443350:Watery [Qualitative Concept]

Phrase: "ad libitum for the following 4wk"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1879743:ad libitum [Qualitative Concept]

Phrase: ":"

Phrase: "PIO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "[C57BL/6J"

Phrase: ":"

Phrase: "0.02%"

Phrase: "(wt/wt), 31.30.3mg kg1 day1"

Phrase: ";"
Processing 00000000.tx.31: db/db: 0.02% (wt/wt), 34.20.4mg kg1 day1], P+B [C57BL/6J: 0.02% (wt/wt), 29.20.5mg kg1 day1; 

Phrase: "db/db"

Phrase: ":"

Phrase: "0.02%"

Phrase: "(wt/wt), 34.20.4mg kg1 day1"

Phrase: "],"

Phrase: "P+B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "[C57BL/6J"

Phrase: ":"

Phrase: "0.02%"

Phrase: "(wt/wt), 29.20.5mg kg1 day1"

Phrase: ";"
Processing 00000000.tx.32: db/db: 0.02% (wt/wt), 33.30.4mg kg1 day1]+[C57BL/6J: 0.06% (wt/wt), 97.31.5mg kg1 day1; 

Phrase: "db/db"

Phrase: ":"

Phrase: "0.02%"

Phrase: "(wt/wt), 33.30.4mg kg1 day1"

Phrase: "]+"

Phrase: "[C57BL/6J"

Phrase: ":"

Phrase: "0.06%"

Phrase: "(wt/wt), 97.31.5mg kg1 day1"

Phrase: ";"
Processing 00000000.tx.33: db/db: 0.07% (wt/wt) 111.01.5mg kg1 day1], and KRP-297 [C57BL/6J: 0.02% (wt/wt), 30.20.3mg kg1 day1; 

Phrase: "db/db"

Phrase: ":"

Phrase: "0.07%"

Phrase: "(wt/wt) 111.01.5mg kg1 day1"

Phrase: "],"

Phrase: "and"

Phrase: "KRP-297"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0760735:KRP 297 [Organic Chemical]
   861   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   861   C1706585:KRP [Gene or Genome]
   861   C1833135:KRP [Gene or Genome]

Phrase: "[C57BL/6J"

Phrase: ":"

Phrase: "0.02%"

Phrase: "(wt/wt), 30.20.3mg kg1 day1"

Phrase: ";"
Processing 00000000.tx.34: db/db: 0.02% (wt/wt), 32.20.4mg kg1 day1]. 

Phrase: "db/db"

Phrase: ":"

Phrase: "0.02%"

Phrase: "(wt/wt), 32.20.4mg kg1 day1"

Phrase: "]."
Processing 00000000.tx.35: Food intake, water intake, and body weight of all mice were measured in the morning 3to 4times/wk. 

Phrase: "Food intake,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013470:Food Intake [Organism Function]
   861   C1512806:Intake [Functional Concept]

Phrase: "water intake,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0013123:Water Intake [Organism Function]
   861   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   861   C0599638:WATER [Substance]
   861   C1512806:Intake [Functional Concept]
   861   C1550678:Water [Inorganic Chemical]
   789 E C0443350:Watery [Qualitative Concept]

Phrase: "and"

Phrase: "body weight of all mice"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   806   C0005910:Body Weight [Organism Attribute]
           weight
   806   C1305866:body weight [Diagnostic Procedure]
           weight
   760   C0043100:Weight [Quantitative Concept]
   760   C0242821:body [Human]
   760   C0460148:Body [Anatomical Structure]
   760   C1268086:Body [Anatomical Structure]
   760   C1705104:Weight [Idea or Concept]

Phrase: "were"

Phrase: "measured in the morning 3to 4times/wk."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   748   C0332170:Morning [Temporal Concept]
   748   C0332174:/wk [Temporal Concept]
   748   C0439230:wk [Temporal Concept]
   748   C0444706:Measured [Qualitative Concept]
   748   C3541902:MEASURED [Diagnostic Procedure]
   714 E C0079809:Measure [Quantitative Concept]
   714 E C0242485:Measure [Functional Concept]
Processing 00000000.tx.36: Mice were fasted overnight and underwent operation for in situ pancreatic perfusion. 

Phrase: "Mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "were"

Phrase: "fasted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0015663:Fast [Finding]
   966   C0456962:Fast [Qualitative Concept]

Phrase: "overnight"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439583:Overnight [Temporal Concept]

Phrase: "and"

Phrase: "underwent"

Phrase: "operation for in situ pancreatic perfusion."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0543467:Operation [Health Care Activity]
   753   C3241922:Operation [Activity]
Processing 00000000.tx.37: Measurement of metabolic parameters in plasma. 

Phrase: "Measurement of metabolic parameters"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0242485:Measurement [Functional Concept]

Phrase: "in plasma."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032105:Plasma [Body Substance]
  1000   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
Processing 00000000.tx.38: Blood from the retroorbital sinus of 10-wk-old mice in a nonfasting state was collected into hematocrit tubes coated with EDTA. 

Phrase: "Blood from the retroorbital sinus of 10-wk-old mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   741   C1511225:Mouse Blood [Tissue]
   739   C0005767:Blood [Tissue]
   739   C0005768:blood [Body Substance]
   739   C0229664:Blood [Body Substance]

Phrase: "in a nonfasting state"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1301808:State [Geographic Area]
   861   C1442792:State [Functional Concept]
   861   C3148680:State [Geographic Area]

Phrase: "was"

Phrase: "collected into hematocrit tubes"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   770   C0018935:Haematocrit [Laboratory Procedure]
   770   C0175730:tubes [Medical Device]
   770   C0518014:Haematocrit [Laboratory or Test Result]
   770   C1516695:Collected [Idea or Concept]
   770   C1516698:Collected [Functional Concept]
   770   C1547937:Tubes [Intellectual Product]
   770   C1704474:Tubes [Quantitative Concept]
   737 E C1561954:tube [Conceptual Entity]
   737 E C1704730:TUBE [Medical Device]

Phrase: "coated with EDTA."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0013618:EDTA [Organic Chemical,Pharmacologic Substance]
   790   C1522408:Coated [Qualitative Concept]
   756 E C0453946:Coat [Manufactured Object]
   756 E C2987482:Coat [Body Part, Organ, or Organ Component]
Processing 00000000.tx.39: Plasma glucose and triglycerides were determined with a Fuji Dry-Chem 5500(Fuji Film, Tokyo, Japan). 

Phrase: "Plasma glucose"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0202042:Plasma glucose [Laboratory Procedure]
  1000   C0455280:plasma glucose [Laboratory or Test Result]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   861   C0032105:Plasma [Body Substance]
   861   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "and"

Phrase: "triglycerides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041004:Triglycerides [Biologically Active Substance,Lipid]

Phrase: "were"

Phrase: "determined with a Fuji"

Phrase: "Dry-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011682:Dry [Natural Phenomenon or Process]
  1000   C0205222:Dry [Qualitative Concept]
  1000   C1512080:Dry [Qualitative Concept]

Phrase: "Chem 5500"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0201682:CHEM [Laboratory Procedure]

Phrase: "(Fuji Film,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0086296:Film [Manufactured Object]
   861   C1561571:film [Biomedical or Dental Material]
   861   C1561572:film [Substance]

Phrase: "Tokyo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")."
Processing 00000000.tx.40: Plasma nonesterified fatty acid (NEFA) concentration was determined by the NEFA-C test (Wako Pure Chemical Industries, Osaka, Japan). 

Phrase: "Plasma nonesterified fatty acid (NEFA) concentration"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   897   C0683150:plasma concentration [Quantitative Concept]
   804   C0086045:Concentration [Mental Process]
   804   C1446561:Concentration [Quantitative Concept]
   733 E C1880165:Concentrated [Biomedical or Dental Material]
   717   C0015688:Non-esterified fatty acid [Lipid]

Phrase: "was"

Phrase: "determined by the NEFA-C test"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   800   C0015688:Non-esterified fatty acid [Lipid]
   770   C0015684:Fatty acid [Lipid]
   744   C0001128:Acid [Chemical]
   744   C0022885:Test [Laboratory Procedure]
   744   C0039593:Test [Functional Concept]
   744   C0202406:Acid [Laboratory Procedure]
   744   C0392366:test [Intellectual Product]

Phrase: "(Wako Pure Chemical Industries,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0007983:Industries, Chemical [Organization]
   812   C0021267:Industries [Occupational Activity]

Phrase: "Osaka,"

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")."
Processing 00000000.tx.41: Plasma insulin concentration was determined by enzyme immunoassay (EIA; Morinaga Institute of Biological Science, Yokohama, Japan). 

Phrase: "Plasma insulin concentration"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   913   C0683150:plasma concentration [Quantitative Concept]
   827   C0086045:Concentration [Mental Process]
   827   C1446561:Concentration [Quantitative Concept]
   755 E C1880165:Concentrated [Biomedical or Dental Material]
   734   C0857690:plasma insulin [Laboratory Procedure]

Phrase: "was"

Phrase: "determined by enzyme immunoassay"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0086231:Enzyme Immunoassay [Laboratory Procedure]
   770   C0014442:Enzyme [Enzyme,Organic Chemical]
   770   C0020980:Immunoassay [Laboratory Procedure]
   770   C0021060:immunoassay [Laboratory Procedure]

Phrase: "(EIA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0014661:EIA [Disease or Syndrome]
  1000   C0086231:EIA [Laboratory Procedure]

Phrase: "; Morinaga Institute of Biological Science,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021622:institute [Organization]
   760   C1272753:Institute [Idea or Concept]

Phrase: "Yokohama,"

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")."
Processing 00000000.tx.42: Pancreatic insulin content. 

Phrase: "Pancreatic insulin content."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   827   C0423896:Content [Mental Process]
   827   C0456205:Content [Conceptual Entity]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.43: Each pancreatic specimen was homogenized in 1.8ml of acid ethanol. 

Phrase: "Each pancreatic specimen"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0370003:Specimen [Substance]
   861   C2347026:Specimen [Conceptual Entity]

Phrase: "was"

Phrase: "homogenized in 1.8ml of acid ethanol."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0001128:Acid [Chemical]
   748   C0001962:Ethanol [Organic Chemical]
   748   C0202406:Acid [Laboratory Procedure]
Processing 00000000.tx.44: The homogenates were stored at 4C for 48h and then centrifuged at 10,000rpm for 10min at 4C. 

Phrase: "The homogenates"

Phrase: "were"

Phrase: "stored at 4C"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0450376:4c [Intellectual Product]
   756   C1698986:Store [Functional Concept]

Phrase: "for 48h"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442464:48H [Temporal Concept]

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "centrifuged at 10,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C0179834:centrifuge [Medical Device]

Phrase: "000rpm for 10min"

Phrase: "at 4C."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450376:4c [Intellectual Product]
Processing 00000000.tx.45: The supernatants were pooled, and the pellets were then resuspended in 0.2ml of acid ethanol. 

Phrase: "The supernatants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1550101:Supernatant [Body Substance]

Phrase: "were"

Phrase: "pooled"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1709595:Pooled [Conceptual Entity]
  1000   C2349200:Pooled [Functional Concept]
   966 E C0337051:Pool [Geographic Area]
   966 E C1509144:pool [Clinical Attribute]

Phrase: ","

Phrase: "and"

Phrase: "the pellets"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0993610:pellets [Biomedical or Dental Material]
   966 E C0441436:Pellet [Manufactured Object]
   966 E C1998480:Pellet [Quantitative Concept]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "resuspended in 0.2ml of acid ethanol."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0001128:Acid [Chemical]
   748   C0001962:Ethanol [Organic Chemical]
   748   C0202406:Acid [Laboratory Procedure]
Processing 00000000.tx.46: After centrifugation, the supernatants were diluted 1:10,000 in 0.1M PBS containing 0.25% BSA. 

Phrase: "After centrifugation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0007703:Centrifugation [Laboratory Procedure]

Phrase: "the supernatants"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1550101:Supernatant [Body Substance]

Phrase: "were"

Phrase: "diluted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1720119:Dilute [Functional Concept]
   966   C1948037:Dilute [Functional Concept]

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "10,000 in 0.1M PBS"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0470296:1M [Quantitative Concept]
   753   C1720830:PBS [Disease or Syndrome]
   753   C1823521:PBS [Gene or Genome]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "0.25% BSA."
Processing 00000000.tx.47: Insulin concentration was determined by EIA. 

Phrase: "Insulin concentration"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "was"

Phrase: "determined by EIA."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0014661:EIA [Disease or Syndrome]
   790   C0086231:EIA [Laboratory Procedure]
Processing 00000000.tx.48: In situ pancreatic perfusion. 

Phrase: "In situ pancreatic perfusion."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   923   C0031006:In situ perfusion [Therapeutic or Preventive Procedure]
   812   C0031001:Perfusion [Therapeutic or Preventive Procedure]
Processing 00000000.tx.49: The mice were anesthetized with 50mg/kg pentobarbital sodium after an overnight fast. 

Phrase: "The mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "were"

Phrase: "anesthetized with 50mg/kg pentobarbital sodium"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0700349:Pentobarbital Sodium [Organic Chemical,Pharmacologic Substance]
   753   C0022718:KG [Geographic Area]
   753   C0030883:Pentobarbital [Organic Chemical,Pharmacologic Substance]
   753   C0037473:Sodium [Biologically Active Substance,Element, Ion, or Isotope]
   753   C0439209:kg [Quantitative Concept]
   753   C0597484:Sodium+ [Element, Ion, or Isotope,Pharmacologic Substance]
   753   C1720436:Anesthetized [Finding]

Phrase: "after an overnight fast."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0015663:Fast [Finding]
   861   C0456962:Fast [Qualitative Concept]
Processing 00000000.tx.50: The celiac artery and portal vein were cannulated after other vessels had been ligated. 

Phrase: "The celiac artery"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0007569:Celiac Artery [Body Part, Organ, or Organ Component]
  1000   C1268965:Celiac artery [Body Part, Organ, or Organ Component]
   861   C0003842:Artery [Body Part, Organ, or Organ Component]
   861   C0226004:artery [Body System]
   789 E C0221464:Arterial [Spatial Concept]

Phrase: "and"

Phrase: "portal vein"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0032718:Portal Vein [Body Part, Organ, or Organ Component]
  1000   C0226735:Portal vein [Body Part, Organ, or Organ Component]
  1000   C1281393:Portal vein [Body Part, Organ, or Organ Component]
  1000   C1305775:Portal vein [Body Part, Organ, or Organ Component]
   861   C0042449:Vein [Body Part, Organ, or Organ Component]
   861   C0205054:Portal [Body Location or Region]
   861   C1278960:Vein [Body Part, Organ, or Organ Component]

Phrase: "were"

Phrase: "cannulated after other vessels"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0005847:Vessels [Body Part, Organ, or Organ Component]
   737 E C1511228:Vessel [Tissue]

Phrase: "had"

Phrase: "been"

Phrase: "ligated."
Processing 00000000.tx.51: Nonrecirculating perfusion was begun at a constant flow rate of 0.5ml/min. 

Phrase: "Nonrecirculating perfusion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0031001:Perfusion [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "begun at a constant flow rate of 0.5ml/min."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C2826285:Flow Rate [Quantitative Concept]
   757   C2986811:Rate Constant [Quantitative Concept]
   739   C0702093:/min [Temporal Concept]
   739   C0806140:Flow [Natural Phenomenon or Process]
   739   C0871208:Rate [Activity]
   739   C1521828:Rate [Quantitative Concept]
   739   C1547014:*Constant [Quantitative Concept]
   739   C1948059:Constant [Qualitative Concept]
   706   C0439659:Begin [Temporal Concept]
Processing 00000000.tx.52: The perfusion medium consisted of Krebs-Ringer bicarbonate buffer containing 3.0% (wt/vol) dextran T-40 (Pharmacia, Uppsala, Sweden), 1.0% (wt/vol) BSA (fraction V, RIA grade; Sigma Chemical, St. Louis, MO), and 20mM HEPES. 

Phrase: "The perfusion medium"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0009458:Medium [Intellectual Product]
   861   C0439536:Medium [Quantitative Concept]
   861   C1705217:Medium [Substance]
   861   C3244283:medium [Intellectual Product]

Phrase: "consisted of Krebs-Ringer bicarbonate buffer"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0005367:Bicarbonate [Inorganic Chemical,Pharmacologic Substance]
   753   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   753   C0973231:Bicarbonate [Inorganic Chemical]
   753   C1875730:RINGER'S [Organic Chemical,Pharmacologic Substance]
   753   C2722820:BICARBONATE [Organic Chemical,Pharmacologic Substance]
   719   C0332529:CONSIST [Qualitative Concept]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "3.0%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439086:<3 [Quantitative Concept]
   861   C2827736:3+ [Quantitative Concept]
   861   C2981702:3+ [Classification]

Phrase: "(wt/vol) dextran T-40"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   884   C0011803:Dextran T-40 [Carbohydrate,Pharmacologic Substance]
   853   C0011793:Dextran 40 [Carbohydrate,Pharmacologic Substance]
   804   C0086140:Dextran [Carbohydrate,Pharmacologic Substance]
   804   C0439509:/40 [Temporal Concept]

Phrase: "(Pharmacia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0331955:Pharmacia [Health Care Related Organization]

Phrase: "Uppsala,"

Phrase: "Sweden"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038995:Sweden [Geographic Area]

Phrase: ")"

Phrase: ","

Phrase: "1.0%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: "(wt/vol) BSA (fraction V,"

Phrase: "RIA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034580:RIA [Laboratory Procedure]

Phrase: "grade"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441800:Grade [Classification]
  1000   C0919553:Grade [Classification]
  1000   C3244287:grade [Finding]

Phrase: "; Sigma Chemical, St. Louis,"

Phrase: "MO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538743:MO [Idea or Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "20mM HEPES."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0019215:HEPES [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
Processing 00000000.tx.53: A 95% O2-5% CO2 gas mixture was bubbled through the perfusate, and pH was maintained between 7.35and 7.45.

Phrase: "A 95% O2-5% CO2 gas mixture"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0581444:Gas mixture [Chemical Viewed Structurally]
   799   C0439962:Mixture [Substance]

Phrase: "was"

Phrase: "bubbled through the perfusate,"

Phrase: "and"

Phrase: "pH"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0020283:[pH] [Quantitative Concept]
  1000   C0450407:ph+ [Finding]
  1000   C0450408:ph++ [Finding]
  1000   C0450409:ph+++ [Finding]

Phrase: "was"

Phrase: "maintained between 7.35and 7.45."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1314677:Maintained [Functional Concept]
   719 E C0024501:Maintain [Activity]
Processing 00000000.tx.54: The pancreatic venous effluent was collected into tubes via a catheter in the portal vein at 2-min intervals, frozen immediately, and stored at 20C for subsequent EIA. 

Phrase: "The pancreatic venous effluent"

Phrase: "was"

Phrase: "collected into tubes"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   790   C0175730:tubes [Medical Device]
   790   C1516695:Collected [Idea or Concept]
   790   C1516698:Collected [Functional Concept]
   790   C1547937:Tubes [Intellectual Product]
   790   C1704474:Tubes [Quantitative Concept]
   756 E C1561954:tube [Conceptual Entity]
   756 E C1704730:TUBE [Medical Device]

Phrase: "via a catheter"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0085590:Catheter [Medical Device]
  1000   C1704454:Catheter [Medical Device]

Phrase: "in the portal vein at 2-min intervals,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   799   C1272706:intervals [Temporal Concept]
   766 E C1552654:Interval [Idea or Concept]
   766 E C1552713:Interval [Intellectual Product]

Phrase: "frozen"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0016701:Frozen [Natural Phenomenon or Process]
  1000   C0677542:Frozen [Functional Concept]

Phrase: "immediately,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205548:Immediately [Temporal Concept]

Phrase: "and"

Phrase: "stored at 20C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1698986:Store [Functional Concept]

Phrase: "for subsequent EIA."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014661:EIA [Disease or Syndrome]
   861   C0086231:EIA [Laboratory Procedure]
Processing 00000000.tx.55: To achieve postoperative equilibration, the pancreas was perfused for 15min with a buffer containing the glucose concentration of the initial 10-min experimental period (5.6mM). 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "achieve"

Phrase: "postoperative equilibration,"

Phrase: "the pancreas"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0030274:Pancreas [Body Part, Organ, or Organ Component]
  1000   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "was"

Phrase: "perfused for 15min"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1549542:Perfuse [Functional Concept]

Phrase: "with a buffer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "the glucose concentration of the initial 10-min experimental period"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0427743:Glucose concentration [Laboratory Procedure]
   760   C1287281:Glucose concentration [Laboratory or Test Result]
   757   C2827826:Initial Concentration [Quantitative Concept]
   739   C0086045:Concentration [Mental Process]
   739   C1446561:Concentration [Quantitative Concept]

Phrase: "(5.6mM"

Phrase: ")."
Processing 00000000.tx.56: Thereafter, insulin response to a high-glucose concentration (16.7mM) was examined for 20min, and glucose concentration was then returned to 5.6mM for another 20min. 

Phrase: "Thereafter,"

Phrase: "insulin response to a high-glucose concentration"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0871261:Response [Organism Attribute]
   748   C1704632:Response [Finding]
   748   C1706817:Response [Intellectual Product]
   748   C2911692:Response [Mental Process]

Phrase: "(16.7mM"

Phrase: ")"

Phrase: "was"

Phrase: "examined for 20min,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0332128:Examined [Finding]

Phrase: "and"

Phrase: "glucose concentration"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0427743:Glucose concentration [Laboratory Procedure]
  1000   C1287281:Glucose concentration [Laboratory or Test Result]
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "was"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "returned to 5.6mM"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   816   C0332156:Return to [Qualitative Concept]
           Return

Phrase: "for another 20min."
Processing 00000000.tx.57: Histopathological examination. 

Phrase: "Histopathological examination."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   950   C0677043:Histopathologic Examination [Biomedical Occupation or Discipline]
Processing 00000000.tx.58: Pancreata from mice in all groups that were not operated on for in situ pancreatic perfusion were fixed in 35-38% Formalin for histopathological studies. 

Phrase: "Pancreata from mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   824   C1518865:Mouse Pancreas [Tissue]
   756   C0030274:Pancreas [Body Part, Organ, or Organ Component]
   756   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "in all"

Phrase: "groups"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0441833:Group [Idea or Concept]
  1000   C0687744:group [Population Group]
  1000   C1257890:Group [Population Group]
  1000   C1552516:Group [Health Care Related Organization]
  1000   C1552839:groups [Idea or Concept]
  1000   C1705428:Group [Conceptual Entity]
  1000   C1705429:Group [Population Group]

Phrase: "that"

Phrase: "were"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "operated on"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C3242339:operate [Functional Concept]

Phrase: "for in situ pancreatic perfusion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   923   C0031006:In situ perfusion [Therapeutic or Preventive Procedure]
   812   C0031001:Perfusion [Therapeutic or Preventive Procedure]

Phrase: "were"

Phrase: "fixed in 35-38% Formalin"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0231441:Fixed [Finding]
   760   C0443218:Fixed [Qualitative Concept]
   760   C0949307:Formalin [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]
   760   C2827483:Fixed [Body Substance]

Phrase: "for histopathological studies."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   933   C0677043:Histopathologic Study [Biomedical Occupation or Discipline]
           Histopathology
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]
   789   C0243140:histopathology [Functional Concept]
Processing 00000000.tx.59: The pancreata were embedded in paraffin, sectioned, and then stained with hematoxylin and eosin (H+E). 

Phrase: "The pancreata"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0030274:Pancreas [Body Part, Organ, or Organ Component]
   966   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "were"

Phrase: "embedded in paraffin,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   858   C0085185:embedded paraffin [Laboratory Procedure]
   790   C0030415:Paraffin [Biomedical or Dental Material,Lipid]
   790   C1707903:Embedded [Laboratory Procedure]

Phrase: "sectioned"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0205155:Section [Spatial Concept]
   966   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   966   C1522472:Section [Substance]
   966   C1552923:Section [Quantitative Concept]
   966   C1705191:Section [Physical Object]

Phrase: ","

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "stained with hematoxylin and eosin (H+E)."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   891   C0523207:Haematoxylin and eosin stain [Laboratory Procedure]
   781   C0018964:Haematoxylin stain [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
           Haematoxylin
   760   C0014448:Eosin [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   760   C0885297:eosin [Organic Chemical,Pharmacologic Substance]
   760   C2986582:Stained [Qualitative Concept]
   726 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]
Processing 00000000.tx.60: Immunohistochemical studies were also performed using anti-human insulin guinea pig antibodies (Oriental Yeast, Osaka, Japan) and rabbit anti-GLUT2 polyclonal antibody (Chemicon International, Temecula, CA). 

Phrase: "Immunohistochemical studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0947630:studies [Laboratory Procedure]
   861   C1441616:Immunohistochemical [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "were"

Phrase: "also"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "anti-human insulin guinea pig antibodies"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   911   C0487015:Anti-human insulin antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Human insulin antibody
   898   C0021644:anti insulin antibodies [Immunologic Factor]
           Insulin Antibodies
   895   C1624602:Anti-Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   878 E C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   799   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   766 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "(Oriental Yeast,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036025:yeast [Fungus]
   861   C0043392:Yeast [Food]
   861   C0043393:Yeast [Fungus]
   861   C0717551:YEAST [Immunologic Factor,Pharmacologic Substance]

Phrase: "Osaka,"

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")"

Phrase: "and"

Phrase: "rabbit anti-GLUT2 polyclonal antibody"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   897   C1979003:Rabbit Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   875   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   840   C0312586:Polyclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   804   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "(Chemicon International, Temecula,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1555271:Temecula [Population Group]

Phrase: "CA)."
Processing 00000000.tx.61: Statistical analyses. 

Phrase: "Statistical analyses."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   983   C0871424:statistical analysis [Research Activity]
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]
Processing 00000000.tx.62: All results were expressed as meansSE. 

Phrase: "All results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "were"

Phrase: "expressed as meansSE."
Processing 00000000.tx.63: Statistical analyses were performed with the Statview program (version 5.0-J, SAS Institute, Cary, NC). 

Phrase: "Statistical analyses"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   983   C0871424:statistical analysis [Research Activity]
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]

Phrase: "were"

Phrase: "performed with the Statview program"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0884358:Performed [Functional Concept]
   760   C1709697:Program [Conceptual Entity]
   760   C2728259:Program [Pharmacologic Substance]
   760   C3484370:Program [Functional Concept]
   726 E C2947996:Perform [Pharmacologic Substance]

Phrase: "(version 5.0-J,"

Phrase: "SAS Institute,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021622:institute [Organization]
   861   C1272753:Institute [Idea or Concept]

Phrase: "Cary,"

Phrase: "NC"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0027964:NC [Geographic Area]
  1000   C0028407:NC [Geographic Area]
  1000   C0067895:NC [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: ")."
Processing 00000000.tx.64: Analysis of variance (ANOVA), followed by a post hoc Bonferroni-Dunn multiple comparison test, was used to evaluate differences among groups. 

Phrase: "Analysis of variance (ANOVA),"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0002780:Analysis of Variance [Quantitative Concept]
           Variance Analysis
   790   C0002778:Analysis [Laboratory Procedure]
   790   C0936012:Analysis [Research Activity]
   790   C1524024:analysis [Functional Concept]

Phrase: "followed by a post hoc Bonferroni-Dunn multiple comparison test,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   760   C0332283:Followed by [Temporal Concept]
           followed
   739   C0022885:Test [Laboratory Procedure]
   739   C0039593:Test [Functional Concept]
   739   C0392366:test [Intellectual Product]
   739   C0439064:Multiple [Quantitative Concept]
   739   C0687676:Post [Temporal Concept]
   739   C1704687:Post [Manufactured Object]
   739   C1707455:Comparison [Activity]
   706 E C1719822:Follow [Intellectual Product]

Phrase: "was"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "evaluate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluate [Functional Concept]

Phrase: "differences among groups."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   756   C1705241:*Difference [Quantitative Concept]
   756   C1705242:Difference [Qualitative Concept]
   706 E C0443199:Differential [Qualitative Concept]
Processing 00000000.tx.65: A P value <0.05 was considered statistically significant.  

Phrase: "A P value"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1709380:P-Value [Quantitative Concept]
   827   C1522609:Value [Quantitative Concept]

Phrase: "<0.05"

Phrase: "was"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "statistically significant."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0237881:statistically significant [Quantitative Concept]
           significant
   928 E C1709380:Statistical Significance [Quantitative Concept]
   861   C0038215:Statistically [Occupation or Discipline]
   861   C0750502:Significant [Idea or Concept]
   861   C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.66: RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Body weight change, total food intake, and total water intake. 

Phrase: "RESULTS TOP ABSTRACT INTRODUCTION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Body weight change,"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
  1000   C0005911:Weight Change, Body [Finding]
           Weight change
   901   C0005910:Body Weight [Organism Attribute]
           weight
   901   C1305866:body weight [Diagnostic Procedure]
           weight
   827   C0043100:Weight [Quantitative Concept]
   827   C0242821:body [Human]
   827   C0392747:Change [Functional Concept]
   827   C0443172:change [Quantitative Concept]
   827   C0460148:Body [Anatomical Structure]
   827   C1268086:Body [Anatomical Structure]
   827   C1705104:Weight [Idea or Concept]
   827   C1705241:Change [Quantitative Concept]
   743 E C1995017:Bodies [Cell Component]

Phrase: "total food intake,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0013470:Food Intake [Organism Function]
   827   C1512806:Intake [Functional Concept]

Phrase: "and"

Phrase: "total water intake."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   901   C0013123:Water Intake [Organism Function]
   827   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   827   C0599638:WATER [Substance]
   827   C1512806:Intake [Functional Concept]
   827   C1550678:Water [Inorganic Chemical]
   755 E C0443350:Watery [Qualitative Concept]
Processing 00000000.tx.67: The body weight of animals in PPAR agonist-treated groups increased more than that of animals in the untreated group in both mouse strains (Table 1). 

Phrase: "The body weight of animals"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   806   C0005910:Body Weight [Organism Attribute]
           weight
   806   C1305866:body weight [Diagnostic Procedure]
           weight
   760   C0043100:Weight [Quantitative Concept]
   760   C0242821:body [Human]
   760   C0460148:Body [Anatomical Structure]
   760   C1268086:Body [Anatomical Structure]
   760   C1705104:Weight [Idea or Concept]

Phrase: "in PPAR agonist-treated groups"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   795   C0332293:treated [Therapeutic or Preventive Procedure]
   795   C0441833:Group [Idea or Concept]
   795   C0687744:group [Population Group]
   795   C1257890:Group [Population Group]
   795   C1522326:Treated [Functional Concept]
   795   C1552516:Group [Health Care Related Organization]
   795   C1552839:groups [Idea or Concept]
   795   C1705428:Group [Conceptual Entity]
   795   C1705429:Group [Population Group]
   762 E C1292734:TREAT [Functional Concept]
   710   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   710   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "more than that of animals"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0003062:Animals [Animal]
   760   C0205172:More [Functional Concept]

Phrase: "in the untreated group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "in both mouse strains"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C1513684:Mouse Strains [Mammal]
   861   C0080194:Strains [Injury or Poisoning]
   861   C0456178:strains [Intellectual Product]
   827 E C1518614:Strain [Organism]
   827 E C2987481:Strain [Mental Process]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.68: Body weight gain in the KRP-297-treated group was less than that in other treated groups in db/db mice, but not in C57BL/6J mice. 

Phrase: "Body weight gain in the KRP-297-treated group"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   790   C0043094:Body Weight Gain [Finding]
           Weight Gain
   790   C2986889:Body Weight Gain [Idea or Concept]
   764   C0005910:Body Weight [Organism Attribute]
           weight
   764   C1305866:body weight [Diagnostic Procedure]
           weight
   764   C2911647:Weight gain [Finding]
   742   C0043100:Weight [Quantitative Concept]
   742   C0242821:body [Human]
   742   C0460148:Body [Anatomical Structure]
   742   C1268086:Body [Anatomical Structure]
   742   C1517378:Gain [Quantitative Concept]
   742   C1705104:Weight [Idea or Concept]
   723 E C0231246:weight gaining [Sign or Symptom]

Phrase: "was"

Phrase: "less than that"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   882   C0439092:Less Than [Intellectual Product]
           less
   790   C0547044:Less [Qualitative Concept]

Phrase: "in other treated groups"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   861   C0332293:treated [Therapeutic or Preventive Procedure]
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1522326:Treated [Functional Concept]
   861   C1552516:Group [Health Care Related Organization]
   861   C1552839:groups [Idea or Concept]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]
   827 E C1292734:TREAT [Functional Concept]

Phrase: "in db/db mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "but"

Phrase: "not in C57BL/6J mice."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   797   C0025921:Mice, C57BL [Mammal]
           C57BL
   760   C0025914:Mice [Mammal]
   760   C0025929:mice [Mammal]
   760   C0026809:Mice [Mammal]
   760   C1518422:Not [Functional Concept]
Processing 00000000.tx.69: Total food intake in the PPAR agonist-treated groups was also significantly greater than that in the untreated group in C57BL/6J mice. 

Phrase: "Total food intake in the PPAR agonist-treated groups"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0013470:Food Intake [Organism Function]
   736   C1512806:Intake [Functional Concept]

Phrase: "was"

Phrase: "also significantly greater than that"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   806   C0439093:Greater Than [Quantitative Concept]
   760   C0443228:greater [Quantitative Concept]
   760   C1704243:Greater [Quantitative Concept]
   726 E C0549177:Great [Quantitative Concept]

Phrase: "in the untreated group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "in C57BL/6J mice."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0025921:Mice, C57BL [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]
Processing 00000000.tx.70: On the contrary, total food intake of the KRP-297-treated group was the smallest in db/db mice. 

Phrase: "On the contrary,"

Phrase: "total food intake of the KRP-297-treated group"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   764   C0013470:Food Intake [Organism Function]
   742   C1512806:Intake [Functional Concept]

Phrase: "was"

Phrase: "the smallest in db/db mice."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C2700395:Smallest [Quantitative Concept]
   719 E C0700321:Small [Quantitative Concept]
Processing 00000000.tx.71: The PPAR agonist-treated groups in C57BL/6J mice showed a mild increase in total water intake, whereas the untreated group in db/db mice showed a marked increase.  

Phrase: "The PPAR agonist-treated groups"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   795   C0332293:treated [Therapeutic or Preventive Procedure]
   795   C0441833:Group [Idea or Concept]
   795   C0687744:group [Population Group]
   795   C1257890:Group [Population Group]
   795   C1522326:Treated [Functional Concept]
   795   C1552516:Group [Health Care Related Organization]
   795   C1552839:groups [Idea or Concept]
   795   C1705428:Group [Conceptual Entity]
   795   C1705429:Group [Population Group]
   762 E C1292734:TREAT [Functional Concept]
   710   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   710   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "in C57BL/6J mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0025921:Mice, C57BL [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "a mild increase in total water intake,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0442805:Increase [Functional Concept]

Phrase: "whereas"

Phrase: "the untreated group in db/db mice"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0441833:Group [Idea or Concept]
   748   C0687744:group [Population Group]
   748   C1257890:Group [Population Group]
   748   C1552516:Group [Health Care Related Organization]
   748   C1705428:Group [Conceptual Entity]
   748   C1705429:Group [Population Group]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "a marked increase."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442805:Increase [Functional Concept]
Processing 00000000.tx.72: View this table: [in this window] [in a new window]  Table 1.  

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 1."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.73: Body weight change, total food intake, and total water intake during 4wk in C57BL/6J and db/db mice Metabolic parameters in plasma. 

Phrase: "Body weight change,"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
  1000   C0005911:Weight Change, Body [Finding]
           Weight change
   901   C0005910:Body Weight [Organism Attribute]
           weight
   901   C1305866:body weight [Diagnostic Procedure]
           weight
   827   C0043100:Weight [Quantitative Concept]
   827   C0242821:body [Human]
   827   C0392747:Change [Functional Concept]
   827   C0443172:change [Quantitative Concept]
   827   C0460148:Body [Anatomical Structure]
   827   C1268086:Body [Anatomical Structure]
   827   C1705104:Weight [Idea or Concept]
   827   C1705241:Change [Quantitative Concept]
   743 E C1995017:Bodies [Cell Component]

Phrase: "total food intake,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0013470:Food Intake [Organism Function]
   827   C1512806:Intake [Functional Concept]

Phrase: "and"

Phrase: "total water intake during 4wk"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0013123:Water Intake [Organism Function]
   760   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   760   C0599638:WATER [Substance]
   760   C1512806:Intake [Functional Concept]
   760   C1550678:Water [Inorganic Chemical]

Phrase: "in C57BL/6J"

Phrase: "and"

Phrase: "db/db mice Metabolic parameters in plasma."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   748   C0449381:Parameters [Finding]
   714 E C0549193:Parameter [Spatial Concept]
   714 E C1704769:Parameter [Conceptual Entity]
   714 E C2350001:Parameter [Quantitative Concept]
Processing 00000000.tx.74: Plasma glucose, insulin, triglyceride, and NEFA levels were elevated in untreated db/db mice compared with untreated C57BL/6J mice, and these parameters were significantly ameliorated in the PPAR agonist-treated groups (Fig. 1). 

Phrase: "Plasma glucose,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0202042:Plasma glucose [Laboratory Procedure]
  1000   C0455280:plasma glucose [Laboratory or Test Result]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   861   C0032105:Plasma [Body Substance]
   861   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "triglyceride,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041004:Triglyceride [Biologically Active Substance,Lipid]

Phrase: "and"

Phrase: "NEFA levels"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   923   C0015688:Non-esterified fatty acid [Lipid]
   890   C1281901:Fatty acid level [Laboratory Procedure]
   861   C0015684:Fatty acid [Lipid]
   812   C0001128:Acid [Chemical]
   812   C0202406:Acid [Laboratory Procedure]
   812   C0441889:Levels [Qualitative Concept]
   779 E C0456079:Level [Classification]
   779 E C1547707:Level [Geographic Area]
   779 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "elevated in untreated db/db mice"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0205250:Elevated [Qualitative Concept]
   753   C0332155:untreated [Finding]
   753   C3163633:Elevated [Qualitative Concept]

Phrase: "compared with untreated C57BL/6J mice,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   783   C0025921:Mice, C57BL [Mammal]
           C57BL
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0332155:untreated [Finding]
   753   C1707455:Compared [Activity]

Phrase: "and"

Phrase: "these parameters"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0449381:Parameters [Finding]
   966 E C0549193:Parameter [Spatial Concept]
   966 E C1704769:Parameter [Conceptual Entity]
   966 E C2350001:Parameter [Quantitative Concept]

Phrase: "were"

Phrase: "significantly"

Phrase: "ameliorated in the PPAR agonist-treated groups"
Meta Candidates (Total=19; Excluded=2; Pruned=0; Remaining=17)
   806   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   806   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   760   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   739   C0332293:treated [Therapeutic or Preventive Procedure]
   739   C0441833:Group [Idea or Concept]
   739   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   739   C0687744:group [Population Group]
   739   C0752063:Peroxysome [Cell Component]
   739   C1257890:Group [Population Group]
   739   C1522326:Treated [Functional Concept]
   739   C1552516:Group [Health Care Related Organization]
   739   C1552839:groups [Idea or Concept]
   739   C1705428:Group [Conceptual Entity]
   739   C1705429:Group [Population Group]
   739   C1879547:Activated [Activity]
   739   C2984308:Peroxisome [Functional Concept]
   739   C2987634:Agonist [Pharmacologic Substance]
   706 E C1292734:TREAT [Functional Concept]
   706 E C1515877:Activate [Functional Concept]

Phrase: "(Fig. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.75: View larger version (25K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(25K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.76: 1.  

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.77: Plasma glucose (A), insulin (B), triglyceride (C), and nonesterified fatty acid (NEFA, D) levels at 10wk for untreated groups [solid bars, n=5,C57BL/6J mice shown as reference (C57), and open bars, n=3,(db/db)]; 

Phrase: "Plasma glucose"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0202042:Plasma glucose [Laboratory Procedure]
  1000   C0455280:plasma glucose [Laboratory or Test Result]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   861   C0032105:Plasma [Body Substance]
   861   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "(A"

Phrase: ")"

Phrase: ","

Phrase: "insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "triglyceride"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041004:Triglyceride [Biologically Active Substance,Lipid]

Phrase: "(C),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "and"

Phrase: "nonesterified fatty acid (NEFA, D) levels at 10wk"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   833   C0015688:Non-esterified fatty acid [Lipid]
   799   C1281901:Fatty acid level [Laboratory Procedure]
   790   C0015684:Fatty acid [Lipid]
   753   C0001128:Acid [Chemical]
   753   C0202406:Acid [Laboratory Procedure]
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "for untreated groups"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1552839:groups [Idea or Concept]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "[solid bars,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1707156:BARS [Gene or Genome]
   861   C3274014:BARS [Intellectual Product]
   861   C3541345:BARS [Intellectual Product]

Phrase: "n=5,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0129575:N 5' [Organic Chemical,Pharmacologic Substance]
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "C57BL/6J mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0025921:Mice, C57BL [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "shown as reference"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1514811:Reference [Idea or Concept]
   790   C1706462:Reference [Conceptual Entity]
   756   C1547282:Show [Intellectual Product]

Phrase: "(C57"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "open bars,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1707156:BARS [Gene or Genome]
   861   C3274014:BARS [Intellectual Product]
   861   C3541345:BARS [Intellectual Product]

Phrase: "n=3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]"

Phrase: ";"
Processing 00000000.tx.78: pioglitazone (PIO)-treated group [vertically striped bars, n=5(db/db)]; 

Phrase: "pioglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "(PIO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: ")-"

Phrase: "treated group"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   861   C0332293:treated [Therapeutic or Preventive Procedure]
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1522326:Treated [Functional Concept]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]
   827 E C1292734:TREAT [Functional Concept]

Phrase: "[vertically striped bars,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1707156:BARS [Gene or Genome]
   827   C3274014:BARS [Intellectual Product]
   827   C3541345:BARS [Intellectual Product]

Phrase: "n=5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0129575:N 5' [Organic Chemical,Pharmacologic Substance]
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]"

Phrase: ";"
Processing 00000000.tx.79: combined pioglitazone- and bezafibrate (P+B)-treated group [checked bars, n=5(db/db)]; 

Phrase: "combined pioglitazone- and bezafibrate (P+B)-treated group"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   799   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   799   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
   799   C0205195:Combined [Qualitative Concept]
   799   C0332293:treated [Therapeutic or Preventive Procedure]
   799   C0441833:Group [Idea or Concept]
   799   C0687744:group [Population Group]
   799   C1257890:Group [Population Group]
   799   C1522326:Treated [Functional Concept]
   799   C1552516:Group [Health Care Related Organization]
   799   C1705428:Group [Conceptual Entity]
   799   C1705429:Group [Population Group]
   766 E C0336789:Combine [Manufactured Object]
   766 E C1292734:TREAT [Functional Concept]

Phrase: "[checked bars,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1707156:BARS [Gene or Genome]
   861   C3274014:BARS [Intellectual Product]
   861   C3541345:BARS [Intellectual Product]

Phrase: "n=5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0129575:N 5' [Organic Chemical,Pharmacologic Substance]
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]"

Phrase: ";"
Processing 00000000.tx.80: and KRP-297-treated group [hatched bars, n=5,(db/db)]. 

Phrase: "and"

Phrase: "KRP-297-treated group"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   812   C0332293:treated [Therapeutic or Preventive Procedure]
   812   C0441833:Group [Idea or Concept]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1522326:Treated [Functional Concept]
   812   C1552516:Group [Health Care Related Organization]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   779 E C1292734:TREAT [Functional Concept]

Phrase: "[hatched bars,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1707156:BARS [Gene or Genome]
   861   C3274014:BARS [Intellectual Product]
   861   C3541345:BARS [Intellectual Product]

Phrase: "n=5,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0129575:N 5' [Organic Chemical,Pharmacologic Substance]
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]."
Processing 00000000.tx.81: Each value represents a meanSE. 

Phrase: "Each value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522609:Value [Quantitative Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a meanSE."
Processing 00000000.tx.82: P<0.0083vs. 

Phrase: "P<0.0083vs."
Processing 00000000.tx.83: untreated db/db mice. 

Phrase: "untreated db/db mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0025914:Mice [Mammal]
   812   C0025929:mice [Mammal]
   812   C0026809:Mice [Mammal]
Processing 00000000.tx.84: Pancreatic insulin content. 

Phrase: "Pancreatic insulin content."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   827   C0423896:Content [Mental Process]
   827   C0456205:Content [Conceptual Entity]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.85: Pancreatic insulin content of untreated db/db mice was almost completely diminished compared with untreated C57BL/6J mice (Fig. 2). 

Phrase: "Pancreatic insulin content of untreated db/db mice"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   744   C0423896:Content [Mental Process]
   744   C0456205:Content [Conceptual Entity]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]

Phrase: "was"

Phrase: "almost completely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205197:Completely [Qualitative Concept]

Phrase: "diminished"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205216:Diminished [Quantitative Concept]

Phrase: "compared with untreated C57BL/6J mice"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   783   C0025921:Mice, C57BL [Mammal]
           C57BL
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0332155:untreated [Finding]
   753   C1707455:Compared [Activity]

Phrase: "(Fig. 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.86: Pancreatic insulin content of the PIO- and P+B-treated db/db mice was ameliorated compared with untreated db/db mice, although these differences were not statistically significant (P=0.051by ANOVA). 

Phrase: "Pancreatic insulin content of the PIO-"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   753   C0423896:Content [Mental Process]
   753   C0456205:Content [Conceptual Entity]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]

Phrase: "and"

Phrase: "P+B-treated db/db mice"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "ameliorated"

Phrase: "compared with untreated db/db mice,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0332155:untreated [Finding]
   753   C1707455:Compared [Activity]

Phrase: "although"

Phrase: "these differences"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   966   C1705241:*Difference [Quantitative Concept]
   966   C1705242:Difference [Qualitative Concept]
   916 E C0443199:Differential [Qualitative Concept]

Phrase: "were"

Phrase: "not statistically significant"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   913   C1273937:Not significant [Finding]
   901   C0237881:statistically significant [Quantitative Concept]
           significant
   829 E C1709380:Statistical Significance [Quantitative Concept]
   827   C0038215:Statistically [Occupation or Discipline]
   827   C0750502:Significant [Idea or Concept]
   827   C1546944:Significant [Qualitative Concept]

Phrase: "(P=0.051by ANOVA"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0002780:Analysis of Variance [Quantitative Concept]
           Variance Analysis
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: ")."
Processing 00000000.tx.87: The pancreatic insulin content of the KRP-297-treated db/db mice was almost the same as that of untreated C57BL/6J mice. 

Phrase: "The pancreatic insulin content"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   827   C0423896:Content [Mental Process]
   827   C0456205:Content [Conceptual Entity]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "of the KRP-297-treated db/db mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   799   C0025914:Mice [Mammal]
   799   C0025929:mice [Mammal]
   799   C0026809:Mice [Mammal]

Phrase: "was"

Phrase: "almost"

Phrase: "the same as that of untreated C57BL/6J mice."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   764   C1278655:SAME AS [Classification]
   742   C0445247:Same [Qualitative Concept]
Processing 00000000.tx.88: View larger version (19K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(19K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.89: 2.  

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.90: Pancreatic insulin content at 10wk for untreated group [solid bar, n=3(C57), and open bar, n=5(db/db)]; 

Phrase: "Pancreatic insulin content at 10wk"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   760   C0423896:Content [Mental Process]
   760   C0456205:Content [Conceptual Entity]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "for untreated group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "[solid bar,"

Phrase: "n=3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(C57"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "open bar,"

Phrase: "n=5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0129575:N 5' [Organic Chemical,Pharmacologic Substance]
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]"

Phrase: ";"
Processing 00000000.tx.91: PIO-treated group [vertically striped bars, n=8(db/db)]; 

Phrase: "PIO-treated group"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   827   C0332293:treated [Therapeutic or Preventive Procedure]
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1522326:Treated [Functional Concept]
   827   C1552516:Group [Health Care Related Organization]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   793 E C1292734:TREAT [Functional Concept]

Phrase: "[vertically striped bars,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1707156:BARS [Gene or Genome]
   827   C3274014:BARS [Intellectual Product]
   827   C3541345:BARS [Intellectual Product]

Phrase: "n=8"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]"

Phrase: ";"
Processing 00000000.tx.92: P+B-treated group [checked bars, n=8(db/db)]; 

Phrase: "P+B-treated group"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "[checked bars,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1707156:BARS [Gene or Genome]
   861   C3274014:BARS [Intellectual Product]
   861   C3541345:BARS [Intellectual Product]

Phrase: "n=8"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]"

Phrase: ";"
Processing 00000000.tx.93: and KRP-treated group [hatched bars, n=5(db/db)]. 

Phrase: "and"

Phrase: "KRP-treated group"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   827   C0332293:treated [Therapeutic or Preventive Procedure]
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1522326:Treated [Functional Concept]
   827   C1552516:Group [Health Care Related Organization]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   793 E C1292734:TREAT [Functional Concept]

Phrase: "[hatched bars,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1707156:BARS [Gene or Genome]
   861   C3274014:BARS [Intellectual Product]
   861   C3541345:BARS [Intellectual Product]

Phrase: "n=5"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0129575:N 5' [Organic Chemical,Pharmacologic Substance]
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]."
Processing 00000000.tx.94: Data of untreated C57BL/6J are shown for reference. 

Phrase: "Data of untreated C57BL/6J"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1511726:Data [Idea or Concept]
   760   C3245479:data [Medical Device]

Phrase: "are"

Phrase: "shown for reference."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1514811:Reference [Idea or Concept]
   790   C1706462:Reference [Conceptual Entity]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.95: Each value represents a meanSE. 

Phrase: "Each value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522609:Value [Quantitative Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a meanSE."
Processing 00000000.tx.96: P=0.051by ANOVA. 

Phrase: "P=0.051by ANOVA."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0002780:Analysis of Variance [Quantitative Concept]
           Variance Analysis
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]
Processing 00000000.tx.97: In situ pancreatic perfusion. 

Phrase: "In situ pancreatic perfusion."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   923   C0031006:In situ perfusion [Therapeutic or Preventive Procedure]
   812   C0031001:Perfusion [Therapeutic or Preventive Procedure]
Processing 00000000.tx.98: There was no difference in GSIS among the four groups of C57BL/6J mice (Fig. 3A). 

Phrase: "There"

Phrase: "was"

Phrase: "no difference in GSIS"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1705241:*Difference [Quantitative Concept]
   748   C1705242:Difference [Qualitative Concept]

Phrase: "among the four groups"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1552839:groups [Idea or Concept]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "of C57BL/6J mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0025921:Mice, C57BL [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "(Fig. 3A"

Phrase: ")."
Processing 00000000.tx.99: In db/db mice (Fig. 3B), whereas GSIS in the untreated group was diminished compared with that in C57BL/6J mice, that in the PPAR agonist-treated groups was preserved compared with that in the untreated group. 

Phrase: "In db/db mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "(Fig. 3B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450365:3b [Intellectual Product]
   861   C1706097:3B [Research Activity]

Phrase: ")"

Phrase: ","

Phrase: "whereas"

Phrase: "GSIS in the untreated group"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C1256369:insulin secretion [Cell Function]
   767   C1719133:Glucose/Insulin [Quantitative Concept]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0036536:secretion [Biologic Function]
   744   C0036537:Secretion [Body Substance]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]

Phrase: "was"

Phrase: "diminished"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205216:Diminished [Quantitative Concept]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in C57BL/6J mice,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0025921:Mice, C57BL [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "that in the PPAR agonist-treated groups"
Meta Candidates (Total=19; Excluded=2; Pruned=0; Remaining=17)
   806   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   806   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   760   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   739   C0332293:treated [Therapeutic or Preventive Procedure]
   739   C0441833:Group [Idea or Concept]
   739   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   739   C0687744:group [Population Group]
   739   C0752063:Peroxysome [Cell Component]
   739   C1257890:Group [Population Group]
   739   C1522326:Treated [Functional Concept]
   739   C1552516:Group [Health Care Related Organization]
   739   C1552839:groups [Idea or Concept]
   739   C1705428:Group [Conceptual Entity]
   739   C1705429:Group [Population Group]
   739   C1879547:Activated [Activity]
   739   C2984308:Peroxisome [Functional Concept]
   739   C2987634:Agonist [Pharmacologic Substance]
   706 E C1292734:TREAT [Functional Concept]
   706 E C1515877:Activate [Functional Concept]

Phrase: "was"

Phrase: "preserved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033085:Preserved [Laboratory Procedure]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in the untreated group."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]
Processing 00000000.tx.100: GSIS in the PIO-treated group showed no significant difference from that in the untreated group in db/db mice, whereas GSIS in both the P+B- and the KRP-297-treated groups was significantly increased (Table 2). 

Phrase: "GSIS in the PIO-treated group"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   764   C1256369:insulin secretion [Cell Function]
   762   C1719133:Glucose/Insulin [Quantitative Concept]
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0036536:secretion [Biologic Function]
   742   C0036537:Secretion [Body Substance]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "no significant difference from that"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1705241:*Difference [Quantitative Concept]
   760   C1705242:Difference [Qualitative Concept]

Phrase: "in the untreated group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "in db/db mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "whereas"

Phrase: "GSIS in both"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C1256369:insulin secretion [Cell Function]
   783   C1719133:Glucose/Insulin [Quantitative Concept]
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0036536:secretion [Biologic Function]
   753   C0036537:Secretion [Body Substance]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]

Phrase: "the P+B-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   812   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "the KRP-297-treated groups"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   812   C0332293:treated [Therapeutic or Preventive Procedure]
   812   C0441833:Group [Idea or Concept]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1522326:Treated [Functional Concept]
   812   C1552516:Group [Health Care Related Organization]
   812   C1552839:groups [Idea or Concept]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   779 E C1292734:TREAT [Functional Concept]

Phrase: "was"

Phrase: "significantly"

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.101: View larger version (22K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(22K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.102: 3.  

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.103: Glucose-stimulated insulin secretion (GSIS) by in situ pancreatic perfusion in C57BL/6J mice (A) and db/db mice (B): untreated groups (, n=6for both C57 and db/db); 

Phrase: "Glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(GSIS"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ")"

Phrase: "by in situ pancreatic perfusion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   923   C0031006:In situ perfusion [Therapeutic or Preventive Procedure]
   812   C0031001:Perfusion [Therapeutic or Preventive Procedure]

Phrase: "in C57BL/6J mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0025921:Mice, C57BL [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "(A)"

Phrase: "and"

Phrase: "db/db mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "(B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ")"

Phrase: ":"

Phrase: "untreated groups"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1552839:groups [Idea or Concept]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "(,"

Phrase: "n=6for"

Phrase: "both C57"

Phrase: "and"

Phrase: "db/db"

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.104: PIO-treated groups (, n=6for both C57 and db/db); 

Phrase: "PIO-treated groups"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   827   C0332293:treated [Therapeutic or Preventive Procedure]
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1522326:Treated [Functional Concept]
   827   C1552516:Group [Health Care Related Organization]
   827   C1552839:groups [Idea or Concept]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   793 E C1292734:TREAT [Functional Concept]

Phrase: "(,"

Phrase: "n=6for"

Phrase: "both C57"

Phrase: "and"

Phrase: "db/db"

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.105: P+B-treated groups [, n=6(C57) and 5(db/db)]; 

Phrase: "P+B-treated groups"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "[,"

Phrase: "n=6"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: "(C57"

Phrase: ")"

Phrase: "and"

Phrase: "5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: "(db/db)"

Phrase: "]"

Phrase: ";"
Processing 00000000.tx.106: KRP-treated groups (, n=6for both C57 and db/db). 

Phrase: "KRP-treated groups"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   827   C0332293:treated [Therapeutic or Preventive Procedure]
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1522326:Treated [Functional Concept]
   827   C1552516:Group [Health Care Related Organization]
   827   C1552839:groups [Idea or Concept]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   793 E C1292734:TREAT [Functional Concept]

Phrase: "(,"

Phrase: "n=6for"

Phrase: "both C57"

Phrase: "and"

Phrase: "db/db"

Phrase: ")."
Processing 00000000.tx.107: Each value represents meanSE (A). 

Phrase: "Each value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522609:Value [Quantitative Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "meanSE"

Phrase: "(A"

Phrase: ")."
Processing 00000000.tx.108: Each value of untreated, PIO-treated, and KRP-treated groups represents a meanSE (B). 

Phrase: "Each value of untreated, PIO-treated,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1522609:Value [Quantitative Concept]

Phrase: "and"

Phrase: "KRP-treated groups"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   827   C0332293:treated [Therapeutic or Preventive Procedure]
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1522326:Treated [Functional Concept]
   827   C1552516:Group [Health Care Related Organization]
   827   C1552839:groups [Idea or Concept]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]
   793 E C1292734:TREAT [Functional Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a meanSE"

Phrase: "(B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.109: Each value of P+B-treated group represents a mean+SE (B).  

Phrase: "Each value of P+B-treated group"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   744   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   744   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
   744   C0332293:treated [Therapeutic or Preventive Procedure]
   744   C0441833:Group [Idea or Concept]
   744   C0687744:group [Population Group]
   744   C1257890:Group [Population Group]
   744   C1457900:Each [Quantitative Concept]
   744   C1522326:Treated [Functional Concept]
   744   C1522609:Value [Quantitative Concept]
   744   C1552516:Group [Health Care Related Organization]
   744   C1705428:Group [Conceptual Entity]
   744   C1705429:Group [Population Group]
   711 E C1292734:TREAT [Functional Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a mean+SE (B"

Phrase: ")."
Processing 00000000.tx.110: View this table: [in this window] [in a new window]  Table 2.  

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.111: Glucose-stimulated insulin secretion by in situ pancreatic perfusion in C57BL/6J and db/db mice Histopathological findings. 

Phrase: "Glucose-stimulated insulin secretion by in situ pancreatic perfusion"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   764   C1256369:insulin secretion [Cell Function]
   762   C0030296:Pancreatic Secretion [Body Substance]
   762   C0232787:Pancreatic secretion [Organ or Tissue Function]
   762   C1719133:Glucose/Insulin [Quantitative Concept]
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0036536:secretion [Biologic Function]
   742   C0036537:Secretion [Body Substance]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]

Phrase: "in C57BL/6J"

Phrase: "and"

Phrase: "db/db mice Histopathological findings."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   804   C2607943:findings [Functional Concept]
   804   C2926606:Findings [Clinical Attribute]
   804   C3539655:Findings [Intellectual Product]
   787   C0428093:Histopathology finding [Laboratory or Test Result]
   771 E C0037088:Finding [Sign or Symptom]
   771 E C0243095:Finding [Finding]
   771 E C2825141:Finding [Finding]
Processing 00000000.tx.112: The islets of untreated db/db mice showed hyperplastic changes (Fig. 4). 

Phrase: "The islets of untreated db/db mice"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   757   C1522528:Mouse Islets [Tissue]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "hyperplastic changes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0392747:changes [Functional Concept]
   861   C0443172:changes [Quantitative Concept]
   827 E C1705241:Change [Quantitative Concept]

Phrase: "(Fig. 4"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.113: Insulin in these islets of untreated db/db mice was extremely reduced, and the staining pattern was scattered. 

Phrase: "Insulin in these islets of untreated db/db mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]

Phrase: "was"

Phrase: "extremely"

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: ","

Phrase: "and"

Phrase: "the staining pattern"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449774:Pattern [Spatial Concept]

Phrase: "was"

Phrase: "scattered."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439742:Scattered [Spatial Concept]
Processing 00000000.tx.114: Islets in the PIO- and P+B-treated db/db mice showed hyperplasia and almost normal staining of insulin. 

Phrase: "Islets in the PIO-"

Phrase: "and"

Phrase: "P+B-treated db/db mice"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "hyperplasia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020507:Hyperplasia [Pathologic Function]

Phrase: "and"

Phrase: "almost normal staining of insulin."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0487602:Staining [Laboratory Procedure]
   760   C1704680:Staining [Finding]
Processing 00000000.tx.115: In islets of the KRP-297-treated db/db mice, the hyperplasia was improved, and the staining of insulin was almost normal. 

Phrase: "In islets"

Phrase: "of the KRP-297-treated db/db mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   799   C0025914:Mice [Mammal]
   799   C0025929:mice [Mammal]
   799   C0026809:Mice [Mammal]

Phrase: "the hyperplasia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020507:Hyperplasia [Pathologic Function]

Phrase: "was"

Phrase: "improved"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0184511:Improved [Qualitative Concept]
  1000   C0332272:Improved [Qualitative Concept]
  1000   C1561611:Improved [Intellectual Product]

Phrase: ","

Phrase: "and"

Phrase: "the staining of insulin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0487602:Staining [Laboratory Procedure]
   770   C1704680:Staining [Finding]

Phrase: "was"

Phrase: "almost normal."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205307:Normal [Qualitative Concept]
   861   C0439166:% normal [Quantitative Concept]
   861   C2347086:% Normal [Quantitative Concept]
Processing 00000000.tx.116: The results of the insulin staining were consistent with those of pancreatic insulin content. 

Phrase: "The results of the insulin staining"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   719   C1274040:Result [Functional Concept]
   719   C1546471:Result [Idea or Concept]
   719   C2825142:Result [Finding]

Phrase: "were"

Phrase: "consistent with those of pancreatic insulin content."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   778   C0332290:Consistent with [Idea or Concept]
           Consistent
Processing 00000000.tx.117: GLUT2 was expressed on the -cell membrane of normal C57BL/6J mice. 

Phrase: "GLUT2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420172:GLUT2 [Gene or Genome]

Phrase: "was"

Phrase: "expressed on the -cell membrane of normal C57BL/6J mice."
Meta Candidates (Total=19; Excluded=0; Pruned=0; Remaining=19)
   760   C0007603:Cell Membrane [Cell Component]
   760   C3161472:Cell Membrane [Cell Component]
   757   C0007634:Normal cell [Cell]
           Cell
   757   C0025921:Mice, C57BL [Mammal]
           C57BL
   757   C1268443:Normal cell [Cell]
   739   C0025255:Membrane [Tissue]
   739   C0025914:Mice [Mammal]
   739   C0025929:mice [Mammal]
   739   C0026809:Mice [Mammal]
   739   C0205307:Normal [Qualitative Concept]
   739   C0439166:% normal [Quantitative Concept]
   739   C0596901:Membrane [Cell Component]
   739   C1269647:Cell [Cell]
   739   C1704653:Cell [Medical Device]
   739   C1706182:Membrane [Manufactured Object]
   739   C1948049:Cell [Spatial Concept]
   739   C2347086:% Normal [Quantitative Concept]
Processing 00000000.tx.118: Although GLUT2 expression was not detected in untreated db/db mice, it was preserved in PPAR agonist-treated db/db mice as well as in C57BL/6J mice. 

Phrase: "Although"

Phrase: "GLUT2 expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "detected in untreated db/db mice,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]
   753   C0332155:untreated [Finding]
   753   C0442726:Detected [Finding]
   753   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "it"

Phrase: "was"

Phrase: "preserved in PPAR agonist-treated db/db mice"
Meta Candidates (Total=16; Excluded=2; Pruned=0; Remaining=14)
   797   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   797   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   756   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   738   C0025914:Mice [Mammal]
   738   C0025929:mice [Mammal]
   738   C0026809:Mice [Mammal]
   738   C0033085:Preserved [Laboratory Procedure]
   738   C0332293:treated [Therapeutic or Preventive Procedure]
   738   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   738   C0752063:Peroxysome [Cell Component]
   738   C1522326:Treated [Functional Concept]
   738   C1879547:Activated [Activity]
   738   C2984308:Peroxisome [Functional Concept]
   738   C2987634:Agonist [Pharmacologic Substance]
   704 E C1292734:TREAT [Functional Concept]
   704 E C1515877:Activate [Functional Concept]

Phrase: "as well as in C57BL/6J mice."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   774   C0025921:Mice, C57BL [Mammal]
           C57BL
   748   C0025914:Mice [Mammal]
   748   C0025929:mice [Mammal]
   748   C0026809:Mice [Mammal]
   748   C0205170:Well [Qualitative Concept]
   748   C3146287:Well [Manufactured Object]
Processing 00000000.tx.119: However, there was no significant difference in GLUT2 expression among the PIO-, P+B-, and KRP-297-treated groups of the db/db mice. 

Phrase: "However,"

Phrase: "there"

Phrase: "was"

Phrase: "no significant difference in GLUT2 expression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1705241:*Difference [Quantitative Concept]
   753   C1705242:Difference [Qualitative Concept]

Phrase: "among the PIO-,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "P+B-,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "KRP-297-treated groups of the db/db mice."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   742   C0332293:treated [Therapeutic or Preventive Procedure]
   742   C0441833:Group [Idea or Concept]
   742   C0687744:group [Population Group]
   742   C1257890:Group [Population Group]
   742   C1522326:Treated [Functional Concept]
   742   C1552516:Group [Health Care Related Organization]
   742   C1552839:groups [Idea or Concept]
   742   C1705428:Group [Conceptual Entity]
   742   C1705429:Group [Population Group]
   708 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.120: View larger version (75K): [in this window] [in a new window]  Fig. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(75K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.121: 4.  

Phrase: "4."
Processing 00000000.tx.122: Histopathological examination of pancreas from untreated C57BL/6J mice and db/db mice untreated and treated with PIO, P+B, and KRP. 

Phrase: "Histopathological examination of pancreas"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   783   C0677043:Histopathologic Examination [Biomedical Occupation or Discipline]

Phrase: "from untreated C57BL/6J mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   875   C0025921:Mice, C57BL [Mammal]
   812   C0025914:Mice [Mammal]
   812   C0025929:mice [Mammal]
   812   C0026809:Mice [Mammal]

Phrase: "and"

Phrase: "db/db mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "untreated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332155:untreated [Finding]

Phrase: "and"

Phrase: "treated with PIO,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "P+B,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "KRP."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1706585:KRP [Gene or Genome]
  1000   C1833135:KRP [Gene or Genome]
Processing 00000000.tx.123: H+E, hematoxylin and eosin staining; 

Phrase: "H+E,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0018964:Haematoxylin [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "hematoxylin and eosin staining"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0018964:Haematoxylin [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: ";"
Processing 00000000.tx.124: Insulin, anti-insulin antibody staining; 

Phrase: "Insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "anti-insulin antibody staining"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0487602:Staining [Laboratory Procedure]
   812   C1704680:Staining [Finding]
   756   C0021644:Anti-insulin antibody [Immunologic Factor]
   708   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: ";"
Processing 00000000.tx.125: GLUT2, anti-GLUT2 antibody staining. 

Phrase: "GLUT2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420172:GLUT2 [Gene or Genome]

Phrase: "anti-GLUT2 antibody staining."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0487602:Staining [Laboratory Procedure]
   812   C1704680:Staining [Finding]
   708   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.126: Original magnification: all 80.  

Phrase: "Original magnification"

Phrase: ":"

Phrase: "all 80."
Processing 00000000.tx.127: DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES PPAR agonists are well suited for the treatment of type 2diabetic patients with obesity who have severe insulin resistance. 

Phrase: "DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "are"

Phrase: "well suited for the treatment of type 2diabetic patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0205170:Well [Qualitative Concept]
   742   C3146287:Well [Manufactured Object]

Phrase: "with obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "who"

Phrase: "have"

Phrase: "severe insulin resistance."
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   901   C0021655:Insulin Resistance [Pathologic Function]
   901   C2700570:INSULIN RESISTANCE [Gene or Genome]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0237834:Resistance [Mental Process]
   827   C1514892:Resistance [Physiologic Function]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   755 E C0332325:Resistant [Functional Concept]
   755 E C1550464:resistent [Idea or Concept]
   755 E C2827757:RESISTANT [Laboratory or Test Result]
   743 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.128: However, because PPAR is a master regulator of adipocytes (22), its activation may induce increased fat mass and obesity. 

Phrase: "However,"

Phrase: "because"

Phrase: "PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "a master regulator of adipocytes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0182953:REGULATOR [Medical Device]
   760   C1704734:Regulator [Medical Device]
   760   C1704735:Regulator [Conceptual Entity]

Phrase: "(22"

Phrase: ")"

Phrase: ","

Phrase: "its activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "may"

Phrase: "induce"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "increased fat mass"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0577559:Mass [Finding]
   827   C1306372:*Mass [Quantitative Concept]
   827   C3152252:Mass [Quantitative Concept]

Phrase: "and"

Phrase: "obesity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]
Processing 00000000.tx.129: The degree of body weight gain is dependent on different PPAR agonists (18). 

Phrase: "The degree of body weight gain"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0441889:Degree [Qualitative Concept]
   753   C0449286:Degree [Quantitative Concept]
   753   C0542560:Degree [Intellectual Product]
   753   C1561545:degree [Quantitative Concept]
   753   C2348088:Degree [Quantitative Concept]

Phrase: "is"

Phrase: "dependent on different PPAR agonists"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0851827:Dependent [Qualitative Concept]
   744   C1701901:Dependent [Qualitative Concept]
   744   C3244310:dependent [Functional Concept]

Phrase: "(18"

Phrase: ")."
Processing 00000000.tx.130: Also, body weight gain by PPAR agonists is reported not only in rodents (11, 27) but also in humans (16, 33), and it is speculated to be due to adipogenesis by the drug effect (8, 31, 35) as well as increased food intake (4, 40, 41). 

Phrase: "Also,"

Phrase: "body weight gain by PPAR agonists"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   790   C0043094:Body Weight Gain [Finding]
           Weight Gain
   790   C2986889:Body Weight Gain [Idea or Concept]
   764   C0005910:Body Weight [Organism Attribute]
           weight
   764   C1305866:body weight [Diagnostic Procedure]
           weight
   764   C2911647:Weight gain [Finding]
   742   C0043100:Weight [Quantitative Concept]
   742   C0242821:body [Human]
   742   C0460148:Body [Anatomical Structure]
   742   C1268086:Body [Anatomical Structure]
   742   C1517378:Gain [Quantitative Concept]
   742   C1705104:Weight [Idea or Concept]
   723 E C0231246:weight gaining [Sign or Symptom]

Phrase: "is"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "not only in rodents"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0035804:Rodents [Mammal]
   770   C0205171:Only [Quantitative Concept]
   770   C1518422:Not [Functional Concept]
   770   C1720467:Only [Intellectual Product]

Phrase: "(11,"

Phrase: "27"

Phrase: ")"

Phrase: "but"

Phrase: "also in humans"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0086418:Humans [Human]

Phrase: "(16,"

Phrase: "33"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "it"

Phrase: "is"

Phrase: "speculated"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be due to adipogenesis"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0678226:Due to [Functional Concept]
           due
   770   C0596843:Adipogenesis [Molecular Function]
   770   C2987476:Be [Conceptual Entity]
   770   C3146286:Due [Idea or Concept]

Phrase: "by the drug effect"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
  1000   C0728866:Drug effect [Functional Concept]
  1000   C0728867:Drug effect [Pathologic Function]
  1000   C1411996:drug effect [Biologic Function]
   861   C0013227:Drug [Pharmacologic Substance]
   861   C1254351:Drug [Pharmacologic Substance]
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]
   805 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   805 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   768 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "(8,"

Phrase: "31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "35"

Phrase: ")"

Phrase: "as well as"

Phrase: "increased food intake"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0013470:Food Intake [Organism Function]
   827   C1512806:Intake [Functional Concept]

Phrase: "(4,"

Phrase: "40,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439509:/40 [Temporal Concept]

Phrase: "41"

Phrase: ")."
Processing 00000000.tx.131: However, the effect of PPAR agonists on insulin secretion is unclear. 

Phrase: "However,"

Phrase: "the effect of PPAR agonists"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "on insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "unclear."
Processing 00000000.tx.132: In the present study, body weight in the PPAR agonist-treated groups increased significantly with increased food intake in C57BL/6J mice. 

Phrase: "In the present study,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "body weight in the PPAR agonist-treated groups"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   756   C0005910:Body Weight [Organism Attribute]
           weight
   756   C1305866:body weight [Diagnostic Procedure]
           weight
   738   C0043100:Weight [Quantitative Concept]
   738   C0242821:body [Human]
   738   C0460148:Body [Anatomical Structure]
   738   C1268086:Body [Anatomical Structure]
   738   C1705104:Weight [Idea or Concept]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "significantly with increased food intake"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0013470:Food Intake [Organism Function]
   760   C0016452:Food [Food]
   760   C0205217:Increased [Quantitative Concept]
   760   C0442805:Increased [Functional Concept]
   760   C1512806:Intake [Functional Concept]

Phrase: "in C57BL/6J mice."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0025921:Mice, C57BL [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]
Processing 00000000.tx.133: However, weight gain in db/db mice was less with KRP-297 treatment compared with PIO or P+B treatment. 

Phrase: "However,"

Phrase: "weight gain in db/db mice"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   790   C0043094:Weight Gain [Finding]
   790   C2911647:Weight gain [Finding]
   753   C0005910:weight [Organism Attribute]
   753   C0043100:Weight [Quantitative Concept]
   753   C1305866:weight [Diagnostic Procedure]
   753   C1517378:Gain [Quantitative Concept]
   753   C1705104:Weight [Idea or Concept]
   748 E C0231246:weight gaining [Sign or Symptom]

Phrase: "was"

Phrase: "less with KRP-297 treatment"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   806   C0760735:KRP 297 [Organic Chemical]
   760   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0439092:less [Intellectual Product]
   760   C0547044:Less [Qualitative Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C1706585:KRP [Gene or Genome]
   760   C1833135:KRP [Gene or Genome]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "compared with PIO"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
   790   C1707455:Compared [Activity]

Phrase: "or"

Phrase: "P+B treatment."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.134: We speculate that this is due to the effects of a dual agonist that enhances lipid catabolism and reduces fat mass by PPAR activation, as previously suggested (2,5a). 

Phrase: "We"

Phrase: "speculate"

Phrase: "that"

Phrase: "this"

Phrase: "is due to the effects of a dual agonist"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   764   C0678226:Due to [Functional Concept]
           due
   742   C1280500:effects [Qualitative Concept]
   742   C1554184:Dual [Intellectual Product]
   742   C2987634:Agonist [Pharmacologic Substance]
   742   C3146286:Due [Idea or Concept]
   708 E C2348382:Effect [Qualitative Concept]

Phrase: "that"

Phrase: "enhances"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhance [Activity]

Phrase: "lipid catabolism"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0023796:lipid catabolism [Organism Function]
   861   C0543484:catabolism [Functional Concept]
   861   C0699900:Catabolism [Organism Function]
   861   C1516314:Catabolism [Physiologic Function]

Phrase: "and"

Phrase: "reduces"

Phrase: "fat mass by PPAR activation,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0577559:Mass [Finding]
   744   C1306372:*Mass [Quantitative Concept]
   744   C3152252:Mass [Quantitative Concept]

Phrase: "as"

Phrase: "previously"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "(2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "5a"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553637:5a [Medical Device]

Phrase: ")."
Processing 00000000.tx.135: We consider that KRP-297 ameliorated obesity most, so that pancreatic insulin content of the KRP-297-treated group was almost the same as that in normal mice (26), and the islets of the KRP-297-treated group were not hyperplastic in contrast to those of the PIO- or P+B-treated groups. 

Phrase: "We"

Phrase: "consider"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:consider [Idea or Concept]

Phrase: "that KRP-297 ameliorated obesity most,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0028754:Obesity [Disease or Syndrome]
   804   C1963185:Obesity [Finding]

Phrase: "so"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0037640:SO [Geographic Area]

Phrase: "that pancreatic insulin content of the KRP-297-treated group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   739   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   739   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   739   C0423896:Content [Mental Process]
   739   C0456205:Content [Conceptual Entity]
   739   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   739   C1579433:Insulin [Pharmacologic Substance]

Phrase: "was"

Phrase: "almost"

Phrase: "the same as that"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1278655:SAME AS [Classification]
   770   C0445247:Same [Qualitative Concept]

Phrase: "in normal mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "(26"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the islets of the KRP-297-treated group"

Phrase: "were"

Phrase: "not hyperplastic in contrast to those of the PIO-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0020507:Hyperplastic [Pathologic Function]

Phrase: "or"

Phrase: "P+B-treated groups."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.136: Also, we have shown in this study that PPAR agonists normalized the elevated plasma glucose, insulin, triglyceride, and NEFA levels in db/db mice. 

Phrase: "Also,"

Phrase: "we"

Phrase: "have"

Phrase: "shown in this study"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]
   737   C1547282:Show [Intellectual Product]

Phrase: "that PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "normalized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882115:Normalized [Research Activity]

Phrase: "the elevated plasma glucose,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0202042:Plasma glucose [Laboratory Procedure]
   901   C0455280:plasma glucose [Laboratory or Test Result]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0032105:Plasma [Body Substance]
   827   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "triglyceride,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041004:Triglyceride [Biologically Active Substance,Lipid]

Phrase: "and"

Phrase: "NEFA levels in db/db mice."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   800   C0015688:Non-esterified fatty acid [Lipid]
   770   C0015684:Fatty acid [Lipid]
   767   C1281901:Fatty acid level [Laboratory Procedure]
   744   C0001128:Acid [Chemical]
   744   C0202406:Acid [Laboratory Procedure]
   744   C0441889:Levels [Qualitative Concept]
   711 E C0456079:Level [Classification]
   711 E C1547707:Level [Geographic Area]
   711 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.137: However, we did not find an additional effect of a PPAR agonist on these parameters. 

Phrase: "However,"

Phrase: "we"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "find"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0243095:Find [Finding]

Phrase: "an additional effect of a PPAR agonist"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C1280500:Effect [Qualitative Concept]
   739   C2348382:Effect [Qualitative Concept]

Phrase: "on these parameters."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0449381:Parameters [Finding]
   966 E C0549193:Parameter [Spatial Concept]
   966 E C1704769:Parameter [Conceptual Entity]
   966 E C2350001:Parameter [Quantitative Concept]
Processing 00000000.tx.138: Plasma glucose level in the KRP-297-treated group was the lowest in db/db mice, probably because of the lowest food consumption in addition to the drug effect. 

Phrase: "Plasma glucose level in the KRP-297-treated group"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   790   C0455280:plasma glucose level [Laboratory or Test Result]
           plasma glucose
   764   C0202042:Plasma glucose [Laboratory Procedure]
   764   C0337438:glucose level [Laboratory Procedure]
   764   C0428548:Glucose level [Laboratory or Test Result]
   742   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   742   C0032105:Plasma [Body Substance]
   742   C0441889:Level [Qualitative Concept]
   742   C0456079:Level [Classification]
   742   C1547707:Level [Geographic Area]
   742   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   742   C2946261:Level [Pharmacologic Substance]

Phrase: "was"

Phrase: "the lowest in db/db mice,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   753   C1708760:Lowest [Qualitative Concept]
   719 E C0205251:low [Qualitative Concept]
   719 E C1299352:Low [Qualitative Concept]
   719 E C1550472:low [Idea or Concept]

Phrase: "probably because of the lowest food consumption"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   778   C2983605:Food Consumption [Activity]
   748   C0009830:Consumption [Activity]
   748   C0016452:Food [Food]
   748   C0750492:Probably [Idea or Concept]
   748   C1708760:Lowest [Qualitative Concept]
   748   C1947907:Consumption [Physiologic Function]
   714 E C0205251:low [Qualitative Concept]
   714 E C1299352:Low [Qualitative Concept]
   714 E C1550472:low [Idea or Concept]

Phrase: "in addition to the drug effect."
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
  1000   C0728866:Drug effect [Functional Concept]
  1000   C0728867:Drug effect [Pathologic Function]
  1000   C1411996:drug effect [Biologic Function]
   861   C0013227:Drug [Pharmacologic Substance]
   861   C1254351:Drug [Pharmacologic Substance]
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]
   805 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   805 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   768 E C0456386:Medicament [Pharmacologic Substance]
Processing 00000000.tx.139: GSIS in C57BL/6J mice showed a good response and was not changed by 4-wk treatment with PPAR and/or PPAR agonists. 

Phrase: "GSIS in C57BL/6J mice"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C1256369:insulin secretion [Cell Function]
   767   C1719133:Glucose/Insulin [Quantitative Concept]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0036536:secretion [Biologic Function]
   744   C0036537:Secretion [Body Substance]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "a good response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "changed by 4-wk treatment"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   797   C2919691:Treatment changed [Health Care Activity]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0332174:/wk [Temporal Concept]
   760   C0392747:Changed [Functional Concept]
   760   C0439230:wk [Temporal Concept]
   760   C0443172:Changed [Quantitative Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
   726 E C1705241:Change [Quantitative Concept]

Phrase: "with PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "and/or"

Phrase: "PPAR agonists."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.140: In untreated db/db mice, on the other hand, there was no GSIS response, due to insulin shortage resulting from severe insulin resistance, glucotoxicity, and lipotoxicity. 

Phrase: "In untreated db/db mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0025914:Mice [Mammal]
   812   C0025929:mice [Mammal]
   812   C0026809:Mice [Mammal]

Phrase: "on the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "there"

Phrase: "was"

Phrase: "no GSIS response,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0871261:Response [Organism Attribute]
   804   C1704632:Response [Finding]
   804   C1706817:Response [Intellectual Product]
   804   C2911692:Response [Mental Process]

Phrase: "due to insulin shortage"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   789   C1282927:short [Qualitative Concept]
   789   C1806781:Short [Quantitative Concept]
   789   C2350002:Short [Quantitative Concept]

Phrase: "resulting from severe insulin resistance,"
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
   806   C0021655:Insulin Resistance [Pathologic Function]
   806   C2700570:INSULIN RESISTANCE [Gene or Genome]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0205082:Severe [Qualitative Concept]
   760   C0237834:Resistance [Mental Process]
   760   C0678226:resulting [Functional Concept]
   760   C1514892:Resistance [Physiologic Function]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   726 E C1274040:Result [Functional Concept]
   726 E C1546471:Result [Idea or Concept]
   726 E C2825142:Result [Finding]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "glucotoxicity,"

Phrase: "and"

Phrase: "lipotoxicity."
Processing 00000000.tx.141: Plasma insulin level in untreated db/db mice at this age, however, was higher than that in any other group; 

Phrase: "Plasma insulin level in untreated db/db mice"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   800   C1276042:Plasma insulin level [Laboratory Procedure]
   770   C0202098:Insulin level [Laboratory Procedure]
   770   C0428405:insulin level [Laboratory or Test Result]
   770   C0857690:plasma insulin [Laboratory Procedure]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0032105:Plasma [Body Substance]
   744   C0441889:Level [Qualitative Concept]
   744   C0456079:Level [Classification]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1547707:Level [Geographic Area]
   744   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
   744   C2946261:Level [Pharmacologic Substance]

Phrase: "at this age,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001779:Age [Organism Attribute]

Phrase: "however,"

Phrase: "was"

Phrase: "higher than that"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   756   C0205250:High [Qualitative Concept]
   756   C1299351:High [Qualitative Concept]
   756   C2700149:HIGH [Intellectual Product]
   706 E C0489786:Height [Organism Attribute]

Phrase: "in any"

Phrase: "other group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0441833:Group [Idea or Concept]
  1000   C0687744:group [Population Group]
  1000   C1257890:Group [Population Group]
  1000   C1552516:Group [Health Care Related Organization]
  1000   C1705428:Group [Conceptual Entity]
  1000   C1705429:Group [Population Group]

Phrase: ";"
Processing 00000000.tx.142: the islets of untreated db/db mice secreted insulin against an extremely high plasma glucose level. 

Phrase: "the islets of untreated db/db mice"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   757   C1522528:Mouse Islets [Tissue]

Phrase: "secreted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1327616:Secreted [Cell Function]

Phrase: "insulin against an extremely high plasma glucose level."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   789   C1276042:Plasma insulin level [Laboratory Procedure]
   767   C0020459:high insulin [Disease or Syndrome]
   767   C0202098:Insulin level [Laboratory Procedure]
   767   C0428405:insulin level [Laboratory or Test Result]
   767   C0857690:plasma insulin [Laboratory Procedure]
   767   C1719133:Glucose/Insulin [Quantitative Concept]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.143: The stimulatory glucose level of the perfusate was 16.7mM in our experiments, which was lower than the plasma level of untreated db/db mice. 

Phrase: "The stimulatory glucose level of the perfusate"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0337438:glucose level [Laboratory Procedure]
   778   C0428548:Glucose level [Laboratory or Test Result]
   748   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1547707:Level [Geographic Area]
   748   C2946261:Level [Pharmacologic Substance]

Phrase: "was"

Phrase: "16.7mM in our experiments,"

Phrase: "which"

Phrase: "was"

Phrase: "lower than the plasma level of untreated db/db mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   739   C0441994:Lower [Spatial Concept]
   739   C1548802:Lower [Body Location or Region]
   739   C2003888:Lower [Activity]
Processing 00000000.tx.144: Therefore, we speculate that the islets of untreated db/db mice might be desensitized to glucose and thus did not show a GSIS response at 16.7mM. 

Phrase: "Therefore,"

Phrase: "we"

Phrase: "speculate"

Phrase: "that"

Phrase: "the islets of untreated db/db mice"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   757   C1522528:Mouse Islets [Tissue]

Phrase: "might"

Phrase: "be"

Phrase: "desensitized to glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "thus"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "a GSIS response at 16.7mM."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0871261:Response [Organism Attribute]
   742   C1704632:Response [Finding]
   742   C1706817:Response [Intellectual Product]
   742   C2911692:Response [Mental Process]
Processing 00000000.tx.145: However, we have shown reduced insulin staining with hyperplasia of islets, and pancreatic insulin content was barely detectable in untreated db/db mice, both suggesting insulin shortage. 

Phrase: "However,"

Phrase: "we"

Phrase: "have"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "insulin staining with hyperplasia of islets,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0487602:Staining [Laboratory Procedure]
   753   C1704680:Staining [Finding]

Phrase: "and"

Phrase: "pancreatic insulin content"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   827   C0423896:Content [Mental Process]
   827   C0456205:Content [Conceptual Entity]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "barely detectable in untreated db/db mice,"

Phrase: "both"

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "insulin shortage."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   789   C1282927:short [Qualitative Concept]
   789   C1806781:Short [Quantitative Concept]
   789   C2350002:Short [Quantitative Concept]
Processing 00000000.tx.146: In the present study, GSIS in db/db mice was preserved by PPAR agonist treatment. 

Phrase: "In the present study,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "GSIS in db/db mice"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C1256369:insulin secretion [Cell Function]
   767   C1719133:Glucose/Insulin [Quantitative Concept]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0036536:secretion [Biologic Function]
   744   C0036537:Secretion [Body Substance]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]

Phrase: "was"

Phrase: "preserved by PPAR agonist treatment."
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   833   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   833   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   770   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   744   C0033085:Preserved [Laboratory Procedure]
   744   C0039798:treatment [Functional Concept]
   744   C0087111:Treatment [Therapeutic or Preventive Procedure]
   744   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   744   C0752063:Peroxysome [Cell Component]
   744   C1522326:Treatment [Functional Concept]
   744   C1533734:Treatment [Therapeutic or Preventive Procedure]
   744   C1705169:Treatment [Conceptual Entity]
   744   C1879547:Activated [Activity]
   744   C2984308:Peroxisome [Functional Concept]
   744   C2987634:Agonist [Pharmacologic Substance]
   744   C3538994:TREATMENT [Research Activity]
   711 E C1515877:Activate [Functional Concept]
Processing 00000000.tx.147: There was amelioration of plasma glucose, insulin, triglycerides, and NEFA levels in these groups. 

Phrase: "There"

Phrase: "was"

Phrase: "amelioration of plasma glucose,"

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "triglycerides,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041004:Triglycerides [Biologically Active Substance,Lipid]

Phrase: "and"

Phrase: "NEFA levels in these groups."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   814   C0015688:Non-esterified fatty acid [Lipid]
   780   C1281901:Fatty acid level [Laboratory Procedure]
   778   C0015684:Fatty acid [Lipid]
   748   C0001128:Acid [Chemical]
   748   C0202406:Acid [Laboratory Procedure]
   748   C0441889:Levels [Qualitative Concept]
   714 E C0456079:Level [Classification]
   714 E C1547707:Level [Geographic Area]
   714 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.148: We also observed preserved insulin staining in the islets of the PPAR agonist-treated groups, and we concluded that the insulin-saving effects of PPAR agonists were mediated by ameliorating insulin resistance. 

Phrase: "We also"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: "preserved insulin staining in the islets"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0487602:Staining [Laboratory Procedure]
   753   C1704680:Staining [Finding]

Phrase: "of the PPAR agonist-treated groups,"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   795   C0332293:treated [Therapeutic or Preventive Procedure]
   795   C0441833:Group [Idea or Concept]
   795   C0687744:group [Population Group]
   795   C1257890:Group [Population Group]
   795   C1522326:Treated [Functional Concept]
   795   C1552516:Group [Health Care Related Organization]
   795   C1552839:groups [Idea or Concept]
   795   C1705428:Group [Conceptual Entity]
   795   C1705429:Group [Population Group]
   762 E C1292734:TREAT [Functional Concept]
   710   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   710   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "and"

Phrase: "we"

Phrase: "concluded"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "that"

Phrase: "the insulin-"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "saving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2347840:Save [Machine Activity]

Phrase: "effects of PPAR agonists"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]

Phrase: "were"

Phrase: "mediated by ameliorating insulin resistance."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   806   C0021655:Insulin Resistance [Pathologic Function]
   806   C2700570:INSULIN RESISTANCE [Gene or Genome]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0086597:mediated [Social Behavior]
   760   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]
   760   C0237834:Resistance [Mental Process]
   760   C1514892:Resistance [Physiologic Function]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.149: De Souza et al. 

Phrase: "De Souza et al."
Processing 00000000.tx.150: (3) also suggested amelioration of insulin resistance in Zucker diabetic fatty (ZDF) rats. 

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: "also suggested amelioration of insulin resistance"

Phrase: "in Zucker diabetic fatty (ZDF) rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
Processing 00000000.tx.151: These authors showed that there was no direct effect of pioglitazone on the pancreas in perifusion experiments. 

Phrase: "These authors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0221193:Authors [Professional or Occupational Group]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that there"

Phrase: "was"

Phrase: "no direct effect of pioglitazone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C1301751:No effect [Qualitative Concept]
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "on the pancreas"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0030274:Pancreas [Body Part, Organ, or Organ Component]
  1000   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "in perifusion experiments."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0681814:Experiments [Research Activity]
   827 E C1706386:Experiment [Conceptual Entity]
   777 E C1517586:Experimental [Qualitative Concept]
Processing 00000000.tx.152: Although P+B and KRP-297 treatments in our study significantly increased GSIS in db/db mice, it is unclear why GSIS was increased by the addition of a PPAR agonist. 

Phrase: "Although"

Phrase: "P+B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "KRP-297 treatments in our study significantly increased GSIS"
Meta Candidates (Total=8; Excluded=5; Pruned=0; Remaining=3)
   751   C0745343:insulin treatments [Therapeutic or Preventive Procedure]
   736   C0087111:Treatments [Therapeutic or Preventive Procedure]
   734   C3161471:Treatment Study [Research Activity]
   703 E C0039798:treatment [Functional Concept]
   703 E C1522326:Treatment [Functional Concept]
   703 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   703 E C1705169:Treatment [Conceptual Entity]
   703 E C3538994:TREATMENT [Research Activity]

Phrase: "in db/db mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "it"

Phrase: "is"

Phrase: "unclear why GSIS"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   839   C1719133:Glucose/Insulin [Quantitative Concept]
   827   C1256369:insulin secretion [Cell Function]
   799   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   799   C0036536:secretion [Biologic Function]
   799   C0036537:Secretion [Body Substance]
   799   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   799   C1579433:Insulin [Pharmacologic Substance]
   743 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   716 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "increased by the addition of a PPAR agonist."
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   797   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   797   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   756   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   738   C0205217:Increased [Quantitative Concept]
   738   C0442805:Increased [Functional Concept]
   738   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   738   C0752063:Peroxysome [Cell Component]
   738   C1879547:Activated [Activity]
   738   C1883712:Addition [Functional Concept]
   738   C2984308:Peroxisome [Functional Concept]
   738   C2987634:Agonist [Pharmacologic Substance]
   704 E C1515877:Activate [Functional Concept]
Processing 00000000.tx.153: Because there was no difference in plasma glucose, insulin, triglyceride, and NEFA levels among the PIO-, P+B-, and KRP-297-treated groups, increased insulin secretion in the P+B- and KRP-297-treated groups might not be through amelioration of glucolipotoxicity but through increased glucose sensitivity in pancreatic -cells. 

Phrase: "Because"

Phrase: "there"

Phrase: "was"

Phrase: "no difference in plasma glucose,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1705241:*Difference [Quantitative Concept]
   760   C1705242:Difference [Qualitative Concept]

Phrase: "insulin,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "triglyceride,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041004:Triglyceride [Biologically Active Substance,Lipid]

Phrase: "and"

Phrase: "NEFA levels among the PIO-,"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   814   C0015688:Non-esterified fatty acid [Lipid]
   780   C1281901:Fatty acid level [Laboratory Procedure]
   778   C0015684:Fatty acid [Lipid]
   748   C0001128:Acid [Chemical]
   748   C0202406:Acid [Laboratory Procedure]
   748   C0441889:Levels [Qualitative Concept]
   714 E C0456079:Level [Classification]
   714 E C1547707:Level [Geographic Area]
   714 E C2946261:Level [Pharmacologic Substance]

Phrase: "P+B-,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "KRP-297-treated groups,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   812   C0332293:treated [Therapeutic or Preventive Procedure]
   812   C0441833:Group [Idea or Concept]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1522326:Treated [Functional Concept]
   812   C1552516:Group [Health Care Related Organization]
   812   C1552839:groups [Idea or Concept]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   779 E C1292734:TREAT [Functional Concept]

Phrase: "increased insulin secretion in the P+B-"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   800   C1372360:Increased Insulin Secretion [Organ or Tissue Function]
   770   C0020459:increased insulin [Disease or Syndrome]
   770   C1256369:insulin secretion [Cell Function]
   744   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0036536:secretion [Biologic Function]
   744   C0036537:Secretion [Body Substance]
   744   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
   744   C0205217:Increased [Quantitative Concept]
   744   C0442805:Increased [Functional Concept]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]

Phrase: "and"

Phrase: "KRP-297-treated groups"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   812   C0332293:treated [Therapeutic or Preventive Procedure]
   812   C0441833:Group [Idea or Concept]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1522326:Treated [Functional Concept]
   812   C1552516:Group [Health Care Related Organization]
   812   C1552839:groups [Idea or Concept]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   779 E C1292734:TREAT [Functional Concept]

Phrase: "might"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "be through amelioration of glucolipotoxicity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2987476:Be [Conceptual Entity]

Phrase: "but through increased glucose sensitivity"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   806   C0860803:increased glucose [Finding]
   797   C1881189:INCREASED SENSITIVITY [Phenomenon or Process]
   797   C2346484:INCREASED SENSITIVITY [Phenomenon or Process]
           SENSITIVITY
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0205217:Increased [Quantitative Concept]
   760   C0233535:but [Mental or Behavioral Dysfunction]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C0442805:Increased [Functional Concept]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C2349185:Sensitivity [Qualitative Concept]

Phrase: "in pancreatic -cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.154: Lipotoxicity may cause -cell abnormalities, loss of GSIS and GLUT2, and triglyceride accumulation (37, 38). 

Phrase: "Lipotoxicity"

Phrase: "may"

Phrase: "cause -"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "cell abnormalities,"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   861   C0000768:Abnormalities [Congenital Abnormality]
   861   C0000769:abnormalities [Functional Concept]
   827 E C1704258:Abnormality [Finding]
   777 E C0205161:Abnormal [Qualitative Concept]
   777 E C2347472:% Abnormal [Quantitative Concept]
   777 E C2699333:ABNORMAL [Intellectual Product]

Phrase: "loss of GSIS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1517945:Loss [Quantitative Concept]

Phrase: "and"

Phrase: "GLUT2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420172:GLUT2 [Gene or Genome]

Phrase: "and"

Phrase: "triglyceride accumulation"

Phrase: "(37,"

Phrase: "38"

Phrase: ")."
Processing 00000000.tx.155: Higa et al. 

Phrase: "Higa et al."
Processing 00000000.tx.156: (9), using ZDF rats, reported that troglitazone prevented these features of lipotoxicity. 

Phrase: "(9"

Phrase: ")"

Phrase: ","

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "ZDF rats,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that troglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0245514:troglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "prevented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "these features of lipotoxicity."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   737   C1521970:Feature [Qualitative Concept]
   737   C1706388:Feature [Conceptual Entity]
   737   C2346469:Feature [Qualitative Concept]
   737   C2348519:Feature [Qualitative Concept]
Processing 00000000.tx.157: Because the peroxisome proliferator response element (PPRE) was identified in the rat GLUT2 gene (promoter) (17), PPAR and/or PPAR agonists may affect PPRE in the GLUT2 gene in pancreatic -cells. 

Phrase: "Because"

Phrase: "the peroxisome proliferator response element (PPRE)"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   861   C0600508:Response Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0013879:Element [Element, Ion, or Isotope]
   812   C0752063:Peroxysome [Cell Component]
   812   C0871261:Response [Organism Attribute]
   812   C1704632:Response [Finding]
   812   C1705248:Element [Conceptual Entity]
   812   C1706817:Response [Intellectual Product]
   812   C2911692:Response [Mental Process]
   812   C2984308:Peroxisome [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "was"

Phrase: "identified in the rat GLUT2 gene"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0017337:Gene [Gene or Genome]
   753   C0034693:Rat, NOS [Mammal]
   753   C0034721:Rat [Mammal]
   753   C0205396:Identified [Qualitative Concept]
   753   C1420172:GLUT2 [Gene or Genome]
   753   C1550043:Identified [Finding]
   753   C1551388:Identified [Functional Concept]

Phrase: "(promoter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: "(17"

Phrase: ")"

Phrase: ","

Phrase: "PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "and/or"

Phrase: "PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "may"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "PPRE in the GLUT2 gene"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   770   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   770   C0600508:Response Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C0013879:Element [Element, Ion, or Isotope]
   744   C0752063:Peroxysome [Cell Component]
   744   C0871261:Response [Organism Attribute]
   744   C1704632:Response [Finding]
   744   C1705248:Element [Conceptual Entity]
   744   C1706817:Response [Intellectual Product]
   744   C2911692:Response [Mental Process]
   744   C2984308:Peroxisome [Functional Concept]

Phrase: "in pancreatic -cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.158: Wang et al. 

Phrase: "Wang et al."
Processing 00000000.tx.159: (39) suggested that PPAR might be one of the transcription factors involved in the direct upregulation of GLUT2 in normal rat islets. 

Phrase: "(39"

Phrase: ")"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "might"

Phrase: "be"

Phrase: "one of the transcription factors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205447:One [Quantitative Concept]

Phrase: "involved in the direct upregulation of GLUT2"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0041904:Up-Regulation [Cell Function,Molecular Function]
   748   C0162493:Up-Regulation [Genetic Function]
   748   C0439851:Direct [Qualitative Concept]
   748   C1314939:Involved [Functional Concept]
   748   C1420172:GLUT2 [Gene or Genome]
   748   C1947931:Direct [Qualitative Concept]

Phrase: "in normal rat islets."
Processing 00000000.tx.160: Furthermore, Zhou et al. 

Phrase: "Furthermore,"

Phrase: "Zhou et al."
Processing 00000000.tx.161: (42) reported that expression of PPAR was suppressed in ZDF rat islets. 

Phrase: "(42"

Phrase: ")"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that expression of PPAR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   774   C0597360:receptor expression [Genetic Function]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "suppressed in ZDF rat islets."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   774   C0034719:Zucker rat [Mammal]
   748   C0034693:Rat, NOS [Mammal]
   748   C0034721:Rat [Mammal]
   748   C0241863:DIABETIC [Finding]
   748   C1260953:Suppressed [Functional Concept]
   748   C2700303:Zucker [Mammal]
Processing 00000000.tx.162: In the present study, GSIS was increased by addition of a PPAR agonist, and we evaluated the staining of GLUT2, which is associated with glucose sensing and GSIS. 

Phrase: "In the present study,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "GSIS"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "increased by addition of a PPAR agonist,"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   806   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   806   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   760   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   739   C0205217:Increased [Quantitative Concept]
   739   C0442805:Increased [Functional Concept]
   739   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   739   C0752063:Peroxysome [Cell Component]
   739   C1879547:Activated [Activity]
   739   C1883712:Addition [Functional Concept]
   739   C2984308:Peroxisome [Functional Concept]
   739   C2987634:Agonist [Pharmacologic Substance]
   706 E C1515877:Activate [Functional Concept]

Phrase: "and"

Phrase: "we"

Phrase: "evaluated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluated [Functional Concept]

Phrase: "the staining of GLUT2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0487602:Staining [Laboratory Procedure]
   770   C1704680:Staining [Finding]

Phrase: "which"

Phrase: "is"

Phrase: "associated with glucose sensing"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C1658150:glucose sensing [Cell Function]
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   737   C0036658:sense [Organ or Tissue Function]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "and"

Phrase: "GSIS."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.163: We showed that treatment with PPAR agonist preserved GLUT2 in db/db mice. 

Phrase: "We"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that treatment with PPAR agonist"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0039798:treatment [Functional Concept]
   744   C0087111:Treatment [Therapeutic or Preventive Procedure]
   744   C1522326:Treatment [Functional Concept]
   744   C1533734:Treatment [Therapeutic or Preventive Procedure]
   744   C1705169:Treatment [Conceptual Entity]
   744   C3538994:TREATMENT [Research Activity]

Phrase: "preserved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033085:Preserved [Laboratory Procedure]

Phrase: "GLUT2 in db/db mice."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1420172:GLUT2 [Gene or Genome]
Processing 00000000.tx.164: However, it was difficult to identify differences in GLUT2 staining among the PIO-, P+B-, and KRP-297-treated groups. 

Phrase: "However,"

Phrase: "it"

Phrase: "was"

Phrase: "difficult to"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0332218:Difficult [Qualitative Concept]
   789 E C1299586:Difficulty [Finding]

Phrase: "identify"

Phrase: "differences in GLUT2 staining"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C1705241:*Difference [Quantitative Concept]
   737   C1705242:Difference [Qualitative Concept]

Phrase: "among the PIO-,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "P+B-,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "KRP-297-treated groups."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   812   C0332293:treated [Therapeutic or Preventive Procedure]
   812   C0441833:Group [Idea or Concept]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1522326:Treated [Functional Concept]
   812   C1552516:Group [Health Care Related Organization]
   812   C1552839:groups [Idea or Concept]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   779 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.165: It is possible that a PPAR agonist reduced the islet triglyceride content in db/db mice, although we were not able to examine this. 

Phrase: "It"

Phrase: "is"

Phrase: "possible"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332149:Possible [Qualitative Concept]
  1000   C1705910:Possible [Qualitative Concept]
  1000   C2362652:Possible [Qualitative Concept]

Phrase: "that"

Phrase: "a PPAR agonist"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C2987634:Agonist [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "the islet triglyceride content in db/db mice,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0423896:Content [Mental Process]
   744   C0456205:Content [Conceptual Entity]

Phrase: "although"

Phrase: "we"

Phrase: "were"

Phrase: "not able to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0085732:Able [Organism Attribute]
   827   C1299581:Able [Finding]
   827   C1518422:Not [Functional Concept]

Phrase: "examine"

Phrase: "this."
Processing 00000000.tx.166: Further studies will be needed to clarify the direct effect of PPAR on islet function. 

Phrase: "Further studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "will"

Phrase: "be"

Phrase: "needed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027552:Needed [Qualitative Concept]
  1000   C0686904:needed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "clarify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986669:Clarify [Activity]

Phrase: "the direct effect of PPAR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "on islet function."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   861   C0031843:function [Physiologic Function]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1705273:Function [Intellectual Product]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.167: To summarize, body weight in PPAR agonist-treated groups increased significantly with increased food intake in C57BL/6J mice. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "summarize"

Phrase: ","

Phrase: "body weight in PPAR agonist-treated groups"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C0005910:Body Weight [Organism Attribute]
           weight
   760   C1305866:body weight [Diagnostic Procedure]
           weight
   739   C0043100:Weight [Quantitative Concept]
   739   C0242821:body [Human]
   739   C0460148:Body [Anatomical Structure]
   739   C1268086:Body [Anatomical Structure]
   739   C1705104:Weight [Idea or Concept]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "significantly with increased food intake"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0013470:Food Intake [Organism Function]
   760   C0016452:Food [Food]
   760   C0205217:Increased [Quantitative Concept]
   760   C0442805:Increased [Functional Concept]
   760   C1512806:Intake [Functional Concept]

Phrase: "in C57BL/6J mice."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0025921:Mice, C57BL [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]
Processing 00000000.tx.168: In contrast, weight gain in db/db mice was less with KRP-297 treatment compared with PIO- or P+B treatment. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "weight gain in db/db mice"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   790   C0043094:Weight Gain [Finding]
   790   C2911647:Weight gain [Finding]
   753   C0005910:weight [Organism Attribute]
   753   C0043100:Weight [Quantitative Concept]
   753   C1305866:weight [Diagnostic Procedure]
   753   C1517378:Gain [Quantitative Concept]
   753   C1705104:Weight [Idea or Concept]
   748 E C0231246:weight gaining [Sign or Symptom]

Phrase: "was"

Phrase: "less with KRP-297 treatment"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   806   C0760735:KRP 297 [Organic Chemical]
   760   C0027120:KRP [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0439092:less [Intellectual Product]
   760   C0547044:Less [Qualitative Concept]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C1706585:KRP [Gene or Genome]
   760   C1833135:KRP [Gene or Genome]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "compared with PIO-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
   790   C1707455:Compared [Activity]

Phrase: "or"

Phrase: "P+B treatment."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.169: PPAR agonists ameliorated the diminished GSIS by improving insulin sensitivity in db/db mice, and GSIS was further increased by the combined PPAR and PPAR agonists. 

Phrase: "PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "ameliorated"

Phrase: "the diminished GSIS by improving insulin sensitivity"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   760   C1256369:insulin secretion [Cell Function]
   757   C0920563:Insulin Sensitivity [Pathologic Function]
   757   C1719133:Glucose/Insulin [Quantitative Concept]
   739   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   739   C0036536:secretion [Biologic Function]
   739   C0036537:Secretion [Body Substance]
   739   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   739   C1579433:Insulin [Pharmacologic Substance]

Phrase: "in db/db mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "and"

Phrase: "GSIS"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "increased by the combined PPAR"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   833   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   833   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   770   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   744   C0205195:Combined [Qualitative Concept]
   744   C0205217:Increased [Quantitative Concept]
   744   C0442805:Increased [Functional Concept]
   744   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   744   C0752063:Peroxysome [Cell Component]
   744   C1879547:Activated [Activity]
   744   C2984308:Peroxisome [Functional Concept]
   711 E C0336789:Combine [Manufactured Object]
   711 E C1515877:Activate [Functional Concept]

Phrase: "and"

Phrase: "PPAR agonists."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
Processing 00000000.tx.170: We conclude that combination therapy with PPAR and PPAR agonists may be more useful than PPAR alone with respect to body weight gain and pancreatic GSIS in type 2diabetes with obesity.  

Phrase: "We"

Phrase: "conclude"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "that combination therapy with PPAR"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0009429:Combination Therapy [Therapeutic or Preventive Procedure]
   770   C0556895:Combination therapy [Therapeutic or Preventive Procedure]
   744   C0039798:therapy [Functional Concept]
   744   C0087111:Therapy [Therapeutic or Preventive Procedure]
   744   C1363945:Therapy [Finding]

Phrase: "and"

Phrase: "PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0243192:agonists [Pharmacologic Substance]
   804   C2987634:agonists [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "may"

Phrase: "be"

Phrase: "more useful than PPAR"

Phrase: "alone with respect to body weight gain"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0205171:Alone [Quantitative Concept]
   748   C0439044:alone [Finding]
   748   C0679994:alone [Group Attribute]

Phrase: "and"

Phrase: "pancreatic GSIS in type 2diabetes"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   770   C1256369:insulin secretion [Cell Function]
   767   C0030296:Pancreatic Secretion [Body Substance]
   767   C0232787:Pancreatic secretion [Organ or Tissue Function]
   767   C0457592:Insulin type [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   767   C1719133:Glucose/Insulin [Quantitative Concept]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0036536:secretion [Biologic Function]
   744   C0036537:Secretion [Body Substance]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]

Phrase: "with obesity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]
Processing 00000000.tx.171: FOOTNOTES Address for reprint requests and other correspondence: K.Yajima, Dept. of Internal Medicine, Keio Univ. 

Phrase: "FOOTNOTES Address for reprint requests"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0376649:Address [Intellectual Product]
   760   C1442065:Address [Spatial Concept]

Phrase: "and"

Phrase: "other correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282413:Correspondence [Intellectual Product]

Phrase: ":"

Phrase: "K.Yajima,"

Phrase: "Dept."

Phrase: "of Internal Medicine,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0021782:Internal Medicine [Biomedical Occupation or Discipline]
  1000   C1555750:Internal Medicine [Intellectual Product]
   861   C0013227:Medicine, NOS [Pharmacologic Substance]
   861   C0025118:Medicine [Biomedical Occupation or Discipline]
   861   C0205102:Internal [Spatial Concept]
   861   C1553872:Internal [Intellectual Product]
   861   C1619620:Internal [Intellectual Product]

Phrase: "Keio Univ."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041740:UNIV [Manufactured Object,Organization]
Processing 00000000.tx.172: School of Medicine, 35Shinanomachi, Shinjuku-ku, Tokyo 160-8582,Japan (E-mail: n62383{at}sc.itc.keio.ac.jp ). 

Phrase: "School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0036375:School [Manufactured Object,Organization]

Phrase: "35Shinanomachi,"

Phrase: "Shinjuku-ku,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1532717:ku [Quantitative Concept]
   861   C1881335:kU [Quantitative Concept]

Phrase: "Tokyo 160-8582,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: "(E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "n62383{at}sc.itc.keio.ac.jp"

Phrase: ")."
Processing 00000000.tx.173: The costs of publication of this article were defrayed in part by the payment of page charges. 

Phrase: "The costs of publication of this article"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0010186:Costs [Quantitative Concept]
   748   C0220812:Costs [Quantitative Concept]

Phrase: "were"

Phrase: "defrayed in part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0449719:Part [Spatial Concept]
   790   C1709471:Part [Quantitative Concept]

Phrase: "by the payment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0220808:payment [Quantitative Concept]
  1000   C0680264:payment [Quantitative Concept]

Phrase: "of page charges."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0007961:Charges [Quantitative Concept]
   827 E C1706211:Charge [Organism Attribute]
Processing 00000000.tx.174: The article must therefore be hereby marked "advertisement" in accordance with 18U.S.C. 

Phrase: "The article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "must"

Phrase: "therefore"

Phrase: "be"

Phrase: "hereby"

Phrase: "marked"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0522501:Marked [Qualitative Concept]
  1000   C1706089:Marked [Qualitative Concept]

Phrase: """advertisement"""
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0949214:advertisement [Intellectual Product]

Phrase: "in accordance with 18U.S.C."
Processing 00000000.tx.175: Section 1734solely to indicate this fact. 

Phrase: "Section 1734solely to"

Phrase: "indicate"

Phrase: "this fact."
Processing 00000000.tx.176: 10.1152/ajpendo.00149.2002 Received 8 April 2002; 

Phrase: "10.1152/ajpendo.00149.2002"

Phrase: "Received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "8 April 2002"

Phrase: ";"
Processing 00000000.tx.177: accepted in final form 10 December 2002.  

Phrase: "accepted in final form 10 December 2002."
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   748   C0205088:Final [Temporal Concept]
   748   C0348078:Form [Qualitative Concept]
   748   C0376315:Form [Manufactured Object]
   748   C1272684:Accepted [Qualitative Concept]
   748   C1522492:Form [Functional Concept]
   748   C1546485:Final [Idea or Concept]
   748   C1548435:Accepted [Idea or Concept]
   714 E C1548601:Accept [Idea or Concept]
Processing 00000000.tx.178: REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES 1.  

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "TOP ABSTRACT INTRODUCTION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS RESULTS DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.179: Braissant, O, Foufelle F, Scotto C, Dauca M, and Wahli W. 

Phrase: "Braissant,"

Phrase: "O,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439114:O NOS [Intellectual Product]

Phrase: "Foufelle F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Scotto C,"

Phrase: "Dauca M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Wahli W."
Processing 00000000.tx.180: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. 

Phrase: "Differential expression of peroxisome proliferator-activated receptors (PPARs)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C0597360:receptor expression [Genetic Function]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: ":"

Phrase: "tissue distribution of PPAR-alpha, -"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0040287:Tissue Distribution [Quantitative Concept]
   770   C0220927:tissue distribution [Functional Concept]
   744   C0040300:Tissue [Tissue]
   744   C0520511:distribution [Idea or Concept]
   744   C1547928:Tissue [Intellectual Product]
   744   C1704711:Distribution [Functional Concept]
   703   C0166415:Peroxisome Proliferator-Activated Receptor alpha [Amino Acid, Peptide, or Protein,Receptor]
   703   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA [Gene or Genome]

Phrase: "beta,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0330390:Beta [Plant]
  1000   C0439096:Beta [Intellectual Product]
  1000   C2004068:Beta [Qualitative Concept]

Phrase: "and -"

Phrase: "gamma in the adult rat."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0017011:Gamma [Natural Phenomenon or Process]
   760   C1552644:Gamma [Intellectual Product]
   760   C2349976:Gamma [Quantitative Concept]
Processing 00000000.tx.181: Endocrinology 137: 354-366, 1996[Abstract]. 

Phrase: "Endocrinology 137"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014137:Endocrinology [Biomedical Occupation or Discipline]
   789 E C0694557:endocrinologic [Functional Concept]

Phrase: ":"

Phrase: "354-366,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.182: 2.  

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.183: Chaput, E, Saladin R, Silvestre M, and Edgar AD. 

Phrase: "Chaput,"

Phrase: "E,"

Phrase: "Saladin R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Silvestre M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Edgar AD."
Processing 00000000.tx.184: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. 

Phrase: "Fenofibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033228:Fenofibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "rosiglitazone lower serum triglycerides with opposing effects"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   778   C0542495:serum triglycerides [Laboratory Procedure]
   774   C0858892:Lower triglycerides [Finding]
   748   C0041004:Triglycerides [Biologically Active Substance,Lipid]
   748   C0229671:Serum [Body Substance]
   748   C1546774:Serum [Intellectual Product]
   748   C1550100:Serum [Body Substance]

Phrase: "on body weight."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0005910:Body Weight [Organism Attribute]
           weight
  1000   C1305866:body weight [Diagnostic Procedure]
           weight
   861   C0043100:Weight [Quantitative Concept]
   861   C0242821:body [Human]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1705104:Weight [Idea or Concept]
   777 E C1995017:Bodies [Cell Component]
Processing 00000000.tx.185: Biochem Biophys Res Commun 271: 445-450, 2000[ISI][Medline]. 

Phrase: "Biochem Biophys Res Commun 271"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C2347379:RES [Finding]

Phrase: ":"

Phrase: "445-450,"

Phrase: "2000"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.186: 3.  

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.187: De Souza, CJ, Yu JH, Robinson DD, Ulrich RG, and Meglasson MD. 

Phrase: "De Souza,"

Phrase: "CJ,"

Phrase: "Yu JH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: "Robinson DD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538867:DD [Gene or Genome]

Phrase: "Ulrich RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "and"

Phrase: "Meglasson MD."
Processing 00000000.tx.188: Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. 

Phrase: "Insulin secretory defect in Zucker fa/fa rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1457869:Defect [Functional Concept]
   744   C1861101:DEFECT [Disease or Syndrome]

Phrase: "is"

Phrase: "improved by ameliorating insulin resistance."
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   806   C0021655:Insulin Resistance [Pathologic Function]
   806   C2700570:INSULIN RESISTANCE [Gene or Genome]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0184511:Improved [Qualitative Concept]
   760   C0237834:Resistance [Mental Process]
   760   C0332272:Improved [Qualitative Concept]
   760   C1514892:Resistance [Physiologic Function]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1561611:Improved [Intellectual Product]
   760   C1579433:Insulin [Pharmacologic Substance]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.189: Diabetes 44: 984-991, 1995[Abstract]. 

Phrase: "Diabetes 44"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "984-991,"

Phrase: "1995"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.190: 4.  

Phrase: "4."
Processing 00000000.tx.191: De Vos, P, Lefebvre AM, Miller SG, Guerre Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, and Auwerx J. 

Phrase: "De Vos,"

Phrase: "P,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Lefebvre"

Phrase: "AM"

Phrase: ","

Phrase: "Miller SG,"

Phrase: "Guerre Millo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Wong K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Saladin R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Hamann LG,"

Phrase: "Staels B,"

Phrase: "Briggs MR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347167:Mr. [Conceptual Entity]

Phrase: "and"

Phrase: "Auwerx J."
Processing 00000000.tx.192: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. 

Phrase: "Thiazolidinediones"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1257987:Thiazolidinediones [Organic Chemical,Pharmacologic Substance]
   966 E C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   966 E C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "repress"

Phrase: "ob gene expression in rodents"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0017262:Gene Expression [Genetic Function]
   760   C0017337:Gene [Gene or Genome]
   760   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "via activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879547:Activation [Activity]

Phrase: "of peroxisome proliferator-activated receptor gamma."
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0017011:Gamma [Natural Phenomenon or Process]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1552644:Gamma [Intellectual Product]
   804   C1879547:Activated [Activity]
   804   C2349976:Gamma [Quantitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]
Processing 00000000.tx.193: J Clin Invest 98: 1004-1009, 1996[Abstract/Free FullText]. 

Phrase: "J"

Phrase: "Clin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]

Phrase: "Invest"

Phrase: "98"

Phrase: ":"

Phrase: "1004-1009,"

Phrase: "1996"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.194: 5.  

Phrase: "5."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]
Processing 00000000.tx.195: Dubois, M, Pattou F, Kerr Conte J, Gmyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, and Lefebvre J. 

Phrase: "Dubois,"

Phrase: "M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "Pattou F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Kerr Conte J,"

Phrase: "Gmyr V,"

Phrase: "Vandewalle B,"

Phrase: "Desreumaux P,"

Phrase: "Auwerx J,"

Phrase: "Schoonjans K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "and"

Phrase: "Lefebvre J."
Processing 00000000.tx.196: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. 

Phrase: "Expression of peroxisome proliferator-activated receptor gamma (PPARgamma)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0597360:receptor expression [Genetic Function]
   748   C0185117:Expression [Therapeutic or Preventive Procedure]
   731   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   731   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]

Phrase: "in normal human pancreatic islet cells."
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   881   C0007634:Normal cell [Cell]
           Cells
   881   C1268443:Normal cell [Cell]
   875   C0427861:Human cells [Laboratory or Test Result]
   867   C0734999:Pancreatic islet cell [Cell]
   840   C0022131:Islet Cells [Body Part, Organ, or Organ Component]
   806 E C1522529:Islet Cell [Cell]
   804   C3282337:Cells [Cell]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.197: Diabetologia 43: 1165-1169, 2000[ISI][Medline]. 

Phrase: "Diabetologia 43"

Phrase: ":"

Phrase: "1165-1169,"

Phrase: "2000"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.198: 5a.  

Phrase: "5a."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553637:5a [Medical Device]
Processing 00000000.tx.199: Etgen, GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker A, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR, Jr, Ogilvie KM, Liu S, and Kauffman RF. 

Phrase: "Etgen,"

Phrase: "GJ,"

Phrase: "Oldham BA,"

Phrase: "Johnson WT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2700323:WT [Fish]

Phrase: "Broderick CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Montrose CR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0201975:Cr [Laboratory Procedure]
   861   C3539604:CR [Gene or Genome]

Phrase: "Brozinick JT,"

Phrase: "Misener EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: "Bean JS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552154:Js [Body Part, Organ, or Organ Component]

Phrase: "Bensch WR,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C1420193:WR [Gene or Genome]
   861   C1425679:WR [Gene or Genome]
   861   C1862190:WR [Immunologic Factor]
   861   C3538902:WR [Gene or Genome]

Phrase: "Brooks DA,"

Phrase: "Shuker A,"

Phrase: "Rito CJ,"

Phrase: "McCarthy JR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1708595:Jr [Idea or Concept]
   861   C3280986:JR [Disease or Syndrome]

Phrase: "Ardecky RJ,"

Phrase: "Tyhonas JS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552154:Js [Body Part, Organ, or Organ Component]

Phrase: "Dana SL,"

Phrase: "Bilakovics JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Paterniti JR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1708595:Jr [Idea or Concept]
   861   C3280986:JR [Disease or Syndrome]

Phrase: "Jr,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1708595:Jr [Idea or Concept]
  1000   C3280986:JR [Disease or Syndrome]

Phrase: "Ogilvie KM,"

Phrase: "Liu S,"

Phrase: "and"

Phrase: "Kauffman RF."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035448:RF [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0201660:RF [Laboratory Procedure]
   861   C0748398:RF [Finding]
Processing 00000000.tx.200: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance, and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. 

Phrase: "A tailored therapy for the metabolic syndrome"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0587059:Metabolic therapy [Therapeutic or Preventive Procedure]
   748   C0039798:therapy [Functional Concept]
   748   C0087111:Therapy [Therapeutic or Preventive Procedure]
   748   C1363945:Therapy [Finding]

Phrase: ":"

Phrase: "the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   791   C1122224:LY465608 [Organic Chemical,Pharmacologic Substance]
   709   C2916838:Peroxisome Proliferator Receptor alpha Agonist [Pharmacologic Substance]
   709   C2917405:Peroxisome Proliferator Receptor gamma Agonist [Pharmacologic Substance]
   708   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
   708   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   707   C0166415:Peroxisome Proliferator-Activated Receptor alpha [Amino Acid, Peptide, or Protein,Receptor]
   707   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA [Gene or Genome]

Phrase: "ameliorates"

Phrase: "insulin resistance,"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "diabetic hyperglycemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "while"

Phrase: "improving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1272745:Improving [Qualitative Concept]

Phrase: "cardiovascular risk factors in preclinical models."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   816   C0850624:cardiovascular risk factor [Disease or Syndrome]
   790   C0035648:risk factors [Quantitative Concept]
   790   C1553898:risk factors [Idea or Concept]
   787   C0679713:risk factor model [Intellectual Product]
   719   C1521761:Factor [Functional Concept]
   719   C2827422:Factor [Conceptual Entity]
Processing 00000000.tx.201: Diabetes 51: 1083-1087, 2002[Abstract/Free FullText]. 

Phrase: "Diabetes 51"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "1083-1087,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.202: 6.  

Phrase: "6."
Processing 00000000.tx.203: Fukushima, M, Taniguchi A, Sakai M, Doi K, Nagata I, Nagasaka S, Tokuyama K, and Nakai Y. 

Phrase: "Fukushima,"

Phrase: "M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "Taniguchi A,"

Phrase: "Sakai M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Doi K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Nagata I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Nagasaka S,"

Phrase: "Tokuyama K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "and"

Phrase: "Nakai Y."
Processing 00000000.tx.204: Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2diabetic patients. 

Phrase: "Effect of bezafibrate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "on insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "in nonobese Japanese type 2diabetic patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.205: Diabetes Care 23: 259, 2000[Free FullText]. 

Phrase: "Diabetes Care 23"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0450348:23 [Quantitative Concept]
   827   C1947933:Care [Activity]

Phrase: ":"

Phrase: "259,"

Phrase: "2000"

Phrase: "[Free FullText"

Phrase: "]."
Processing 00000000.tx.206: 7.  

Phrase: "7."
Processing 00000000.tx.207: Guerre-Millo, M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, and Staels B. 

Phrase: "Guerre-Millo,"

Phrase: "M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "Gervois P,"

Phrase: "Raspe E,"

Phrase: "Madsen L,"

Phrase: "Poulain P,"

Phrase: "Derudas B,"

Phrase: "Herbert JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Winegar DA,"

Phrase: "Willson TM,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0145779:TM [Amino Acid, Peptide, or Protein,Receptor]
   861   C3540468:TM [Gene or Genome]

Phrase: "Fruchart JC,"

Phrase: "Berge RK,"

Phrase: "and"

Phrase: "Staels B."
Processing 00000000.tx.208: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. 

Phrase: "Peroxisome proliferator-activated receptor alpha activators"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   920   C2267030:Peroxisome proliferator receptor alpha activator [Pharmacologic Substance]
   780   C0166415:Peroxisome Proliferator-Activated Receptor alpha [Amino Acid, Peptide, or Protein,Receptor]
   780   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA [Gene or Genome]
           PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
   734   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]

Phrase: "improve"

Phrase: "insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "reduce"

Phrase: "adiposity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Adiposity [Disease or Syndrome]
  1000   C1563743:adiposity [Organism Attribute]
Processing 00000000.tx.209: J Biol Chem 275: 16638-16642, 2000[Abstract/Free FullText]. 

Phrase: "J Biol Chem 275"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "16638-16642,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.210: 8.  

Phrase: "8."
Processing 00000000.tx.211: Hallakou, S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, and Ferre P. 

Phrase: "Hallakou,"

Phrase: "S,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "Doare L,"

Phrase: "Foufelle F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Kergoat M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Guerre-Millo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Berthault MF,"

Phrase: "Dugail I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Morin J,"

Phrase: "Auwerx J,"

Phrase: "and"

Phrase: "Ferre P."
Processing 00000000.tx.212: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. 

Phrase: "Pioglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "in vivo adipocyte differentiation in the obese Zucker fa/fa rat."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   756   C1159884:adipocyte differentiation [Cell Function]
   738   C0007589:Differentiation [Cell Function]
   738   C1511938:Differentiation [Clinical Attribute]
   738   C2945687:Differentiation [Functional Concept]
Processing 00000000.tx.213: Diabetes 46: 1393-1399, 1997[Abstract]. 

Phrase: "Diabetes 46"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "1393-1399,"

Phrase: "1997"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.214: 9.  

Phrase: "9."
Processing 00000000.tx.215: Higa, M, Zhou YT, Ravazzola M, Baetens D, Orci L, and Unger RH. 

Phrase: "Higa,"

Phrase: "M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "Zhou YT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412122:YT [Gene or Genome]

Phrase: "Ravazzola M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Baetens D,"

Phrase: "Orci L,"

Phrase: "and"

Phrase: "Unger RH."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]
Processing 00000000.tx.216: Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. 

Phrase: "Troglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0245514:troglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "prevents"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0309872:PREVENT [Pharmacologic Substance]
  1000   C1292733:Prevents [Functional Concept]

Phrase: "mitochondrial alterations,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   983   C0544926:Mitochondrial alteration [Cell or Molecular Dysfunction]
   827   C1515926:Alteration [Idea or Concept]

Phrase: "beta cell destruction,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1261381:Destruction [Therapeutic or Preventive Procedure]
   827   C1948029:Destruction [Activity]
   734   C0030281:Beta cell [Cell]

Phrase: "and"

Phrase: "diabetes in obese prediabetic rats."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.217: Proc Natl Acad Sci USA 96: 11513-11518, 1999[Abstract/Free FullText]. 

Phrase: "Proc Natl Acad Sci USA 96"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "11513-11518,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.218: 10.  

Phrase: "10."
Processing 00000000.tx.219: Hirose, H, Lee YH, Inman LR, Nagasawa Y, Johnson JH, and Unger RH. 

Phrase: "Hirose,"

Phrase: "H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Lee YH,"

Phrase: "Inman LR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0023617:LR [Geographic Area]
   861   C2986899:LR [Idea or Concept]

Phrase: "Nagasawa Y,"

Phrase: "Johnson JH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: "and"

Phrase: "Unger RH."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]
Processing 00000000.tx.220: Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. 

Phrase: "Defective fatty acid-mediated beta-cell compensation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   795   C0152057:Compensation [Mental Process]
   795   C0152058:Compensation [Physiologic Function]
   795   C0220808:Compensation [Quantitative Concept]

Phrase: "in Zucker diabetic fatty rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
Processing 00000000.tx.221: Pathogenic implications for obesity-dependent diabetes. 

Phrase: "Pathogenic implications for obesity-dependent diabetes."
Processing 00000000.tx.222: J Biol Chem 271: 5633-5637, 1996[Abstract/Free FullText]. 

Phrase: "J Biol Chem 271"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "5633-5637,"

Phrase: "1996"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.223: 11.  

Phrase: "11."
Processing 00000000.tx.224: Hirshman, MF, Fagnant PM, Horton ED, King PA, and Horton ES. 

Phrase: "Hirshman,"

Phrase: "MF,"

Phrase: "Fagnant PM, Horton ED,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C3538926:ED [Idea or Concept]

Phrase: "King"

Phrase: "PA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3541314:PA [Idea or Concept]

Phrase: "and"

Phrase: "Horton ES."
Processing 00000000.tx.225: Pioglitazone treatment for 7days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes. 

Phrase: "Pioglitazone treatment for 7days"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "failed to correct"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0231175:Failed [Functional Concept]
   790   C2349182:Correct [Qualitative Concept]

Phrase: "the defect in glucose transport"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   844   C0342750:Glucose transport defect [Disease or Syndrome]
   760   C1457869:Defect [Functional Concept]
   760   C1861101:DEFECT [Disease or Syndrome]

Phrase: "and"

Phrase: "glucose transporter translocation in obese Zucker rat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0040715:Translocation [Cell or Molecular Dysfunction]
   748   C2987521:Translocation [Activity]

Phrase: "(fa/fa) skeletal muscle plasma membranes."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   827   C0007603:Plasma Membranes [Cell Component]
   799   C0025255:Membranes [Tissue]
   799   C0032105:Plasma [Body Substance]
   799   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   766 E C0596901:Membrane [Cell Component]
   766 E C1706182:Membrane [Manufactured Object]
   716 E C0205287:Membranous [Qualitative Concept]
Processing 00000000.tx.226: Biochem Biophys Res Commun 208: 835-845, 1995[ISI][Medline]. 

Phrase: "Biochem Biophys Res Commun 208"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C2347379:RES [Finding]

Phrase: ":"

Phrase: "835-845,"

Phrase: "1995"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.227: 12.  

Phrase: "12."
Processing 00000000.tx.228: Ide, T, Nakazawa T, Mochizuki T, and Murakami K. 

Phrase: "Ide,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0328104:Ide [Fish]
  1000   C1415875:IDE [Gene or Genome]
  1000   C2826366:IDE [Idea or Concept]

Phrase: "T,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Nakazawa T,"

Phrase: "Mochizuki T,"

Phrase: "and"

Phrase: "Murakami K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.229: Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. 

Phrase: "Tissue-specific actions of antidiabetic thiazolidinediones"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C1955394:Tissue specific [Body Substance]
   753   C0040300:Tissue [Tissue]
   753   C0205369:Specific [Qualitative Concept]
   753   C0441472:actions [Functional Concept]
   753   C1547928:Tissue [Intellectual Product]
   753   C1552740:specific [Intellectual Product]
   719 E C3266814:Action [Activity]

Phrase: "on the reduced fatty acid oxidation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   923   C1158366:fatty acid oxidation [Molecular Function]
   861   C0015684:Fatty acid [Lipid]
   812   C0001128:Acid [Chemical]
   812   C0030011:Oxidation [Molecular Function]
   812   C0202406:Acid [Laboratory Procedure]

Phrase: "in skeletal muscle"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0242692:Muscle, Skeletal [Tissue]
  1000   C1280260:Skeletal muscle [Body Part, Organ, or Organ Component]
   861   C0026845:Muscle [Tissue]
   861   C0037253:skeletal [Body System]
   861   C0521324:Skeletal [Spatial Concept]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "and"

Phrase: "liver of Zucker diabetic fatty rats."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   783   C0015695:Fatty Liver [Disease or Syndrome]
   767   C1882726:Rat Liver [Body Part, Organ, or Organ Component]
   753   C0023884:Liver [Body Part, Organ, or Organ Component]
   753   C0736268:LIVER [Body Part, Organ, or Organ Component]
   753   C1278929:Liver [Body Part, Organ, or Organ Component]
   753   C2346688:LIVER [Food]
Processing 00000000.tx.230: Metabolism 49: 521-525, 2000[ISI][Medline]. 

Phrase: "Metabolism 49"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025519:Metabolism [Organism Function]
   861   C0025520:metabolism [Functional Concept]

Phrase: ":"

Phrase: "521-525,"

Phrase: "2000"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.231: 13.  

Phrase: "13."
Processing 00000000.tx.232: Inoue, Y, Tanigawa K, Nakamura S, Xu G, Kawaguchi M, Kato Y, and Tamura K. 

Phrase: "Inoue,"

Phrase: "Y,"

Phrase: "Tanigawa K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Nakamura S,"

Phrase: "Xu G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Kawaguchi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Kato Y,"

Phrase: "and"

Phrase: "Tamura K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.233: Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats. 

Phrase: "Lack of effect of CS-045,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0332268:lack [Qualitative Concept]

Phrase: "a new antidiabetic agent,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0935929:Anti-diabetic Agent [Pharmacologic Substance]
           antidiabetic
   827   C0450442:Agent [Chemical Viewed Functionally]
   827   C1254351:Agent [Pharmacologic Substance]
   827   C1521826:Agent [Intellectual Product]

Phrase: "on insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "in the remnant pancreas"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0030274:Pancreas [Body Part, Organ, or Organ Component]
   861   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "after 90% pancreatectomy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030279:Pancreatectomy [Therapeutic or Preventive Procedure]

Phrase: "in rats."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]
Processing 00000000.tx.234: Diabetes Res Clin Pract 27: 19-26, 1995[ISI][Medline]. 

Phrase: "Diabetes Res Clin Pract 27"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0011849:Diabetes [Disease or Syndrome]
   804   C1315013:CLIN [Intellectual Product]
   804   C2347379:RES [Finding]

Phrase: ":"

Phrase: "19-26,"

Phrase: "1995"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.235: 14.  

Phrase: "14."
Processing 00000000.tx.236: Jones, IR, Swai A, Taylor R, Miller M, Laker MF, and Alberti KG. 

Phrase: "Jones,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443013:Jones [Intellectual Product]

Phrase: "IR,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0022065:IR [Geographic Area]
  1000   C0022071:Ir [Element, Ion, or Isotope]
  1000   C0034818:IR [Amino Acid, Peptide, or Protein,Enzyme,Receptor]

Phrase: "Swai A,"

Phrase: "Taylor R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Miller M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Laker MF,"

Phrase: "and"

Phrase: "Alberti KG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022718:KG [Geographic Area]
   861   C0439209:kg [Quantitative Concept]
Processing 00000000.tx.237: Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. 

Phrase: "Lowering of plasma glucose concentrations"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0441994:lowering [Spatial Concept]
   760   C2003888:Lowering [Activity]
   726 E C1548802:Lower [Body Location or Region]

Phrase: "with bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with moderately controlled NIDDM."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0011860:NIDDM [Disease or Syndrome]
   827   C3273872:NIDDM [Gene or Genome]
Processing 00000000.tx.238: Diabetes Care 13: 855-863, 1990[Abstract]. 

Phrase: "Diabetes Care 13"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C1947933:Care [Activity]

Phrase: ":"

Phrase: "855-863,"

Phrase: "1990"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.239: 16.  

Phrase: "16."
Processing 00000000.tx.240: Kawai, T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S, Katsukawa F, Hirose H, Shimada A, Watanabe K, and Saruta T. 

Phrase: "Kawai,"

Phrase: "T,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Takei I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Oguma Y,"

Phrase: "Ohashi N,"

Phrase: "Tokui M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Oguchi S,"

Phrase: "Katsukawa F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Hirose H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Shimada A,"

Phrase: "Watanabe K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "and"

Phrase: "Saruta T."
Processing 00000000.tx.241: Effects of troglitazone on fat distribution in the treatment of male type 2diabetes. 

Phrase: "Effects of troglitazone"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C1280500:effects [Qualitative Concept]
   756 E C2348382:Effect [Qualitative Concept]

Phrase: "on fat distribution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0520511:distribution [Idea or Concept]
   861   C1704711:Distribution [Functional Concept]

Phrase: "in the treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "of male type 2diabetes."
Processing 00000000.tx.242: Metabolism 48: 1102-1107, 1999[ISI][Medline]. 

Phrase: "Metabolism 48"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025519:Metabolism [Organism Function]
   861   C0025520:metabolism [Functional Concept]

Phrase: ":"

Phrase: "1102-1107,"

Phrase: "1999"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.243: 17.  

Phrase: "17."
Processing 00000000.tx.244: Kim, HI, Kim JW, Kim SH, Cha JY, Kim KS, and Ahn YH. 

Phrase: "Kim,"

Phrase: "HI,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0018619:HI [Geographic Area]
  1000   C0239849:HI [Congenital Abnormality,Disease or Syndrome]
  1000   C1412082:HI [Gene or Genome]
  1000   C1412316:HI [Gene or Genome]

Phrase: "Kim JW,"

Phrase: "Kim SH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0038108:SH [Geographic Area]

Phrase: "Cha JY,"

Phrase: "Kim KS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541894:ks [Quantitative Concept]

Phrase: "and"

Phrase: "Ahn YH."
Processing 00000000.tx.245: Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. 

Phrase: "Identification"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020792:Identification [Mental Process]
  1000   C0205396:Identification [Qualitative Concept]

Phrase: "and"

Phrase: "functional characterization of the peroxisomal proliferator response element"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1880022:Characterization [Activity]

Phrase: "in rat GLUT2 promoter."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.246: Diabetes 49: 1517-1524, 2000[Abstract]. 

Phrase: "Diabetes 49"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "1517-1524,"

Phrase: "2000"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.247: 18.  

Phrase: "18."
Processing 00000000.tx.248: King, AB. 

Phrase: "King,"

Phrase: "AB."
Processing 00000000.tx.249: A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. 

Phrase: "A comparison in a clinical setting of the efficacy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1707455:Comparison [Activity]

Phrase: "and"

Phrase: "side effects of three thiazolidinediones."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   806   C0001688:side effects [Functional Concept]
   773 E C0879626:Side Effect [Pathologic Function]
   760   C0441987:Side [Spatial Concept]
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.250: Diabetes Care 23: 557, 2000. 

Phrase: "Diabetes Care 23"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0450348:23 [Quantitative Concept]
   827   C1947933:Care [Activity]

Phrase: ":"

Phrase: "557,"

Phrase: "2000."
Processing 00000000.tx.251: 19.  

Phrase: "19."
Processing 00000000.tx.252: Kobayashi, M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, and Baba S. 

Phrase: "Kobayashi,"

Phrase: "M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "Shigeta Y,"

Phrase: "Hirata Y,"

Phrase: "Omori Y,"

Phrase: "Sakamoto N,"

Phrase: "Nambu S,"

Phrase: "and"

Phrase: "Baba S."
Processing 00000000.tx.253: Improvement of glucose tolerance in NIDDM by clofibrate. 

Phrase: "Improvement of glucose tolerance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2986411:Improvement [Conceptual Entity]

Phrase: "in NIDDM"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011860:NIDDM [Disease or Syndrome]
  1000   C3273872:NIDDM [Gene or Genome]

Phrase: "by clofibrate."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0009002:Clofibrate [Organic Chemical,Pharmacologic Substance]
   944 E C0591129:Atromid S [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.254: Randomized double-blind study. 

Phrase: "Randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: "double-blind study."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C0013072:Double-Blind Study [Research Activity]
           DOUBLE BLIND
   901   C2347038:blind study [Research Activity]
   827   C0150108:Blind [Research Activity]
   827   C0205173:Double [Functional Concept]
   827   C0456909:Blind [Disease or Syndrome]
   827   C0525065:blind [Patient or Disabled Group]
   827   C0557651:Study [Manufactured Object]
   827   C1705764:Double [Activity]
   827   C1705765:Double [Qualitative Concept]
   827   C2603343:Study [Research Activity]
Processing 00000000.tx.255: Diabetes Care 11: 495-499, 1988[Abstract]. 

Phrase: "Diabetes Care 11"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C1947933:Care [Activity]

Phrase: ":"

Phrase: "495-499,"

Phrase: "1988"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.256: 20.  

Phrase: "20."
Processing 00000000.tx.257: Lee, Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, and Unger RH. 

Phrase: "Lee,"

Phrase: "Y,"

Phrase: "Hirose H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ohneda M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Johnson JH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: "McGarry JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "and"

Phrase: "Unger RH."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]
Processing 00000000.tx.258: Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. 

Phrase: "Beta-cell lipotoxicity in the pathogenesis"

Phrase: "of non-insulin-dependent diabetes mellitus"
Meta Candidates (Total=17; Excluded=2; Pruned=0; Remaining=15)
  1000   C0011860:Diabetes Mellitus, Non-Insulin-Dependent [Disease or Syndrome]
           Non-Insulin Dependent Diabetes
  1000   C2697407:DIABETES MELLITUS, NONINSULIN-DEPENDENT [Gene or Genome]
   937   C0011854:Diabetes Mellitus, Insulin-Dependent [Disease or Syndrome]
           Insulin Dependent Diabetes
   840   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C0851827:Dependent [Qualitative Concept]
   804   C1518422:Non [Functional Concept]
   804   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   804   C1579433:Insulin [Pharmacologic Substance]
   804   C1701901:Dependent [Qualitative Concept]
   804   C3244310:dependent [Functional Concept]
   748 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   721 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "of obese rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]

Phrase: ":"

Phrase: "impairment in adipocyte-beta-cell relationships."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0684336:Impairment [Pathologic Function]
Processing 00000000.tx.259: Proc Natl Acad Sci USA 91: 10878-10882, 1994[Abstract/Free FullText]. 

Phrase: "Proc Natl Acad Sci USA 91"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "10878-10882,"

Phrase: "1994"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.260: 21.  

Phrase: "21."
Processing 00000000.tx.261: Lefebvre, AM, Peinado Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, and Staels B. 

Phrase: "Lefebvre,"

Phrase: "AM"

Phrase: ","

Phrase: "Peinado Onsurbe J,"

Phrase: "Leitersdorf I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Briggs MR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347167:Mr. [Conceptual Entity]

Phrase: "Paterniti JR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1708595:Jr [Idea or Concept]
   861   C3280986:JR [Disease or Syndrome]

Phrase: "Fruchart JC,"

Phrase: "Fievet C,"

Phrase: "Auwerx J,"

Phrase: "and"

Phrase: "Staels B."
Processing 00000000.tx.262: Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. 

Phrase: "Regulation of lipoprotein metabolism"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1327341:regulation of lipoprotein metabolism [Molecular Function]
   881   C1159402:regulation of metabolism [Organism Function]
           metabolism regulation
   770   C0851285:Regulation [Governmental or Regulatory Activity]
   770   C1327622:Regulation [Biologic Function]

Phrase: "by thiazolidinediones"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1257987:Thiazolidinediones [Organic Chemical,Pharmacologic Substance]
   966 E C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   966 E C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "occurs through a distinct"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1709305:Occur [Activity]
   770   C2745955:OCCUR [Temporal Concept]

Phrase: "but"

Phrase: "complementary mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "relative to fibrates."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0080103:Relative [Family Group]
   790   C0205345:Relative [Qualitative Concept]
   790   C1547039:*Relative [Quantitative Concept]
Processing 00000000.tx.263: Arterioscler Thromb Vasc Biol 17: 1756-1764, 1997[Abstract/Free FullText]. 

Phrase: "Arterioscler Thromb Vasc Biol 17"

Phrase: ":"

Phrase: "1756-1764,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.264: 22.  

Phrase: "22."
Processing 00000000.tx.265: Lehmann, JM, Moore LB, Smith Oliver TA, Wilkison WO, Willson TM, and Kliewer SA. 

Phrase: "Lehmann,"

Phrase: "JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022337:JM [Geographic Area]

Phrase: "Moore LB,"

Phrase: "Smith Oliver TA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1506978:Ta [Immunologic Factor]
   827   C1705538:TA [Idea or Concept]

Phrase: "Wilkison WO,"

Phrase: "Willson TM,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0145779:TM [Amino Acid, Peptide, or Protein,Receptor]
   861   C3540468:TM [Gene or Genome]

Phrase: "and"

Phrase: "Kliewer SA."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036243:SA [Geographic Area]
   861   C1539696:SA [Gene or Genome]
   861   C1825840:SA [Gene or Genome]
   861   C3539736:Sa [Spatial Concept]
Processing 00000000.tx.266: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). 

Phrase: "An antidiabetic thiazolidinedione"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   861   C1257987:Thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   861   C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "is"

Phrase: "a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   775   C0683185:receptor ligand affinity [Molecular Function]
   757   C1621296:receptor ligand [Molecular Function]
   739   C0023688:Ligand [Chemical]
Processing 00000000.tx.267: J Biol Chem 270: 12953-12956, 1995[Abstract/Free FullText]. 

Phrase: "J Biol Chem 270"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "12953-12956,"

Phrase: "1995"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.268: 23.  

Phrase: "23."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]
Processing 00000000.tx.269: Masuda, K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, and Seino Y. 

Phrase: "Masuda,"

Phrase: "K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Okamoto Y,"

Phrase: "Tsuura Y,"

Phrase: "Kato S,"

Phrase: "Miura T,"

Phrase: "Tsuda K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Horikoshi H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ishida H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Seino Y."
Processing 00000000.tx.270: Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. 

Phrase: "Effects of Troglitazone"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C1280500:effects [Qualitative Concept]
   756 E C2348382:Effect [Qualitative Concept]

Phrase: "(CS-045"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0056565:CS 045 [Organic Chemical,Pharmacologic Substance]
   861   C3540510:cs [Quantitative Concept]

Phrase: ")"

Phrase: "on insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "in isolated rat pancreatic islets"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022131:Pancreatic Islets [Body Part, Organ, or Organ Component]
   812   C0030274:Pancreatic [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "HIT cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: ":"

Phrase: "an insulinotropic mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]

Phrase: "distinct from glibenclamide."
Processing 00000000.tx.271: Diabetologia 38: 24-30, 1995[ISI][Medline]. 

Phrase: "Diabetologia 38"

Phrase: ":"

Phrase: "24-30,"

Phrase: "1995"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.272: 24.  

Phrase: "24."
Processing 00000000.tx.273: Matsui, H, Okumura K, Kawakami K, Hibino M, Toki Y, and Ito T. 

Phrase: "Matsui,"

Phrase: "H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Okumura K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Kawakami K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Hibino M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Toki Y,"

Phrase: "and"

Phrase: "Ito T."
Processing 00000000.tx.274: Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides. 

Phrase: "Improved insulin sensitivity by bezafibrate"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   806   C0920563:Insulin Sensitivity [Pathologic Function]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "in rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]

Phrase: ":"

Phrase: "relationship to fatty acid composition of skeletal-muscle triglycerides."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0439849:Relationship [Qualitative Concept]
   742   C1705630:Relationship [Idea or Concept]
   742   C1706279:Relationship [Idea or Concept]
   742   C3540605:Relationship [Intellectual Product]
Processing 00000000.tx.275: Diabetes 46: 348-353, 1997[Abstract]. 

Phrase: "Diabetes 46"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "348-353,"

Phrase: "1997"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.276: 25.  

Phrase: "25."
Processing 00000000.tx.277: Murakami, K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, and Kadowaki T. 

Phrase: "Murakami,"

Phrase: "K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Tobe K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Ide T,"

Phrase: "Mochizuki T,"

Phrase: "Ohashi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Akanuma Y,"

Phrase: "Yazaki Y,"

Phrase: "and"

Phrase: "Kadowaki T."
Processing 00000000.tx.278: A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. 

Phrase: "A novel insulin sensitizer acts as a coligand"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   711   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "for peroxisome proliferator-activated receptor-alpha (PPAR-alpha)"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166415:Peroxisome Proliferator-Activated Receptor alpha [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA [Gene or Genome]
           PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0439095:Alpha [Intellectual Product]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2003941:Alpha [Intellectual Product]
   804   C2350010:Alpha [Qualitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "and"

Phrase: "PPAR-gamma"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166417:Peroxisome Proliferator-Activated Receptor gamma [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1335238:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA [Gene or Genome]
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0017011:Gamma [Natural Phenomenon or Process]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1552644:Gamma [Intellectual Product]
   804   C1879547:Activated [Activity]
   804   C2349976:Gamma [Quantitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: ":"

Phrase: "effect of PPAR-alpha activation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]
   703   C0166415:Peroxisome Proliferator-Activated Receptor alpha [Amino Acid, Peptide, or Protein,Receptor]
   703   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA [Gene or Genome]

Phrase: "on abnormal lipid metabolism"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0598783:Lipid Metabolism [Molecular Function]
   901   C1517898:Lipid Metabolism [Molecular Function]
   827   C0023779:Lipid [Lipid]
   827   C0025519:Metabolism [Organism Function]
   827   C0025520:metabolism [Functional Concept]

Phrase: "in liver"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0023884:Liver [Body Part, Organ, or Organ Component]
  1000   C0736268:LIVER [Body Part, Organ, or Organ Component]
  1000   C1278929:Liver [Body Part, Organ, or Organ Component]
  1000   C2346688:LIVER [Food]
   944 E C0205054:Hepatic [Body Location or Region]

Phrase: "of Zucker fatty rats."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0034719:Rats, Zucker [Mammal]
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C2700303:Zucker [Mammal]
Processing 00000000.tx.279: Diabetes 47: 1841-1847, 1998[Abstract]. 

Phrase: "Diabetes 47"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "1841-1847,"

Phrase: "1998"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.280: 26.  

Phrase: "26."
Processing 00000000.tx.281: Murakami, K, Tsunoda M, Ide T, Ohashi M, and Mochizuki T. 

Phrase: "Murakami,"

Phrase: "K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Tsunoda M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Ide T,"

Phrase: "Ohashi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Mochizuki T."
Processing 00000000.tx.282: Amelioration by KRP-297, a new thiazolidinedione, of impaired glucose uptake in skeletal muscle from obese insulin-resistant animals. 

Phrase: "Amelioration by KRP-297,"

Phrase: "a new thiazolidinedione,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   861   C1257987:Thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   861   C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "of impaired glucose uptake"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C1159527:glucose uptake [Cell Function]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0243144:Uptake [Physiologic Function]
   827   C0347980:% uptake [Quantitative Concept]

Phrase: "in skeletal muscle"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0242692:Muscle, Skeletal [Tissue]
  1000   C1280260:Skeletal muscle [Body Part, Organ, or Organ Component]
   861   C0026845:Muscle [Tissue]
   861   C0037253:skeletal [Body System]
   861   C0521324:Skeletal [Spatial Concept]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "from obese insulin-resistant animals."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0003062:Animals [Animal]
Processing 00000000.tx.283: Metabolism 48: 1450-1454, 1999[ISI][Medline]. 

Phrase: "Metabolism 48"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025519:Metabolism [Organism Function]
   861   C0025520:metabolism [Functional Concept]

Phrase: ":"

Phrase: "1450-1454,"

Phrase: "1999"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.284: 27.  

Phrase: "27."
Processing 00000000.tx.285: Murase, K, Odaka H, Suzuki M, Tayuki N, and Ikeda H. 

Phrase: "Murase,"

Phrase: "K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Odaka H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Suzuki M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Tayuki N,"

Phrase: "and"

Phrase: "Ikeda H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.286: Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. 

Phrase: "Pioglitazone time-dependently"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0040223:Time [Temporal Concept]
   827   C0071097:pioglitazone [Organic Chemical,Pharmacologic Substance]
   827   C3541383:Time [Temporal Concept]
   771 E C0442043:Temporal [Spatial Concept]
   771 E C2362314:Temporal [Temporal Concept]
   743 E C1632851:Times [Quantitative Concept]

Phrase: "reduces"

Phrase: "tumour necrosis factor-alpha level in muscle"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1547707:Level [Geographic Area]
   748   C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "improves"

Phrase: "metabolic abnormalities in Wistar fatty rats."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0000768:Abnormalities [Congenital Abnormality]
   753   C0000769:abnormalities [Functional Concept]
   719 E C1704258:Abnormality [Finding]
Processing 00000000.tx.287: Diabetologia 41: 257-264, 1998[ISI][Medline]. 

Phrase: "Diabetologia 41"

Phrase: ":"

Phrase: "257-264,"

Phrase: "1998"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.288: 28.  

Phrase: "28."
Processing 00000000.tx.289: Ogawa, S, Takeuchi K, Sugimura K, Fukuda M, Lee R, Ito S, and Sato T. 

Phrase: "Ogawa,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443037:Ogawa [Intellectual Product]

Phrase: "S,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "Takeuchi K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Sugimura K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Fukuda M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Lee R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Ito S,"

Phrase: "and"

Phrase: "Sato T."
Processing 00000000.tx.290: Bezafibrate reduces blood glucose in type 2diabetes mellitus. 

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "reduces"

Phrase: "blood glucose in type 2diabetes mellitus."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0005802:Blood Glucose [Carbohydrate]
   783   C0005810:blood type [Classification]
   783   C1383165:Blood Type [Clinical Attribute]
   783   C3274467:Blood Type [Diagnostic Procedure]
   753   C0005767:Blood [Tissue]
   753   C0005768:blood [Body Substance]
   753   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   753   C0229664:Blood [Body Substance]
Processing 00000000.tx.291: Metabolism 49: 331-334, 2000[ISI][Medline]. 

Phrase: "Metabolism 49"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025519:Metabolism [Organism Function]
   861   C0025520:metabolism [Functional Concept]

Phrase: ":"

Phrase: "331-334,"

Phrase: "2000"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.292: 29.  

Phrase: "29."
Processing 00000000.tx.293: Ohtani, K, Shimizu H, Tanaka Y, Sato N, and Mori M. 

Phrase: "Ohtani,"

Phrase: "K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Shimizu H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Tanaka Y,"

Phrase: "Sato N,"

Phrase: "and"

Phrase: "Mori M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.294: Pioglitazone hydrochloride stimulates insulin secretion in HIT-T 15cells by inducing Ca2+ influx. 

Phrase: "Pioglitazone hydrochloride"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0872972:Pioglitazone hydrochloride [Organic Chemical,Pharmacologic Substance]
   861   C1512523:hydrochloride [Inorganic Chemical,Pharmacologic Substance]

Phrase: "stimulates"

Phrase: "insulin secretion in HIT-T 15cells"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C1256369:insulin secretion [Cell Function]
   753   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C0036536:secretion [Biologic Function]
   753   C0036537:Secretion [Body Substance]
   753   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   753   C1579433:Insulin [Pharmacologic Substance]

Phrase: "by inducing Ca2+ influx."
Processing 00000000.tx.295: J Endocrinol 150: 107-111, 1996[Abstract]. 

Phrase: "J Endocrinol 150"

Phrase: ":"

Phrase: "107-111,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.296: 30.  

Phrase: "30."
Processing 00000000.tx.297: Ohtani, KI, Shimizu H, Sato N, and Mori M. 

Phrase: "Ohtani,"

Phrase: "KI,"

Phrase: "Shimizu H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Sato N,"

Phrase: "and"

Phrase: "Mori M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.298: Troglitazone (CS-045) inhibits beta-cell proliferation rate following stimulation of insulin secretion in HIT-T 15cells. 

Phrase: "Troglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0245514:troglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "(CS-045"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0056565:CS 045 [Organic Chemical,Pharmacologic Substance]
   861   C3540510:cs [Quantitative Concept]

Phrase: ")"

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "beta-cell proliferation rate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0871208:Rate [Activity]
   812   C1521828:Rate [Quantitative Concept]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "stimulation of insulin secretion"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C2245393:stimulation of insulin secretion [Cell Function]
   881   C2259155:stimulation of secretion [Cell Function]
   770   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   770   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "in HIT-T 15cells."
Processing 00000000.tx.299: Endocrinology 139: 172-178, 1998[Abstract/Free FullText]. 

Phrase: "Endocrinology 139"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0014137:Endocrinology [Biomedical Occupation or Discipline]
   789 E C0694557:endocrinologic [Functional Concept]

Phrase: ":"

Phrase: "172-178,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.300: 31.  

Phrase: "31."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]
Processing 00000000.tx.301: Pickavance, L, Widdowson PS, King P, Ishii S, Tanaka H, and Williams G. 

Phrase: "Pickavance,"

Phrase: "L,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Widdowson PS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1418867:Ps [Gene or Genome]
   861   C1518860:PS [Geographic Area]
   861   C1552158:Ps [Body Part, Organ, or Organ Component]

Phrase: "King"

Phrase: "P,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Ishii S,"

Phrase: "Tanaka H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Williams G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.302: The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. 

Phrase: "The development of overt diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0243107:development [Physiologic Function]
   760   C0678723:Development [Organism Function]
   760   C1527148:Development [Functional Concept]

Phrase: "in young Zucker Diabetic Fatty"

Phrase: "(ZDF"

Phrase: ")"

Phrase: "rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034693:rats [Mammal]
  1000   C0034721:Rats [Mammal]

Phrase: "and"

Phrase: "the effects of chronic MCC-555 treatment."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   757   C1518681:Treatment Effect [Finding]
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.303: Br J Pharmacol 125: 767-770, 1998[Abstract]. 

Phrase: "Br J Pharmacol 125"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1704648:Br. [Conceptual Entity]

Phrase: ":"

Phrase: "767-770,"

Phrase: "1998"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.304: 32.  

Phrase: "32."
Processing 00000000.tx.305: Prigeon, RL, Kahn SE, and Porte D. 

Phrase: "Prigeon,"

Phrase: "RL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1419337:RL [Gene or Genome]
  1000   C3539667:RL [Gene or Genome]

Phrase: "Kahn SE,"

Phrase: "and"

Phrase: "Porte D."
Processing 00000000.tx.306: Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2diabetes mellitus. 

Phrase: "Effect of troglitazone"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "on B cell function,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   901   C0007613:Cell Function [Cell Function]
   827   C0031843:function [Physiologic Function]
   827   C0542341:Function [Functional Concept]
   827   C0700205:FUNCTION [Classification]
   827   C1705273:Function [Intellectual Product]
   755 E C0205245:Functional [Functional Concept]
   755 E C2700217:Functional [Conceptual Entity]
   734   C0004561:B-cell [Cell]

Phrase: "insulin sensitivity,"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "glycemic control in subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]

Phrase: "with type 2diabetes mellitus."
Processing 00000000.tx.307: J Clin Endocrinol Metab 83: 819-823, 1998[Abstract/Free FullText]. 

Phrase: "J Clin Endocrinol Metab 83"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "819-823,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.308: 33.  

Phrase: "33."
Processing 00000000.tx.309: Schwartz, S, Raskin P, Fonseca V, and Graveline JF. 

Phrase: "Schwartz,"

Phrase: "S,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603362:S' [Clinical Attribute]

Phrase: "Raskin P,"

Phrase: "Fonseca V,"

Phrase: "and"

Phrase: "Graveline JF."
Processing 00000000.tx.310: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. 

Phrase: "Effect of troglitazone"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "in insulin-treated patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "with type II diabetes mellitus."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
  1000   C0011860:Diabetes Mellitus, Type 2 [Disease or Syndrome]
           Type 2 Diabetes
  1000   C2984301:Type II diabetes mellitus [Functional Concept]
   875   C1320657:type diabetes [Finding]
   861   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   861   C0441730:Type II [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.311: Troglitazone and Exogenous Insulin Study Group. 

Phrase: "Troglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0245514:troglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "Exogenous Insulin Study Group."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   812   C0441833:Group [Idea or Concept]
   812   C0557651:Study [Manufactured Object]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1552516:Group [Health Care Related Organization]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   812   C2603343:Study [Research Activity]
Processing 00000000.tx.312: N Engl J Med 338: 861-866, 1998[Abstract/Free FullText]. 

Phrase: "N Engl J Med 338"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "861-866,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.313: 34.  

Phrase: "34."
Processing 00000000.tx.314: Shibata, T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, and Wakitani K. 

Phrase: "Shibata,"

Phrase: "T,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Takeuchi S,"

Phrase: "Yokota S,"

Phrase: "Kakimoto K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Yonemori F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "and"

Phrase: "Wakitani K."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.315: Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. 

Phrase: "Effects of peroxisome proliferator-activated receptor-alpha"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   748   C1280500:effects [Qualitative Concept]
   731   C0166415:Peroxisome Proliferator-Activated Receptor alpha [Amino Acid, Peptide, or Protein,Receptor]
   731   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA [Gene or Genome]
   714 E C2348382:Effect [Qualitative Concept]

Phrase: "and -"

Phrase: "gamma agonist,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2987634:Agonist [Pharmacologic Substance]

Phrase: "JTT-501,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0675074:JTT 501 [Organic Chemical,Pharmacologic Substance]

Phrase: "on diabetic complications"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0342257:Diabetic Complications [Pathologic Function]
   861   C0009566:Complications [Pathologic Function]
   861   C1171258:complications [Pathologic Function]
   827 E C2362589:Complication [Idea or Concept]
   777 E C0231242:Complicated [Functional Concept]

Phrase: "in Zucker diabetic fatty rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
Processing 00000000.tx.316: Br J Pharmacol 130: 495-504, 2000[Abstract/Free FullText]. 

Phrase: "Br J Pharmacol 130"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1704648:Br. [Conceptual Entity]

Phrase: ":"

Phrase: "495-504,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.317: 35.  

Phrase: "35."
Processing 00000000.tx.318: Shimaya, A, Kurosaki E, Nakano R, Hirayama R, Shibasaki M, and Shikama H. 

Phrase: "Shimaya,"

Phrase: "A,"

Phrase: "Kurosaki E,"

Phrase: "Nakano R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Hirayama R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Shibasaki M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Shikama H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.319: The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. 

Phrase: "The novel hypoglycemic agent YM440"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0913191:YM440 [Organic Chemical,Pharmacologic Substance]

Phrase: "normalizes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882115:Normalize [Research Activity]

Phrase: "hyperglycemia without changing body fat weight"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "in diabetic db/db mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0025914:Mice [Mammal]
   812   C0025929:mice [Mammal]
   812   C0026809:Mice [Mammal]
Processing 00000000.tx.320: Metabolism 49: 411-417, 2000[ISI][Medline]. 

Phrase: "Metabolism 49"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025519:Metabolism [Organism Function]
   861   C0025520:metabolism [Functional Concept]

Phrase: ":"

Phrase: "411-417,"

Phrase: "2000"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.321: 36.  

Phrase: "36."
Processing 00000000.tx.322: Taniguchi, A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, and Nakai Y. 

Phrase: "Taniguchi,"

Phrase: "A,"

Phrase: "Fukushima M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Sakai M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Tokuyama K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Nagata I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Fukunaga A,"

Phrase: "Kishimoto H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Doi K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Yamashita Y,"

Phrase: "Matsuura T,"

Phrase: "Kitatani N,"

Phrase: "Okumura T,"

Phrase: "Nagasaka S,"

Phrase: "Nakaishi S,"

Phrase: "and"

Phrase: "Nakai Y."
Processing 00000000.tx.323: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2diabetic patients. 

Phrase: "Effects of bezafibrate"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C1280500:effects [Qualitative Concept]
   756 E C2348382:Effect [Qualitative Concept]

Phrase: "on insulin sensitivity"
Meta Candidates (Total=15; Excluded=4; Pruned=0; Remaining=11)
  1000   C0920563:Insulin Sensitivity [Pathologic Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "insulin secretion in non-obese Japanese type 2diabetic patients."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   764   C1256369:insulin secretion [Cell Function]
   762   C0457592:Insulin type [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0036536:secretion [Biologic Function]
   742   C0036537:Secretion [Body Substance]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]
Processing 00000000.tx.324: Metabolism 50: 477-480, 2001[ISI][Medline]. 

Phrase: "Metabolism 50"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025519:Metabolism [Organism Function]
   861   C0025520:metabolism [Functional Concept]

Phrase: ":"

Phrase: "477-480,"

Phrase: "2001"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.325: 37.  

Phrase: "37."
Processing 00000000.tx.326: Unger, RH. 

Phrase: "Unger,"

Phrase: "RH."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035493:Rh [Element, Ion, or Isotope]
  1000   C2699077:Rh- [Classification]
  1000   C2699078:Rh+ [Classification]
Processing 00000000.tx.327: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. 

Phrase: "Lipotoxicity in the pathogenesis of obesity-dependent NIDDM."
Processing 00000000.tx.328: Genetic and clinical implications. 

Phrase: "Genetic"
Meta Candidates (Total=16; Excluded=14; Pruned=0; Remaining=2)
  1000   C0017296:GENETIC [Therapeutic or Preventive Procedure]
  1000   C0314603:Genetic [Functional Concept]
   944 E C0005615:Birth [Organism Function]
   944 E C0035150:Reproduction [Organism Function]
   944 E C0079946:origin [Classification]
   944 E C0439659:Origin [Temporal Concept]
   944 E C1550512:origin [Intellectual Product]
   944 E C1550722:birth [Idea or Concept]
   944 E C3245487:birth [Intellectual Product]
   916 E C0454729:Natal [Geographic Area]
   916 E C0559522:Genital [Body System]
   916 E C1546649:Genital [Intellectual Product]
   916 E C1550642:Genital [Body Substance]
   907 E C0205313:Original [Idea or Concept]
   907 E C2347409:Original [Occupational Activity]
   888 E C0598240:originality [Mental Process]

Phrase: "and"

Phrase: "clinical implications."
Processing 00000000.tx.329: Diabetes 44: 863-870, 1995[Abstract]. 

Phrase: "Diabetes 44"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "863-870,"

Phrase: "1995"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.330: 38.  

Phrase: "38."
Processing 00000000.tx.331: Unger, RH, Zhou YT, and Orci L. 

Phrase: "Unger,"

Phrase: "RH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035493:Rh [Element, Ion, or Isotope]
  1000   C2699077:Rh- [Classification]
  1000   C2699078:Rh+ [Classification]

Phrase: "Zhou YT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412122:YT [Gene or Genome]

Phrase: "and"

Phrase: "Orci L."
Processing 00000000.tx.332: Regulation of fatty acid homeostasis in cells: novel role of leptin. 

Phrase: "Regulation of fatty acid homeostasis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0851285:Regulation [Governmental or Regulatory Activity]
   760   C1327622:Regulation [Biologic Function]

Phrase: "in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: ":"

Phrase: "novel role of leptin."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.333: Proc Natl Acad Sci USA 96: 2327-2332, 1999[Abstract/Free FullText]. 

Phrase: "Proc Natl Acad Sci USA 96"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "2327-2332,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.334: 39.  

Phrase: "39."
Processing 00000000.tx.335: Wang, MY, Koyama K, Shimabukuro M, Mangelsdorf D, Newgard CB, and Unger RH. 

Phrase: "Wang,"

Phrase: "MY,"

Phrase: "Koyama K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Shimabukuro M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Mangelsdorf D,"

Phrase: "Newgard CB,"

Phrase: "and"

Phrase: "Unger RH."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]
Processing 00000000.tx.336: Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion. 

Phrase: "Overexpression of leptin receptors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1514559:Overexpression [Genetic Function]

Phrase: "in pancreatic islets"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0022131:Pancreatic Islets [Body Part, Organ, or Organ Component]
   861   C0030274:Pancreatic [Body Part, Organ, or Organ Component]

Phrase: "of Zucker diabetic fatty rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]

Phrase: "restores"

Phrase: "GLUT-2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1420172:GLUT2 [Gene or Genome]
   861   C1335837:GLUT [Gene or Genome]
   861   C1705603:GLUT [Gene or Genome]

Phrase: "glucokinase,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C1415014:GLUCOKINASE [Gene or Genome]

Phrase: "and"

Phrase: "glucose-stimulated insulin secretion."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.337: Proc Natl Acad Sci USA 95: 11921-11926, 1998[Abstract/Free FullText]. 

Phrase: "Proc Natl Acad Sci USA 95"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "11921-11926,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.338: 40.  

Phrase: "40."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439509:/40 [Temporal Concept]
Processing 00000000.tx.339: Wang, Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D, Buckingham R, and Williams G. 

Phrase: "Wang,"

Phrase: "Q,"

Phrase: "Dryden S,"

Phrase: "Frankish HM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0262500:hm [Health Care Activity]
   861   C1512358:HM [Geographic Area]
   861   C3538713:HM [Idea or Concept]

Phrase: "Bing C,"

Phrase: "Pickavance L,"

Phrase: "Hopkins D,"

Phrase: "Buckingham R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "and"

Phrase: "Williams G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.340: Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653(rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. 

Phrase: "Increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "feeding in fatty Zucker rats"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0204695:Feeding [Health Care Activity]
   760   C2987508:Feeding [Activity]

Phrase: "by the thiazolidinedione BRL 49653"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0289314:BRL 49653 [Organic Chemical,Pharmacologic Substance]
   827   C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   827   C1257987:Thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   827   C1412820:BRL [Gene or Genome]
   827   C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "(rosiglitazone"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0289313:rosiglitazone [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "and"

Phrase: "the possible involvement of leptin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1314939:Involvement [Functional Concept]

Phrase: "and"

Phrase: "hypothalamic neuropeptide Y."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0027893:neuropeptide Y [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
   901   C1417815:NEUROPEPTIDE Y [Gene or Genome]
   827   C0027895:Neuropeptide [Amino Acid, Peptide, or Protein,Neuroreactive Substance or Biogenic Amine]
Processing 00000000.tx.341: Br J Pharmacol 122: 1405-1410, 1997[Abstract]. 

Phrase: "Br J Pharmacol 122"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1704648:Br. [Conceptual Entity]

Phrase: ":"

Phrase: "1405-1410,"

Phrase: "1997"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "]."
Processing 00000000.tx.342: 41.  

Phrase: "41."
Processing 00000000.tx.343: Zhang, B, Graziano MP, Doebber TW, Leibowitz MD, White Carrington S, Szalkowski DM, Hey PJ, Wu M, Cullinan CA, Bailey P, Lollmann B, Frederich R, Flier JS, Strader CD, and Smith RG. 

Phrase: "Zhang,"

Phrase: "B,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Graziano MP,"

Phrase: "Doebber TW,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0039260:TW [Geographic Area]
   861   C0332293:TW [Therapeutic or Preventive Procedure]

Phrase: "Leibowitz MD,"

Phrase: "White Carrington S,"

Phrase: "Szalkowski DM,"

Phrase: "Hey PJ,"

Phrase: "Wu M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Cullinan CA,"

Phrase: "Bailey P,"

Phrase: "Lollmann B,"

Phrase: "Frederich R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Flier JS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552154:Js [Body Part, Organ, or Organ Component]

Phrase: "Strader CD,"

Phrase: "and"

Phrase: "Smith RG."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]
Processing 00000000.tx.344: Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. 

Phrase: "Down-regulation of the expression of the obese gene"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   804   C0017263:Regulation of Gene Expression [Genetic Function]
           Gene Expression Regulation
           Gene Regulation
   784   C0920533:Gene Down-Regulation [Genetic Function]
   764   C0013081:Down-Regulation [Cell Function,Molecular Function]
   742   C0851285:Regulation [Governmental or Regulatory Activity]
   742   C1327622:Regulation [Biologic Function]

Phrase: "by an antidiabetic thiazolidinedione"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0289779:thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   861   C1257987:Thiazolidinedione [Organic Chemical,Pharmacologic Substance]
   861   C3537039:Thiazolidinedione [Pharmacologic Substance]

Phrase: "in Zucker diabetic fatty rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C0034719:Rats, Zucker [Mammal]
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]

Phrase: "and"

Phrase: "db/db mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]
Processing 00000000.tx.345: J Biol Chem 271: 9455-9459, 1996[Abstract/Free FullText]. 

Phrase: "J Biol Chem 271"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "9455-9459,"

Phrase: "1996"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.346: 42.  

Phrase: "42."
Processing 00000000.tx.347: Zhou, YT, Shimabukuro M, Wang MY, Lee Y, Higa M, Milburn JL, Newgard CB, and Unger RH. 

Phrase: "Zhou,"

Phrase: "YT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1412122:YT [Gene or Genome]

Phrase: "Shimabukuro M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Wang"

Phrase: "MY,"

Phrase: "Lee Y,"

Phrase: "Higa M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Milburn JL,"

Phrase: "Newgard CB,"

Phrase: "and"

Phrase: "Unger RH."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]
Processing 00000000.tx.348: Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. 

Phrase: "Role of peroxisome proliferator-activated receptor alpha"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]
   731   C0166415:Peroxisome Proliferator-Activated Receptor alpha [Amino Acid, Peptide, or Protein,Receptor]
   731   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA [Gene or Genome]

Phrase: "in disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "of pancreatic beta cells."
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
  1000   C0030281:Pancreatic beta Cells [Cell]
           Beta cell
   827   C0007634:Cells [Cell]
   827   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   827   C0330390:Beta [Plant]
   827   C0439096:Beta [Intellectual Product]
   827   C2004068:Beta [Qualitative Concept]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.349: Proc Natl Acad Sci USA 95: 8898-8903, 1998[Abstract/Free FullText]. 

Phrase: "Proc Natl Acad Sci USA 95"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "8898-8903,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "]."
Processing 00000000.tx.350: Am J Physiol Endocrinol Metab 284(5):E966-E971 0193-1849/03 $5.00 Copyright  2003 the American Physiological Society

Phrase: "Am"

Phrase: "J Physiol Endocrinol Metab 284"

Phrase: "(5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ":"

Phrase: "E966-E971 0193-1849/03 $5.00 Copyright  2003"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   791   C0009993:Copyright [Intellectual Product]
   791   C1552856:copyright [Idea or Concept]

Phrase: "the American Physiological Society"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   827   C0037455:society [Organization]
   827   C0205463:Physiological [Functional Concept]
   827   C0596070:American [Population Group]
   755 E C0031842:Physiology [Biomedical Occupation or Discipline]
   755 E C0031843:physiology [Physiologic Function]

